id	sid	tid	token	lemma	pos
dpc-3325	1	1	dermatology	dermatology	NOUN
dpc-3325	1	2	:	:	PUNCT
dpc-3325	1	3	practical	practical	ADJ
dpc-3325	1	4	and	and	CCONJ
dpc-3325	1	5	conceptual	conceptual	ADJ
dpc-3325	1	6	original	original	ADJ
dpc-3325	1	7	article	article	NOUN
dpc-3325	1	8	|	|	ADV
dpc-3325	1	9	dermatol	dermatol	ADJ
dpc-3325	1	10	pract	pract	NOUN
dpc-3325	1	11	concept	concept	NOUN
dpc-3325	1	12	.	.	PUNCT
dpc-3325	2	1	2023;13(4):e2023272	2023;13(4):e2023272	NUM
dpc-3325	2	2	1	1	NUM
dpc-3325	2	3	cytokine	cytokine	ADJ
dpc-3325	2	4	profiles	profile	NOUN
dpc-3325	2	5	of	of	ADP
dpc-3325	2	6	chronic	chronic	ADJ
dpc-3325	2	7	urticaria	urticaria	NOUN
dpc-3325	2	8	patients	patient	NOUN
dpc-3325	2	9	and	and	CCONJ
dpc-3325	2	10	 	 	SPACE
dpc-3325	2	11	the	the	DET
dpc-3325	2	12	effect	effect	NOUN
dpc-3325	2	13	of	of	ADP
dpc-3325	2	14	omalizumab	omalizumab	NOUN
dpc-3325	2	15	treatment	treatment	NOUN
dpc-3325	2	16	ozge	ozge	PROPN
dpc-3325	2	17	can	can	AUX
dpc-3325	2	18	bostan1	bostan1	VERB
dpc-3325	2	19	,	,	PUNCT
dpc-3325	2	20	ebru	ebru	NOUN
dpc-3325	2	21	damadoglu1	damadoglu1	PROPN
dpc-3325	2	22	,	,	PUNCT
dpc-3325	2	23	basak	basak	PROPN
dpc-3325	2	24	ezgi	ezgi	PROPN
dpc-3325	2	25	sarac2	sarac2	PROPN
dpc-3325	2	26	,	,	PUNCT
dpc-3325	2	27	busra	busra	ADJ
dpc-3325	2	28	kilic2	kilic2	PROPN
dpc-3325	2	29	,	,	PUNCT
dpc-3325	2	30	umit	umit	PROPN
dpc-3325	2	31	murat	murat	PROPN
dpc-3325	2	32	sahiner3	sahiner3	PROPN
dpc-3325	2	33	,	,	PUNCT
dpc-3325	2	34	cagatay	cagatay	NOUN
dpc-3325	2	35	karaaslan2	karaaslan2	NOUN
dpc-3325	2	36	,	,	PUNCT
dpc-3325	2	37	gul	gul	PROPN
dpc-3325	2	38	karakaya1	karakaya1	PROPN
dpc-3325	2	39	,	,	PUNCT
dpc-3325	2	40	ali	ali	PROPN
dpc-3325	2	41	fuat	fuat	PROPN
dpc-3325	2	42	kalyoncu1	kalyoncu1	PROPN
dpc-3325	2	43	1	1	NUM
dpc-3325	2	44	hacettepe	hacettepe	PROPN
dpc-3325	2	45	university	university	NOUN
dpc-3325	2	46	faculty	faculty	NOUN
dpc-3325	2	47	of	of	ADP
dpc-3325	2	48	medicine	medicine	NOUN
dpc-3325	2	49	,	,	PUNCT
dpc-3325	2	50	department	department	NOUN
dpc-3325	2	51	of	of	ADP
dpc-3325	2	52	chest	chest	NOUN
dpc-3325	2	53	diseases	disease	NOUN
dpc-3325	2	54	,	,	PUNCT
dpc-3325	2	55	division	division	NOUN
dpc-3325	2	56	of	of	ADP
dpc-3325	2	57	allergy	allergy	NOUN
dpc-3325	2	58	and	and	CCONJ
dpc-3325	2	59	immunology	immunology	NOUN
dpc-3325	2	60	,	,	PUNCT
dpc-3325	2	61	ankara	ankara	PROPN
dpc-3325	2	62	,	,	PUNCT
dpc-3325	2	63	turkey	turkey	PROPN
dpc-3325	2	64	2	2	NUM
dpc-3325	2	65	hacettepe	hacettepe	NOUN
dpc-3325	2	66	university	university	NOUN
dpc-3325	2	67	faculty	faculty	NOUN
dpc-3325	2	68	of	of	ADP
dpc-3325	2	69	science	science	NOUN
dpc-3325	2	70	,	,	PUNCT
dpc-3325	2	71	department	department	NOUN
dpc-3325	2	72	of	of	ADP
dpc-3325	2	73	biology	biology	NOUN
dpc-3325	2	74	,	,	PUNCT
dpc-3325	2	75	molecular	molecular	ADJ
dpc-3325	2	76	biology	biology	NOUN
dpc-3325	2	77	section	section	NOUN
dpc-3325	2	78	,	,	PUNCT
dpc-3325	2	79	ankara	ankara	PROPN
dpc-3325	2	80	,	,	PUNCT
dpc-3325	2	81	turkey	turkey	PROPN
dpc-3325	2	82	3	3	NUM
dpc-3325	2	83	hacettepe	hacettepe	NOUN
dpc-3325	2	84	university	university	NOUN
dpc-3325	2	85	faculty	faculty	NOUN
dpc-3325	2	86	of	of	ADP
dpc-3325	2	87	medicine	medicine	NOUN
dpc-3325	2	88	,	,	PUNCT
dpc-3325	2	89	department	department	NOUN
dpc-3325	2	90	of	of	ADP
dpc-3325	2	91	pediatric	pediatric	ADJ
dpc-3325	2	92	allergy	allergy	NOUN
dpc-3325	2	93	and	and	CCONJ
dpc-3325	2	94	asthma	asthma	NOUN
dpc-3325	2	95	,	,	PUNCT
dpc-3325	2	96	ankara	ankara	PROPN
dpc-3325	2	97	,	,	PUNCT
dpc-3325	2	98	turkey	turkey	PROPN
dpc-3325	2	99	key	key	ADJ
dpc-3325	2	100	words	word	NOUN
dpc-3325	2	101	:	:	PUNCT
dpc-3325	2	102	chronic	chronic	ADJ
dpc-3325	2	103	spontaneous	spontaneous	ADJ
dpc-3325	2	104	urticaria	urticaria	NOUN
dpc-3325	2	105	,	,	PUNCT
dpc-3325	2	106	biomarker	biomarker	NOUN
dpc-3325	2	107	,	,	PUNCT
dpc-3325	2	108	cytokine	cytokine	NOUN
dpc-3325	2	109	,	,	PUNCT
dpc-3325	2	110	tnf	tnf	PROPN
dpc-3325	2	111	-	-	PUNCT
dpc-3325	2	112	α	α	PROPN
dpc-3325	2	113	,	,	PUNCT
dpc-3325	2	114	il-17	il-17	PART
dpc-3325	2	115	citation	citation	NOUN
dpc-3325	2	116	:	:	PUNCT
dpc-3325	2	117	can	can	AUX
dpc-3325	2	118	bostan	bostan	VERB
dpc-3325	2	119	o	o	NOUN
dpc-3325	2	120	,	,	PUNCT
dpc-3325	2	121	damadoglu	damadoglu	PROPN
dpc-3325	2	122	e	e	NOUN
dpc-3325	2	123	,	,	PUNCT
dpc-3325	2	124	sarac	sarac	NOUN
dpc-3325	2	125	be	be	AUX
dpc-3325	2	126	,	,	PUNCT
dpc-3325	2	127	et	et	PROPN
dpc-3325	2	128	al	al	PROPN
dpc-3325	2	129	.	.	PROPN
dpc-3325	2	130	cytokine	cytokine	ADJ
dpc-3325	2	131	profiles	profile	NOUN
dpc-3325	2	132	of	of	ADP
dpc-3325	2	133	chronic	chronic	ADJ
dpc-3325	2	134	urticaria	urticaria	NOUN
dpc-3325	2	135	patients	patient	NOUN
dpc-3325	2	136	and	and	CCONJ
dpc-3325	2	137	the	the	DET
dpc-3325	2	138	effect	effect	NOUN
dpc-3325	2	139	of	of	ADP
dpc-3325	2	140	omalizumab	omalizumab	NOUN
dpc-3325	2	141	treatment	treatment	NOUN
dpc-3325	2	142	.	.	PUNCT
dpc-3325	3	1	dermatol	dermatol	NOUN
dpc-3325	3	2	pract	pract	PROPN
dpc-3325	3	3	concept	concept	NOUN
dpc-3325	3	4	.	.	PUNCT
dpc-3325	4	1	2023;13(4):e2023272	2023;13(4):e2023272	X
dpc-3325	4	2	.	.	PUNCT
dpc-3325	5	1	doi	doi	PROPN
dpc-3325	5	2	:	:	PUNCT
dpc-3325	5	3	https://doi.org/10.5826/dpc.1304a272	https://doi.org/10.5826/dpc.1304a272	PROPN
dpc-3325	5	4	accepted	accept	VERB
dpc-3325	5	5	:	:	PUNCT
dpc-3325	5	6	june	june	PROPN
dpc-3325	5	7	26	26	NUM
dpc-3325	5	8	,	,	PUNCT
dpc-3325	5	9	2023	2023	NUM
dpc-3325	5	10	;	;	PUNCT
dpc-3325	5	11	published	publish	VERB
dpc-3325	5	12	:	:	PUNCT
dpc-3325	6	1	october	october	PROPN
dpc-3325	6	2	2023	2023	NUM
dpc-3325	6	3	copyright	copyright	NOUN
dpc-3325	6	4	:	:	PUNCT
dpc-3325	6	5	©	©	PROPN
dpc-3325	6	6	2023	2023	NUM
dpc-3325	6	7	can	can	AUX
dpc-3325	6	8	bostan	bostan	VERB
dpc-3325	6	9	et	et	PROPN
dpc-3325	6	10	al	al	PROPN
dpc-3325	6	11	.	.	PUNCT
dpc-3325	7	1	this	this	PRON
dpc-3325	7	2	is	be	AUX
dpc-3325	7	3	an	an	DET
dpc-3325	7	4	open	open	ADJ
dpc-3325	7	5	-	-	PUNCT
dpc-3325	7	6	access	access	NOUN
dpc-3325	7	7	article	article	NOUN
dpc-3325	7	8	distributed	distribute	VERB
dpc-3325	7	9	under	under	ADP
dpc-3325	7	10	the	the	DET
dpc-3325	7	11	terms	term	NOUN
dpc-3325	7	12	of	of	ADP
dpc-3325	7	13	the	the	DET
dpc-3325	7	14	creative	creative	ADJ
dpc-3325	7	15	commons	common	NOUN
dpc-3325	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-3325	7	17	license	license	NOUN
dpc-3325	7	18	(	(	PUNCT
dpc-3325	7	19	by	by	ADP
dpc-3325	7	20	-	-	PUNCT
dpc-3325	7	21	nc-4.0	nc-4.0	NOUN
dpc-3325	7	22	)	)	PUNCT
dpc-3325	7	23	,	,	PUNCT
dpc-3325	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-3325	7	25	,	,	PUNCT
dpc-3325	7	26	which	which	PRON
dpc-3325	7	27	permits	permit	VERB
dpc-3325	7	28	unrestricted	unrestricted	ADJ
dpc-3325	7	29	noncommercial	noncommercial	ADJ
dpc-3325	7	30	use	use	NOUN
dpc-3325	7	31	,	,	PUNCT
dpc-3325	7	32	distribution	distribution	NOUN
dpc-3325	7	33	,	,	PUNCT
dpc-3325	7	34	and	and	CCONJ
dpc-3325	7	35	reproduction	reproduction	NOUN
dpc-3325	7	36	in	in	ADP
dpc-3325	7	37	any	any	DET
dpc-3325	7	38	medium	medium	NOUN
dpc-3325	7	39	,	,	PUNCT
dpc-3325	7	40	provided	provide	VERB
dpc-3325	7	41	the	the	DET
dpc-3325	7	42	original	original	ADJ
dpc-3325	7	43	authors	author	NOUN
dpc-3325	7	44	and	and	CCONJ
dpc-3325	7	45	source	source	NOUN
dpc-3325	7	46	are	be	AUX
dpc-3325	7	47	credited	credit	VERB
dpc-3325	7	48	.	.	PUNCT
dpc-3325	8	1	funding	funding	NOUN
dpc-3325	8	2	:	:	PUNCT
dpc-3325	8	3	the	the	DET
dpc-3325	8	4	study	study	NOUN
dpc-3325	8	5	was	be	AUX
dpc-3325	8	6	supported	support	VERB
dpc-3325	8	7	by	by	ADP
dpc-3325	8	8	hacettepe	hacettepe	PROPN
dpc-3325	8	9	university	university	NOUN
dpc-3325	8	10	scientific	scientific	ADJ
dpc-3325	8	11	research	research	NOUN
dpc-3325	8	12	projects	project	NOUN
dpc-3325	8	13	coordination	coordination	NOUN
dpc-3325	8	14	unit	unit	NOUN
dpc-3325	8	15	(	(	PUNCT
dpc-3325	8	16	project	project	NOUN
dpc-3325	8	17	no	no	PRON
dpc-3325	8	18	:	:	PUNCT
dpc-3325	8	19	thd-2020	thd-2020	NOUN
dpc-3325	8	20	-	-	PUNCT
dpc-3325	8	21	18771	18771	NUM
dpc-3325	8	22	)	)	PUNCT
dpc-3325	8	23	.	.	PUNCT
dpc-3325	9	1	competing	compete	VERB
dpc-3325	9	2	interests	interest	NOUN
dpc-3325	9	3	:	:	PUNCT
dpc-3325	9	4	none	none	NOUN
dpc-3325	9	5	.	.	PUNCT
dpc-3325	10	1	authorship	authorship	NOUN
dpc-3325	10	2	:	:	PUNCT
dpc-3325	10	3	all	all	DET
dpc-3325	10	4	authors	author	NOUN
dpc-3325	10	5	have	have	AUX
dpc-3325	10	6	contributed	contribute	VERB
dpc-3325	10	7	significantly	significantly	ADV
dpc-3325	10	8	to	to	ADP
dpc-3325	10	9	this	this	DET
dpc-3325	10	10	publication	publication	NOUN
dpc-3325	10	11	.	.	PUNCT
dpc-3325	11	1	corresponding	correspond	VERB
dpc-3325	11	2	author	author	NOUN
dpc-3325	11	3	:	:	PUNCT
dpc-3325	11	4	ozge	ozge	PROPN
dpc-3325	11	5	can	can	AUX
dpc-3325	11	6	bostan	bostan	VERB
dpc-3325	11	7	,	,	PUNCT
dpc-3325	11	8	hacettepe	hacettepe	PROPN
dpc-3325	11	9	üniversitesi	üniversitesi	NOUN
dpc-3325	11	10	hastanesi	hastanesi	NOUN
dpc-3325	11	11	,	,	PUNCT
dpc-3325	11	12	06230	06230	NUM
dpc-3325	11	13	,	,	PUNCT
dpc-3325	11	14	altındağ	altındağ	NOUN
dpc-3325	11	15	,	,	PUNCT
dpc-3325	11	16	ankara	ankara	PROPN
dpc-3325	11	17	,	,	PUNCT
dpc-3325	11	18	turkey	turkey	PROPN
dpc-3325	11	19	.	.	PUNCT
dpc-3325	12	1	tel	tel	ADP
dpc-3325	12	2	:	:	PUNCT
dpc-3325	12	3	+905079901336	+905079901336	NOUN
dpc-3325	12	4	e	e	NOUN
dpc-3325	12	5	-	-	NOUN
dpc-3325	12	6	mail	mail	NOUN
dpc-3325	12	7	:	:	PUNCT
dpc-3325	13	1	ozge.can20@hotmail.com	ozge.can20@hotmail.com	X
dpc-3325	13	2	introduction	introduction	NOUN
dpc-3325	13	3	:	:	PUNCT
dpc-3325	13	4	cytokines	cytokine	NOUN
dpc-3325	13	5	are	be	AUX
dpc-3325	13	6	key	key	ADJ
dpc-3325	13	7	mediators	mediator	NOUN
dpc-3325	13	8	in	in	ADP
dpc-3325	13	9	immunological	immunological	ADJ
dpc-3325	13	10	and	and	CCONJ
dpc-3325	13	11	inflammatory	inflammatory	ADJ
dpc-3325	13	12	conditions	condition	NOUN
dpc-3325	13	13	,	,	PUNCT
dpc-3325	13	14	including	include	VERB
dpc-3325	13	15	chronic	chronic	ADJ
dpc-3325	13	16	spontaneous	spontaneous	ADJ
dpc-3325	13	17	urticaria	urticaria	NOUN
dpc-3325	13	18	(	(	PUNCT
dpc-3325	13	19	csu	csu	PROPN
dpc-3325	13	20	)	)	PUNCT
dpc-3325	13	21	.	.	PUNCT
dpc-3325	14	1	objectives	objective	NOUN
dpc-3325	14	2	:	:	PUNCT
dpc-3325	14	3	to	to	PART
dpc-3325	14	4	investigate	investigate	VERB
dpc-3325	14	5	th1	th1	PROPN
dpc-3325	14	6	,	,	PUNCT
dpc-3325	14	7	th2	th2	PROPN
dpc-3325	14	8	,	,	PUNCT
dpc-3325	14	9	and	and	CCONJ
dpc-3325	14	10	th17	th17	PROPN
dpc-3325	14	11	cytokine	cytokine	ADJ
dpc-3325	14	12	profiles	profile	NOUN
dpc-3325	14	13	in	in	ADP
dpc-3325	14	14	csu	csu	PROPN
dpc-3325	14	15	and	and	CCONJ
dpc-3325	14	16	to	to	PART
dpc-3325	14	17	evaluate	evaluate	VERB
dpc-3325	14	18	the	the	DET
dpc-3325	14	19	possible	possible	ADJ
dpc-3325	14	20	effect	effect	NOUN
dpc-3325	14	21	of	of	ADP
dpc-3325	14	22	omalizumab	omalizumab	NOUN
dpc-3325	14	23	treatment	treatment	NOUN
dpc-3325	14	24	.	.	PUNCT
dpc-3325	15	1	methods	method	NOUN
dpc-3325	15	2	:	:	PUNCT
dpc-3325	15	3	patients	patient	NOUN
dpc-3325	15	4	who	who	PRON
dpc-3325	15	5	were	be	AUX
dpc-3325	15	6	followed	follow	VERB
dpc-3325	15	7	up	up	ADP
dpc-3325	15	8	for	for	ADP
dpc-3325	15	9	csu	csu	PROPN
dpc-3325	15	10	,	,	PUNCT
dpc-3325	15	11	as	as	ADV
dpc-3325	15	12	well	well	ADV
dpc-3325	15	13	as	as	ADP
dpc-3325	15	14	healthy	healthy	ADJ
dpc-3325	15	15	volunteers	volunteer	NOUN
dpc-3325	15	16	,	,	PUNCT
dpc-3325	15	17	were	be	AUX
dpc-3325	15	18	included	include	VERB
dpc-3325	15	19	in	in	ADP
dpc-3325	15	20	the	the	DET
dpc-3325	15	21	study	study	NOUN
dpc-3325	15	22	.	.	PUNCT
dpc-3325	16	1	to	to	PART
dpc-3325	16	2	assess	assess	VERB
dpc-3325	16	3	urticaria	urticaria	NOUN
dpc-3325	16	4	activity	activity	NOUN
dpc-3325	16	5	,	,	PUNCT
dpc-3325	16	6	the	the	DET
dpc-3325	16	7	7	7	NUM
dpc-3325	16	8	-	-	PUNCT
dpc-3325	16	9	day	day	NOUN
dpc-3325	16	10	-	-	PUNCT
dpc-3325	16	11	urticaria	urticaria	NOUN
dpc-3325	16	12	activity	activity	NOUN
dpc-3325	16	13	score	score	NOUN
dpc-3325	16	14	(	(	PUNCT
dpc-3325	16	15	uas-7	uas-7	NUM
dpc-3325	16	16	)	)	PUNCT
dpc-3325	16	17	,	,	PUNCT
dpc-3325	16	18	the	the	DET
dpc-3325	16	19	urticaria	urticaria	PROPN
dpc-3325	16	20	control	control	PROPN
dpc-3325	16	21	test	test	PROPN
dpc-3325	16	22	(	(	PUNCT
dpc-3325	16	23	uct	uct	PROPN
dpc-3325	16	24	)	)	PUNCT
dpc-3325	16	25	,	,	PUNCT
dpc-3325	16	26	and	and	CCONJ
dpc-3325	16	27	the	the	DET
dpc-3325	16	28	chronic	chronic	ADJ
dpc-3325	16	29	urticaria	urticaria	NOUN
dpc-3325	16	30	quality	quality	NOUN
dpc-3325	16	31	of	of	ADP
dpc-3325	16	32	life	life	NOUN
dpc-3325	16	33	questionnaire	questionnaire	NOUN
dpc-3325	16	34	(	(	PUNCT
dpc-3325	16	35	cu	cu	NOUN
dpc-3325	16	36	-	-	PUNCT
dpc-3325	16	37	qol	qol	PROPN
dpc-3325	16	38	)	)	PUNCT
dpc-3325	16	39	were	be	AUX
dpc-3325	16	40	filled	fill	VERB
dpc-3325	16	41	.	.	PUNCT
dpc-3325	17	1	serum	serum	NOUN
dpc-3325	17	2	levels	level	NOUN
dpc-3325	17	3	of	of	ADP
dpc-3325	17	4	il-6	il-6	NUM
dpc-3325	17	5	,	,	PUNCT
dpc-3325	17	6	il-17	il-17	X
dpc-3325	17	7	,	,	PUNCT
dpc-3325	17	8	il-31	il-31	PRON
dpc-3325	17	9	,	,	PUNCT
dpc-3325	17	10	eotaxin	eotaxin	PROPN
dpc-3325	17	11	,	,	PUNCT
dpc-3325	17	12	rantes	rante	NOUN
dpc-3325	17	13	,	,	PUNCT
dpc-3325	17	14	tnf	tnf	PROPN
dpc-3325	17	15	-	-	PUNCT
dpc-3325	17	16	α	α	PROPN
dpc-3325	17	17	,	,	PUNCT
dpc-3325	17	18	and	and	CCONJ
dpc-3325	17	19	tslp	tslp	PROPN
dpc-3325	17	20	were	be	AUX
dpc-3325	17	21	analyzed	analyze	VERB
dpc-3325	17	22	by	by	ADP
dpc-3325	17	23	elisa	elisa	NOUN
dpc-3325	17	24	and	and	CCONJ
dpc-3325	17	25	compared	compare	VERB
dpc-3325	17	26	in	in	ADP
dpc-3325	17	27	csu	csu	PROPN
dpc-3325	17	28	and	and	CCONJ
dpc-3325	17	29	control	control	NOUN
dpc-3325	17	30	groups	group	NOUN
dpc-3325	17	31	.	.	PUNCT
dpc-3325	18	1	the	the	DET
dpc-3325	18	2	patients	patient	NOUN
dpc-3325	18	3	were	be	AUX
dpc-3325	18	4	analyzed	analyze	VERB
dpc-3325	18	5	in	in	ADP
dpc-3325	18	6	two	two	NUM
dpc-3325	18	7	groups	group	NOUN
dpc-3325	18	8	as	as	ADP
dpc-3325	18	9	the	the	DET
dpc-3325	18	10	omalizumab	omalizumab	NOUN
dpc-3325	18	11	group	group	NOUN
dpc-3325	18	12	and	and	CCONJ
dpc-3325	18	13	the	the	DET
dpc-3325	18	14	non	non	ADJ
dpc-3325	18	15	-	-	ADJ
dpc-3325	18	16	omalizumab	omalizumab	ADJ
dpc-3325	18	17	group	group	NOUN
dpc-3325	18	18	based	base	VERB
dpc-3325	18	19	on	on	ADP
dpc-3325	18	20	their	their	PRON
dpc-3325	18	21	treatment	treatment	NOUN
dpc-3325	18	22	status	status	NOUN
dpc-3325	18	23	.	.	PUNCT
dpc-3325	19	1	results	result	NOUN
dpc-3325	19	2	:	:	PUNCT
dpc-3325	19	3	total	total	ADJ
dpc-3325	19	4	ige	ige	PROPN
dpc-3325	19	5	,	,	PUNCT
dpc-3325	19	6	esr	esr	PROPN
dpc-3325	19	7	,	,	PUNCT
dpc-3325	19	8	crp	crp	PROPN
dpc-3325	19	9	,	,	PUNCT
dpc-3325	19	10	rantes	rante	NOUN
dpc-3325	19	11	,	,	PUNCT
dpc-3325	19	12	and	and	CCONJ
dpc-3325	19	13	tnf	tnf	PROPN
dpc-3325	19	14	-	-	PUNCT
dpc-3325	19	15	a	a	PROPN
dpc-3325	19	16	were	be	AUX
dpc-3325	19	17	significantly	significantly	ADV
dpc-3325	19	18	different	different	ADJ
dpc-3325	19	19	in	in	ADP
dpc-3325	19	20	the	the	DET
dpc-3325	19	21	overall	overall	ADJ
dpc-3325	19	22	comparison	comparison	NOUN
dpc-3325	19	23	of	of	ADP
dpc-3325	19	24	the	the	DET
dpc-3325	19	25	three	three	NUM
dpc-3325	19	26	groups	group	NOUN
dpc-3325	19	27	:	:	PUNCT
dpc-3325	19	28	csu	csu	NOUN
dpc-3325	19	29	-	-	PUNCT
dpc-3325	19	30	receiving	receive	VERB
dpc-3325	19	31	omalizumab	omalizumab	NOUN
dpc-3325	19	32	,	,	PUNCT
dpc-3325	19	33	csu	csu	VERB
dpc-3325	19	34	-	-	PUNCT
dpc-3325	19	35	not	not	PART
dpc-3325	19	36	receiving	receive	VERB
dpc-3325	19	37	omalizumab	omalizumab	NOUN
dpc-3325	19	38	,	,	PUNCT
dpc-3325	19	39	and	and	CCONJ
dpc-3325	19	40	control	control	NOUN
dpc-3325	19	41	groups	group	NOUN
dpc-3325	19	42	(	(	PUNCT
dpc-3325	19	43	p	p	X
dpc-3325	19	44	<	<	X
dpc-3325	19	45	0.01	0.01	NUM
dpc-3325	19	46	,	,	PUNCT
dpc-3325	19	47	0.015	0.015	NUM
dpc-3325	19	48	,	,	PUNCT
dpc-3325	19	49	<	<	X
dpc-3325	19	50	0.01	0.01	NUM
dpc-3325	19	51	,	,	PUNCT
dpc-3325	19	52	<	<	X
dpc-3325	19	53	0.01	0.01	NUM
dpc-3325	19	54	and	and	CCONJ
dpc-3325	19	55	<	<	X
dpc-3325	19	56	0.01	0.01	NUM
dpc-3325	19	57	respectively	respectively	ADV
dpc-3325	19	58	)	)	PUNCT
dpc-3325	19	59	.	.	PUNCT
dpc-3325	20	1	total	total	PROPN
dpc-3325	20	2	ige	ige	PROPN
dpc-3325	20	3	,	,	PUNCT
dpc-3325	20	4	crp	crp	PROPN
dpc-3325	20	5	,	,	PUNCT
dpc-3325	20	6	rantes	rante	NOUN
dpc-3325	20	7	,	,	PUNCT
dpc-3325	20	8	and	and	CCONJ
dpc-3325	20	9	tnf	tnf	PROPN
dpc-3325	20	10	-	-	PUNCT
dpc-3325	20	11	α	α	PROPN
dpc-3325	20	12	values	value	NOUN
dpc-3325	20	13	were	be	AUX
dpc-3325	20	14	similar	similar	ADJ
dpc-3325	20	15	in	in	ADP
dpc-3325	20	16	those	those	PRON
dpc-3325	20	17	who	who	PRON
dpc-3325	20	18	received	receive	VERB
dpc-3325	20	19	and	and	CCONJ
dpc-3325	20	20	did	do	AUX
dpc-3325	20	21	not	not	PART
dpc-3325	20	22	receive	receive	VERB
dpc-3325	20	23	omalizumab	omalizumab	NOUN
dpc-3325	20	24	,	,	PUNCT
dpc-3325	20	25	yet	yet	CCONJ
dpc-3325	20	26	these	these	DET
dpc-3325	20	27	biomarkers	biomarker	NOUN
dpc-3325	20	28	were	be	AUX
dpc-3325	20	29	significantly	significantly	ADV
dpc-3325	20	30	higher	high	ADJ
dpc-3325	20	31	in	in	ADP
dpc-3325	20	32	both	both	DET
dpc-3325	20	33	groups	group	NOUN
dpc-3325	20	34	than	than	ADP
dpc-3325	20	35	in	in	ADP
dpc-3325	20	36	the	the	DET
dpc-3325	20	37	control	control	NOUN
dpc-3325	20	38	group	group	NOUN
dpc-3325	20	39	(	(	PUNCT
dpc-3325	20	40	p	p	X
dpc-3325	20	41	<	<	X
dpc-3325	20	42	0.05	0.05	NUM
dpc-3325	20	43	)	)	PUNCT
dpc-3325	20	44	.	.	PUNCT
dpc-3325	21	1	statistical	statistical	ADJ
dpc-3325	21	2	significance	significance	NOUN
dpc-3325	21	3	in	in	ADP
dpc-3325	21	4	esr	esr	PROPN
dpc-3325	21	5	was	be	AUX
dpc-3325	21	6	observed	observe	VERB
dpc-3325	21	7	only	only	ADV
dpc-3325	21	8	between	between	ADP
dpc-3325	21	9	the	the	DET
dpc-3325	21	10	csu	csu	NOUN
dpc-3325	21	11	-	-	PUNCT
dpc-3325	21	12	receiving	receive	VERB
dpc-3325	21	13	omalizumab	omalizumab	NOUN
dpc-3325	21	14	group	group	NOUN
dpc-3325	21	15	and	and	CCONJ
dpc-3325	21	16	the	the	DET
dpc-3325	21	17	control	control	NOUN
dpc-3325	21	18	group	group	NOUN
dpc-3325	21	19	(	(	PUNCT
dpc-3325	21	20	p	p	X
dpc-3325	21	21	 	 	SPACE
dpc-3325	21	22	=	=	NOUN
dpc-3325	21	23	 	 	SPACE
dpc-3325	21	24	0.01	0.01	NUM
dpc-3325	21	25	)	)	PUNCT
dpc-3325	21	26	.	.	PUNCT
dpc-3325	22	1	within	within	ADP
dpc-3325	22	2	the	the	DET
dpc-3325	22	3	csu	csu	PROPN
dpc-3325	22	4	patients	patient	NOUN
dpc-3325	22	5	,	,	PUNCT
dpc-3325	22	6	there	there	PRON
dpc-3325	22	7	was	be	VERB
dpc-3325	22	8	a	a	DET
dpc-3325	22	9	slight	slight	ADJ
dpc-3325	22	10	but	but	CCONJ
dpc-3325	22	11	significant	significant	ADJ
dpc-3325	22	12	correlation	correlation	NOUN
dpc-3325	22	13	between	between	ADP
dpc-3325	22	14	uct	uct	PROPN
dpc-3325	22	15	and	and	CCONJ
dpc-3325	22	16	tnf	tnf	PROPN
dpc-3325	22	17	-	-	PUNCT
dpc-3325	22	18	α	α	PROPN
dpc-3325	22	19	(	(	PUNCT
dpc-3325	22	20	p	p	X
dpc-3325	22	21	 	 	SPACE
dpc-3325	22	22	=	=	NOUN
dpc-3325	22	23	 	 	SPACE
dpc-3325	22	24	0.008	0.008	NUM
dpc-3325	22	25	,	,	PUNCT
dpc-3325	22	26	r	r	NOUN
dpc-3325	22	27	=	=	NOUN
dpc-3325	22	28	0.32	0.32	NUM
dpc-3325	22	29	)	)	PUNCT
dpc-3325	22	30	and	and	CCONJ
dpc-3325	22	31	il-17	il-17	NUM
dpc-3325	22	32	(	(	PUNCT
dpc-3325	22	33	p	p	X
dpc-3325	22	34	=	=	PROPN
dpc-3325	22	35	0.06	0.06	NUM
dpc-3325	22	36	,	,	PUNCT
dpc-3325	22	37	r	r	NOUN
dpc-3325	22	38	=	=	SYM
dpc-3325	22	39	0.33	0.33	NUM
dpc-3325	22	40	)	)	PUNCT
dpc-3325	22	41	levels	level	NOUN
dpc-3325	22	42	.	.	PUNCT
dpc-3325	23	1	abstract	abstract	ADJ
dpc-3325	23	2	2	2	NUM
dpc-3325	23	3	original	original	ADJ
dpc-3325	23	4	article	article	NOUN
dpc-3325	23	5	|	|	ADV
dpc-3325	23	6	dermatol	dermatol	ADJ
dpc-3325	23	7	pract	pract	NOUN
dpc-3325	23	8	concept	concept	NOUN
dpc-3325	23	9	.	.	PUNCT
dpc-3325	24	1	2023;13(4):e2023272	2023;13(4):e2023272	NUM
dpc-3325	24	2	introduction	introduction	NOUN
dpc-3325	24	3	chronic	chronic	ADJ
dpc-3325	24	4	spontaneous	spontaneous	ADJ
dpc-3325	24	5	urticaria	urticaria	NOUN
dpc-3325	24	6	(	(	PUNCT
dpc-3325	24	7	csu	csu	PROPN
dpc-3325	24	8	)	)	PUNCT
dpc-3325	24	9	is	be	AUX
dpc-3325	24	10	a	a	DET
dpc-3325	24	11	common	common	ADJ
dpc-3325	24	12	clinical	clinical	ADJ
dpc-3325	24	13	condition	condition	NOUN
dpc-3325	24	14	characterized	characterize	VERB
dpc-3325	24	15	by	by	ADP
dpc-3325	24	16	itchy	itchy	ADJ
dpc-3325	24	17	wheals	wheal	NOUN
dpc-3325	24	18	and/or	and/or	CCONJ
dpc-3325	24	19	swelling	swell	VERB
dpc-3325	24	20	that	that	SCONJ
dpc-3325	24	21	resolves	resolve	NOUN
dpc-3325	24	22	within	within	ADP
dpc-3325	24	23	24	24	NUM
dpc-3325	24	24	hours	hour	NOUN
dpc-3325	24	25	and	and	CCONJ
dpc-3325	24	26	lasts	last	VERB
dpc-3325	24	27	for	for	ADP
dpc-3325	24	28	at	at	ADV
dpc-3325	24	29	least	least	ADV
dpc-3325	24	30	six	six	NUM
dpc-3325	24	31	weeks	week	NOUN
dpc-3325	25	1	[	[	X
dpc-3325	25	2	1	1	NUM
dpc-3325	25	3	]	]	PUNCT
dpc-3325	25	4	.	.	PUNCT
dpc-3325	26	1	symptoms	symptom	NOUN
dpc-3325	26	2	are	be	AUX
dpc-3325	26	3	associated	associate	VERB
dpc-3325	26	4	with	with	ADP
dpc-3325	26	5	impaired	impaired	ADJ
dpc-3325	26	6	quality	quality	NOUN
dpc-3325	26	7	of	of	ADP
dpc-3325	26	8	life	life	NOUN
dpc-3325	26	9	,	,	PUNCT
dpc-3325	26	10	and	and	CCONJ
dpc-3325	26	11	as	as	ADP
dpc-3325	26	12	a	a	DET
dpc-3325	26	13	result	result	NOUN
dpc-3325	26	14	,	,	PUNCT
dpc-3325	26	15	there	there	PRON
dpc-3325	26	16	is	be	VERB
dpc-3325	26	17	a	a	DET
dpc-3325	26	18	high	high	ADJ
dpc-3325	26	19	probability	probability	NOUN
dpc-3325	26	20	of	of	ADP
dpc-3325	26	21	experiencing	experience	VERB
dpc-3325	26	22	depression	depression	NOUN
dpc-3325	26	23	,	,	PUNCT
dpc-3325	26	24	anxiety	anxiety	NOUN
dpc-3325	26	25	,	,	PUNCT
dpc-3325	26	26	and	and	CCONJ
dpc-3325	26	27	sleep	sleep	VERB
dpc-3325	26	28	disorders	disorder	NOUN
dpc-3325	26	29	.	.	PUNCT
dpc-3325	27	1	treatment	treatment	NOUN
dpc-3325	27	2	response	response	NOUN
dpc-3325	27	3	and	and	CCONJ
dpc-3325	27	4	monitoring	monitoring	NOUN
dpc-3325	27	5	of	of	ADP
dpc-3325	27	6	disease	disease	NOUN
dpc-3325	27	7	activity	activity	NOUN
dpc-3325	27	8	in	in	ADP
dpc-3325	27	9	csu	csu	PROPN
dpc-3325	27	10	are	be	AUX
dpc-3325	27	11	mostly	mostly	ADV
dpc-3325	27	12	based	base	VERB
dpc-3325	27	13	on	on	ADP
dpc-3325	27	14	the	the	DET
dpc-3325	27	15	use	use	NOUN
dpc-3325	27	16	of	of	ADP
dpc-3325	27	17	patient	patient	NOUN
dpc-3325	27	18	-	-	PUNCT
dpc-3325	27	19	reported	report	VERB
dpc-3325	27	20	outcomes	outcome	NOUN
dpc-3325	27	21	.	.	PUNCT
dpc-3325	28	1	[	[	X
dpc-3325	28	2	2	2	NUM
dpc-3325	28	3	]	]	PUNCT
dpc-3325	28	4	.	.	PUNCT
dpc-3325	29	1	however	however	ADV
dpc-3325	29	2	,	,	PUNCT
dpc-3325	29	3	the	the	DET
dpc-3325	29	4	main	main	ADJ
dpc-3325	29	5	limitation	limitation	NOUN
dpc-3325	29	6	of	of	ADP
dpc-3325	29	7	these	these	DET
dpc-3325	29	8	extensive	extensive	ADJ
dpc-3325	29	9	questionnaires	questionnaire	NOUN
dpc-3325	29	10	for	for	ADP
dpc-3325	29	11	the	the	DET
dpc-3325	29	12	assessment	assessment	NOUN
dpc-3325	29	13	of	of	ADP
dpc-3325	29	14	csu	csu	PROPN
dpc-3325	29	15	is	be	AUX
dpc-3325	29	16	their	their	PRON
dpc-3325	29	17	subjective	subjective	ADJ
dpc-3325	29	18	nature	nature	NOUN
dpc-3325	29	19	.	.	PUNCT
dpc-3325	30	1	recently	recently	ADV
dpc-3325	30	2	,	,	PUNCT
dpc-3325	30	3	studies	study	NOUN
dpc-3325	30	4	have	have	AUX
dpc-3325	30	5	highlighted	highlight	VERB
dpc-3325	30	6	that	that	SCONJ
dpc-3325	30	7	certain	certain	ADJ
dpc-3325	30	8	cytokines	cytokine	NOUN
dpc-3325	30	9	can	can	AUX
dpc-3325	30	10	be	be	AUX
dpc-3325	30	11	considered	consider	VERB
dpc-3325	30	12	as	as	ADP
dpc-3325	30	13	potential	potential	ADJ
dpc-3325	30	14	biomarkers	biomarker	NOUN
dpc-3325	30	15	related	relate	VERB
dpc-3325	30	16	to	to	ADP
dpc-3325	30	17	the	the	DET
dpc-3325	30	18	disease	disease	NOUN
dpc-3325	30	19	[	[	X
dpc-3325	30	20	3	3	NUM
dpc-3325	30	21	]	]	PUNCT
dpc-3325	30	22	.	.	PUNCT
dpc-3325	31	1	moreover	moreover	ADV
dpc-3325	31	2	,	,	PUNCT
dpc-3325	31	3	the	the	DET
dpc-3325	31	4	emergence	emergence	NOUN
dpc-3325	31	5	of	of	ADP
dpc-3325	31	6	such	such	ADJ
dpc-3325	31	7	biomarkers	biomarker	NOUN
dpc-3325	31	8	contributes	contribute	VERB
dpc-3325	31	9	to	to	ADP
dpc-3325	31	10	studies	study	NOUN
dpc-3325	31	11	on	on	ADP
dpc-3325	31	12	new	new	ADJ
dpc-3325	31	13	biological	biological	ADJ
dpc-3325	31	14	agents	agent	NOUN
dpc-3325	31	15	in	in	ADP
dpc-3325	31	16	the	the	DET
dpc-3325	31	17	management	management	NOUN
dpc-3325	31	18	of	of	ADP
dpc-3325	31	19	resistant	resistant	ADJ
dpc-3325	31	20	csu	csu	PROPN
dpc-3325	31	21	and	and	CCONJ
dpc-3325	31	22	supports	support	VERB
dpc-3325	31	23	personalized	personalized	ADJ
dpc-3325	31	24	treatment	treatment	NOUN
dpc-3325	31	25	and	and	CCONJ
dpc-3325	31	26	follow	follow	VERB
dpc-3325	31	27	-	-	PUNCT
dpc-3325	31	28	up	up	NOUN
dpc-3325	31	29	[	[	X
dpc-3325	31	30	4	4	NUM
dpc-3325	31	31	,	,	PUNCT
dpc-3325	31	32	5	5	NUM
dpc-3325	31	33	]	]	PUNCT
dpc-3325	31	34	.	.	PUNCT
dpc-3325	32	1	activation	activation	NOUN
dpc-3325	32	2	and	and	CCONJ
dpc-3325	32	3	degranulation	degranulation	NOUN
dpc-3325	32	4	of	of	ADP
dpc-3325	32	5	mast	mast	NOUN
dpc-3325	32	6	cells	cell	NOUN
dpc-3325	32	7	and	and	CCONJ
dpc-3325	32	8	migration	migration	NOUN
dpc-3325	32	9	of	of	ADP
dpc-3325	32	10	basophils	basophil	NOUN
dpc-3325	32	11	to	to	ADP
dpc-3325	32	12	the	the	DET
dpc-3325	32	13	tissue	tissue	NOUN
dpc-3325	32	14	are	be	AUX
dpc-3325	32	15	frequently	frequently	ADV
dpc-3325	32	16	observed	observe	VERB
dpc-3325	32	17	in	in	ADP
dpc-3325	32	18	the	the	DET
dpc-3325	32	19	inflammation	inflammation	NOUN
dpc-3325	32	20	of	of	ADP
dpc-3325	32	21	urticaria	urticaria	NOUN
dpc-3325	32	22	.	.	PUNCT
dpc-3325	33	1	in	in	ADP
dpc-3325	33	2	addition	addition	NOUN
dpc-3325	33	3	,	,	PUNCT
dpc-3325	33	4	uncontrolled	uncontrolled	ADJ
dpc-3325	33	5	t	t	NOUN
dpc-3325	33	6	-	-	PUNCT
dpc-3325	33	7	cell	cell	NOUN
dpc-3325	33	8	activation	activation	NOUN
dpc-3325	33	9	has	have	AUX
dpc-3325	33	10	been	be	AUX
dpc-3325	33	11	reported	report	VERB
dpc-3325	33	12	in	in	ADP
dpc-3325	33	13	skin	skin	NOUN
dpc-3325	33	14	biopsies	biopsy	NOUN
dpc-3325	33	15	from	from	ADP
dpc-3325	33	16	the	the	DET
dpc-3325	33	17	lesional	lesional	ADJ
dpc-3325	33	18	/	/	SYM
dpc-3325	33	19	non	non	ADJ
dpc-3325	33	20	-	-	ADJ
dpc-3325	33	21	lesional	lesional	ADJ
dpc-3325	33	22	areas	area	NOUN
dpc-3325	33	23	and	and	CCONJ
dpc-3325	33	24	peripheral	peripheral	ADJ
dpc-3325	33	25	circulation	circulation	NOUN
dpc-3325	33	26	of	of	ADP
dpc-3325	33	27	csu	csu	PROPN
dpc-3325	33	28	patients	patient	NOUN
dpc-3325	33	29	[	[	X
dpc-3325	33	30	6	6	NUM
dpc-3325	33	31	]	]	PUNCT
dpc-3325	33	32	.	.	PUNCT
dpc-3325	34	1	in	in	ADP
dpc-3325	34	2	this	this	DET
dpc-3325	34	3	regard	regard	NOUN
dpc-3325	34	4	,	,	PUNCT
dpc-3325	34	5	a	a	DET
dpc-3325	34	6	high	high	ADJ
dpc-3325	34	7	percentage	percentage	NOUN
dpc-3325	34	8	of	of	ADP
dpc-3325	34	9	inflammatory	inflammatory	ADJ
dpc-3325	34	10	cells	cell	NOUN
dpc-3325	34	11	are	be	AUX
dpc-3325	34	12	composed	compose	VERB
dpc-3325	34	13	of	of	ADP
dpc-3325	34	14	t	t	NOUN
dpc-3325	34	15	lymphocytes	lymphocyte	NOUN
dpc-3325	34	16	and	and	CCONJ
dpc-3325	34	17	monocytes	monocyte	NOUN
dpc-3325	34	18	,	,	PUNCT
dpc-3325	34	19	suggesting	suggest	VERB
dpc-3325	34	20	that	that	SCONJ
dpc-3325	34	21	t	t	PROPN
dpc-3325	34	22	cells	cell	NOUN
dpc-3325	34	23	play	play	VERB
dpc-3325	34	24	an	an	DET
dpc-3325	34	25	important	important	ADJ
dpc-3325	34	26	role	role	NOUN
dpc-3325	34	27	in	in	ADP
dpc-3325	34	28	the	the	DET
dpc-3325	34	29	pathogenesis	pathogenesis	NOUN
dpc-3325	34	30	of	of	ADP
dpc-3325	34	31	csu	csu	PROPN
dpc-3325	35	1	[	[	X
dpc-3325	35	2	7	7	NUM
dpc-3325	35	3	]	]	PUNCT
dpc-3325	35	4	.	.	PUNCT
dpc-3325	36	1	as	as	SCONJ
dpc-3325	36	2	a	a	DET
dpc-3325	36	3	th1	th1	NOUN
dpc-3325	36	4	mediator	mediator	NOUN
dpc-3325	36	5	,	,	PUNCT
dpc-3325	36	6	tumor	tumor	NOUN
dpc-3325	36	7	necrosis	necrosis	NOUN
dpc-3325	36	8	factor	factor	NOUN
dpc-3325	36	9	-	-	PUNCT
dpc-3325	36	10	α	α	X
dpc-3325	36	11	(	(	PUNCT
dpc-3325	36	12	tnf	tnf	PROPN
dpc-3325	36	13	-	-	PUNCT
dpc-3325	36	14	α	α	NOUN
dpc-3325	36	15	)	)	PUNCT
dpc-3325	36	16	is	be	AUX
dpc-3325	36	17	a	a	DET
dpc-3325	36	18	candidate	candidate	NOUN
dpc-3325	36	19	biomarker	biomarker	NOUN
dpc-3325	36	20	for	for	ADP
dpc-3325	36	21	urticaria	urticaria	NOUN
dpc-3325	36	22	released	release	VERB
dpc-3325	36	23	by	by	ADP
dpc-3325	36	24	other	other	ADJ
dpc-3325	36	25	inflammatory	inflammatory	ADJ
dpc-3325	36	26	cells	cell	NOUN
dpc-3325	36	27	that	that	PRON
dpc-3325	36	28	can	can	AUX
dpc-3325	36	29	be	be	AUX
dpc-3325	36	30	detected	detect	VERB
dpc-3325	36	31	in	in	ADP
dpc-3325	36	32	the	the	DET
dpc-3325	36	33	area	area	NOUN
dpc-3325	36	34	of	of	ADP
dpc-3325	36	35	urticaria	urticaria	ADJ
dpc-3325	36	36	lesions	lesion	NOUN
dpc-3325	36	37	together	together	ADV
dpc-3325	36	38	with	with	ADP
dpc-3325	36	39	skin	skin	NOUN
dpc-3325	36	40	mast	mast	NOUN
dpc-3325	36	41	cells	cell	NOUN
dpc-3325	36	42	[	[	X
dpc-3325	36	43	8	8	NUM
dpc-3325	36	44	]	]	PUNCT
dpc-3325	36	45	.	.	PUNCT
dpc-3325	37	1	the	the	DET
dpc-3325	37	2	fact	fact	NOUN
dpc-3325	37	3	that	that	SCONJ
dpc-3325	37	4	inflammatory	inflammatory	ADJ
dpc-3325	37	5	mediators	mediator	NOUN
dpc-3325	37	6	such	such	ADJ
dpc-3325	37	7	as	as	ADP
dpc-3325	37	8	il-6	il-6	NUM
dpc-3325	37	9	and	and	CCONJ
dpc-3325	37	10	il-31	il-31	PRON
dpc-3325	37	11	,	,	PUNCT
dpc-3325	37	12	which	which	PRON
dpc-3325	37	13	are	be	AUX
dpc-3325	37	14	involved	involve	VERB
dpc-3325	37	15	in	in	ADP
dpc-3325	37	16	th2	th2	PROPN
dpc-3325	37	17	inflammation	inflammation	NOUN
dpc-3325	37	18	,	,	PUNCT
dpc-3325	37	19	have	have	AUX
dpc-3325	37	20	higher	high	ADJ
dpc-3325	37	21	levels	level	NOUN
dpc-3325	37	22	in	in	ADP
dpc-3325	37	23	urticaria	urticaria	NOUN
dpc-3325	37	24	patients	patient	NOUN
dpc-3325	37	25	and	and	CCONJ
dpc-3325	37	26	regress	regress	NOUN
dpc-3325	37	27	with	with	ADP
dpc-3325	37	28	treatment	treatment	NOUN
dpc-3325	37	29	or	or	CCONJ
dpc-3325	37	30	remission	remission	NOUN
dpc-3325	37	31	,	,	PUNCT
dpc-3325	37	32	promises	promise	VERB
dpc-3325	37	33	that	that	SCONJ
dpc-3325	37	34	these	these	DET
dpc-3325	37	35	and	and	CCONJ
dpc-3325	37	36	similar	similar	ADJ
dpc-3325	37	37	biomarkers	biomarker	NOUN
dpc-3325	37	38	may	may	AUX
dpc-3325	37	39	be	be	AUX
dpc-3325	37	40	important	important	ADJ
dpc-3325	37	41	in	in	ADP
dpc-3325	37	42	the	the	DET
dpc-3325	37	43	etiopathogenesis	etiopathogenesis	NOUN
dpc-3325	37	44	and	and	CCONJ
dpc-3325	37	45	treatment	treatment	NOUN
dpc-3325	37	46	modalities	modality	NOUN
dpc-3325	37	47	of	of	ADP
dpc-3325	37	48	csu	csu	PROPN
dpc-3325	37	49	[	[	X
dpc-3325	37	50	4	4	NUM
dpc-3325	37	51	,	,	PUNCT
dpc-3325	37	52	9	9	NUM
dpc-3325	37	53	-	-	SYM
dpc-3325	37	54	12	12	NUM
dpc-3325	37	55	]	]	PUNCT
dpc-3325	37	56	.	.	PUNCT
dpc-3325	38	1	many	many	ADJ
dpc-3325	38	2	chemokines	chemokine	NOUN
dpc-3325	38	3	and	and	CCONJ
dpc-3325	38	4	enzymes	enzyme	NOUN
dpc-3325	38	5	involved	involve	VERB
dpc-3325	38	6	in	in	ADP
dpc-3325	38	7	the	the	DET
dpc-3325	38	8	pathogenesis	pathogenesis	NOUN
dpc-3325	38	9	of	of	ADP
dpc-3325	38	10	urticaria	urticaria	NOUN
dpc-3325	38	11	are	be	AUX
dpc-3325	38	12	also	also	ADV
dpc-3325	38	13	being	be	AUX
dpc-3325	38	14	investigated	investigate	VERB
dpc-3325	38	15	.	.	PUNCT
dpc-3325	39	1	among	among	ADP
dpc-3325	39	2	the	the	DET
dpc-3325	39	3	chemokines	chemokine	NOUN
dpc-3325	39	4	,	,	PUNCT
dpc-3325	39	5	rantes	rante	NOUN
dpc-3325	39	6	is	be	AUX
dpc-3325	39	7	a	a	DET
dpc-3325	39	8	protein	protein	NOUN
dpc-3325	39	9	that	that	PRON
dpc-3325	39	10	especially	especially	ADV
dpc-3325	39	11	attracts	attract	VERB
dpc-3325	39	12	t	t	NOUN
dpc-3325	39	13	cells	cell	NOUN
dpc-3325	39	14	to	to	ADP
dpc-3325	39	15	the	the	DET
dpc-3325	39	16	site	site	NOUN
dpc-3325	39	17	of	of	ADP
dpc-3325	39	18	inflammation	inflammation	NOUN
dpc-3325	39	19	and	and	CCONJ
dpc-3325	39	20	has	have	AUX
dpc-3325	39	21	been	be	AUX
dpc-3325	39	22	proposed	propose	VERB
dpc-3325	39	23	to	to	PART
dpc-3325	39	24	be	be	AUX
dpc-3325	39	25	of	of	ADP
dpc-3325	39	26	potential	potential	ADJ
dpc-3325	39	27	importance	importance	NOUN
dpc-3325	39	28	in	in	ADP
dpc-3325	39	29	the	the	DET
dpc-3325	39	30	etiopathogenesis	etiopathogenesis	NOUN
dpc-3325	39	31	of	of	ADP
dpc-3325	39	32	csu	csu	PROPN
dpc-3325	39	33	without	without	ADP
dpc-3325	39	34	correlation	correlation	NOUN
dpc-3325	39	35	with	with	ADP
dpc-3325	39	36	disease	disease	NOUN
dpc-3325	39	37	activity	activity	NOUN
dpc-3325	39	38	and	and	CCONJ
dpc-3325	39	39	treatment	treatment	NOUN
dpc-3325	39	40	response	response	NOUN
dpc-3325	39	41	 	 	SPACE
dpc-3325	40	1	[	[	X
dpc-3325	40	2	13	13	NUM
dpc-3325	40	3	]	]	PUNCT
dpc-3325	40	4	.	.	PUNCT
dpc-3325	41	1	eotaxin	eotaxin	PROPN
dpc-3325	41	2	is	be	AUX
dpc-3325	41	3	a	a	DET
dpc-3325	41	4	chemokine	chemokine	ADJ
dpc-3325	41	5	that	that	PRON
dpc-3325	41	6	specifically	specifically	ADV
dpc-3325	41	7	regulates	regulate	VERB
dpc-3325	41	8	eosinophil	eosinophil	ADJ
dpc-3325	41	9	selection	selection	NOUN
dpc-3325	41	10	and	and	CCONJ
dpc-3325	41	11	recruitment	recruitment	NOUN
dpc-3325	41	12	.	.	PUNCT
dpc-3325	42	1	circulating	circulate	VERB
dpc-3325	42	2	eotaxin	eotaxin	PROPN
dpc-3325	42	3	levels	level	NOUN
dpc-3325	42	4	have	have	AUX
dpc-3325	42	5	been	be	AUX
dpc-3325	42	6	shown	show	VERB
dpc-3325	42	7	to	to	PART
dpc-3325	42	8	increase	increase	VERB
dpc-3325	42	9	during	during	ADP
dpc-3325	42	10	exacerbations	exacerbation	NOUN
dpc-3325	42	11	of	of	ADP
dpc-3325	42	12	atopic	atopic	NOUN
dpc-3325	42	13	dermatitis	dermatitis	NOUN
dpc-3325	42	14	and	and	CCONJ
dpc-3325	42	15	acute	acute	ADJ
dpc-3325	42	16	urticaria	urticaria	NOUN
dpc-3325	42	17	,	,	PUNCT
dpc-3325	42	18	implying	imply	VERB
dpc-3325	42	19	that	that	SCONJ
dpc-3325	42	20	it	it	PRON
dpc-3325	42	21	probably	probably	ADV
dpc-3325	42	22	serves	serve	VERB
dpc-3325	42	23	to	to	ADP
dpc-3325	42	24	recruit	recruit	VERB
dpc-3325	42	25	and	and	CCONJ
dpc-3325	42	26	activate	activate	VERB
dpc-3325	42	27	eosinophils	eosinophil	NOUN
dpc-3325	42	28	and	and	CCONJ
dpc-3325	42	29	represents	represent	VERB
dpc-3325	42	30	a	a	DET
dpc-3325	42	31	biomarker	biomarker	NOUN
dpc-3325	42	32	of	of	ADP
dpc-3325	42	33	lesional	lesional	ADJ
dpc-3325	42	34	activity	activity	NOUN
dpc-3325	42	35	[	[	X
dpc-3325	42	36	14	14	NUM
dpc-3325	42	37	]	]	PUNCT
dpc-3325	42	38	.	.	PUNCT
dpc-3325	43	1	many	many	ADJ
dpc-3325	43	2	markers	marker	NOUN
dpc-3325	43	3	have	have	AUX
dpc-3325	43	4	been	be	AUX
dpc-3325	43	5	explored	explore	VERB
dpc-3325	43	6	for	for	ADP
dpc-3325	43	7	conceivable	conceivable	ADJ
dpc-3325	43	8	relations	relation	NOUN
dpc-3325	43	9	with	with	ADP
dpc-3325	43	10	csu	csu	NOUN
dpc-3325	43	11	activity	activity	NOUN
dpc-3325	43	12	,	,	PUNCT
dpc-3325	43	13	but	but	CCONJ
dpc-3325	43	14	the	the	DET
dpc-3325	43	15	number	number	NOUN
dpc-3325	43	16	of	of	ADP
dpc-3325	43	17	studies	study	NOUN
dpc-3325	43	18	that	that	PRON
dpc-3325	43	19	predict	predict	VERB
dpc-3325	43	20	response	response	NOUN
dpc-3325	43	21	to	to	ADP
dpc-3325	43	22	treatment	treatment	NOUN
dpc-3325	43	23	and	and	CCONJ
dpc-3325	43	24	assess	assess	VERB
dpc-3325	43	25	the	the	DET
dpc-3325	43	26	levels	level	NOUN
dpc-3325	43	27	of	of	ADP
dpc-3325	43	28	th1	th1	PROPN
dpc-3325	43	29	,	,	PUNCT
dpc-3325	43	30	th2	th2	PROPN
dpc-3325	43	31	,	,	PUNCT
dpc-3325	43	32	and	and	CCONJ
dpc-3325	43	33	th17	th17	PROPN
dpc-3325	43	34	cytokines	cytokine	NOUN
dpc-3325	43	35	together	together	ADV
dpc-3325	43	36	is	be	AUX
dpc-3325	43	37	limited	limited	ADJ
dpc-3325	43	38	,	,	PUNCT
dpc-3325	43	39	and	and	CCONJ
dpc-3325	43	40	the	the	DET
dpc-3325	43	41	results	result	NOUN
dpc-3325	43	42	showed	show	VERB
dpc-3325	43	43	a	a	DET
dpc-3325	43	44	variation	variation	NOUN
dpc-3325	43	45	in	in	ADP
dpc-3325	43	46	cytokine	cytokine	ADJ
dpc-3325	43	47	profiles	profile	NOUN
dpc-3325	43	48	between	between	ADP
dpc-3325	43	49	csu	csu	NOUN
dpc-3325	43	50	patients	patient	NOUN
dpc-3325	43	51	and	and	CCONJ
dpc-3325	43	52	healthy	healthy	ADJ
dpc-3325	43	53	control	control	NOUN
dpc-3325	43	54	groups	group	NOUN
dpc-3325	43	55	,	,	PUNCT
dpc-3325	43	56	with	with	ADP
dpc-3325	43	57	no	no	DET
dpc-3325	43	58	common	common	ADJ
dpc-3325	43	59	and	and	CCONJ
dpc-3325	43	60	definite	definite	ADJ
dpc-3325	43	61	increase	increase	NOUN
dpc-3325	43	62	or	or	CCONJ
dpc-3325	43	63	decrease	decrease	VERB
dpc-3325	43	64	for	for	ADP
dpc-3325	43	65	these	these	DET
dpc-3325	43	66	markers	marker	NOUN
dpc-3325	44	1	[	[	X
dpc-3325	44	2	15	15	NUM
dpc-3325	44	3	-	-	SYM
dpc-3325	44	4	19	19	NUM
dpc-3325	44	5	]	]	PUNCT
dpc-3325	44	6	.	.	PUNCT
dpc-3325	45	1	the	the	DET
dpc-3325	45	2	objective	objective	NOUN
dpc-3325	45	3	of	of	ADP
dpc-3325	45	4	this	this	DET
dpc-3325	45	5	study	study	NOUN
dpc-3325	45	6	was	be	AUX
dpc-3325	45	7	to	to	PART
dpc-3325	45	8	evaluate	evaluate	VERB
dpc-3325	45	9	the	the	DET
dpc-3325	45	10	th1	th1	PROPN
dpc-3325	45	11	,	,	PUNCT
dpc-3325	45	12	th2	th2	PROPN
dpc-3325	45	13	,	,	PUNCT
dpc-3325	45	14	and	and	CCONJ
dpc-3325	45	15	th17	th17	PROPN
dpc-3325	45	16	serum	serum	NOUN
dpc-3325	45	17	cytokine	cytokine	NOUN
dpc-3325	45	18	levels	level	NOUN
dpc-3325	45	19	in	in	ADP
dpc-3325	45	20	csu	csu	PROPN
dpc-3325	45	21	and	and	CCONJ
dpc-3325	45	22	to	to	PART
dpc-3325	45	23	document	document	VERB
dpc-3325	45	24	the	the	DET
dpc-3325	45	25	possible	possible	ADJ
dpc-3325	45	26	effect	effect	NOUN
dpc-3325	45	27	of	of	ADP
dpc-3325	45	28	omalizumab	omalizumab	NOUN
dpc-3325	45	29	on	on	ADP
dpc-3325	45	30	these	these	DET
dpc-3325	45	31	biomarkers	biomarker	NOUN
dpc-3325	45	32	.	.	PUNCT
dpc-3325	46	1	methods	method	NOUN
dpc-3325	46	2	study	study	VERB
dpc-3325	46	3	subjects	subject	VERB
dpc-3325	46	4	the	the	DET
dpc-3325	46	5	present	present	ADJ
dpc-3325	46	6	case	case	NOUN
dpc-3325	46	7	-	-	PUNCT
dpc-3325	46	8	control	control	NOUN
dpc-3325	46	9	study	study	NOUN
dpc-3325	46	10	included	include	VERB
dpc-3325	46	11	csu	csu	PROPN
dpc-3325	46	12	-	-	PUNCT
dpc-3325	46	13	diagnosed	diagnose	VERB
dpc-3325	46	14	patients	patient	NOUN
dpc-3325	46	15	,	,	PUNCT
dpc-3325	46	16	aged	aged	ADJ
dpc-3325	46	17	≥18	≥18	NUM
dpc-3325	46	18	years	year	NOUN
dpc-3325	46	19	,	,	PUNCT
dpc-3325	46	20	and	and	CCONJ
dpc-3325	46	21	followed	follow	VERB
dpc-3325	46	22	up	up	ADP
dpc-3325	46	23	at	at	ADP
dpc-3325	46	24	the	the	DET
dpc-3325	46	25	adult	adult	NOUN
dpc-3325	46	26	allergy	allergy	NOUN
dpc-3325	46	27	and	and	CCONJ
dpc-3325	46	28	immunology	immunology	NOUN
dpc-3325	46	29	clinic	clinic	NOUN
dpc-3325	46	30	between	between	ADP
dpc-3325	46	31	december	december	PROPN
dpc-3325	46	32	2019	2019	NUM
dpc-3325	46	33	december	december	PROPN
dpc-3325	46	34	2021	2021	NUM
dpc-3325	46	35	.	.	PUNCT
dpc-3325	47	1	the	the	DET
dpc-3325	47	2	diagnosis	diagnosis	NOUN
dpc-3325	47	3	of	of	ADP
dpc-3325	47	4	csu	csu	PROPN
dpc-3325	47	5	was	be	AUX
dpc-3325	47	6	made	make	VERB
dpc-3325	47	7	based	base	VERB
dpc-3325	47	8	on	on	ADP
dpc-3325	47	9	the	the	DET
dpc-3325	47	10	recurrence	recurrence	NOUN
dpc-3325	47	11	of	of	ADP
dpc-3325	47	12	spontaneous	spontaneous	ADJ
dpc-3325	47	13	wheals	wheal	NOUN
dpc-3325	47	14	lasting	last	VERB
dpc-3325	47	15	24	24	NUM
dpc-3325	47	16	hours	hour	NOUN
dpc-3325	47	17	for	for	ADP
dpc-3325	47	18	at	at	ADV
dpc-3325	47	19	least	least	ADV
dpc-3325	47	20	6	6	NUM
dpc-3325	47	21	weeks	week	NOUN
dpc-3325	47	22	,	,	PUNCT
dpc-3325	47	23	according	accord	VERB
dpc-3325	47	24	to	to	ADP
dpc-3325	47	25	the	the	DET
dpc-3325	47	26	guidelines	guideline	NOUN
dpc-3325	47	27	[	[	X
dpc-3325	47	28	1	1	NUM
dpc-3325	47	29	]	]	PUNCT
dpc-3325	47	30	.	.	PUNCT
dpc-3325	48	1	patients	patient	NOUN
dpc-3325	48	2	who	who	PRON
dpc-3325	48	3	had	have	VERB
dpc-3325	48	4	inducible	inducible	ADJ
dpc-3325	48	5	or	or	CCONJ
dpc-3325	48	6	known	known	ADJ
dpc-3325	48	7	causedurticaria	causedurticaria	NOUN
dpc-3325	48	8	,	,	PUNCT
dpc-3325	48	9	accompanied	accompany	VERB
dpc-3325	48	10	collagen	collagen	NOUN
dpc-3325	48	11	tissue	tissue	NOUN
dpc-3325	48	12	disease	disease	NOUN
dpc-3325	48	13	or	or	CCONJ
dpc-3325	48	14	urticarial	urticarial	ADJ
dpc-3325	48	15	vasculitis	vasculitis	NOUN
dpc-3325	48	16	,	,	PUNCT
dpc-3325	48	17	patients	patient	NOUN
dpc-3325	48	18	receiving	receive	VERB
dpc-3325	48	19	corticosteroid	corticosteroid	NOUN
dpc-3325	48	20	therapy	therapy	NOUN
dpc-3325	48	21	for	for	ADP
dpc-3325	48	22	any	any	DET
dpc-3325	48	23	reason	reason	NOUN
dpc-3325	48	24	,	,	PUNCT
dpc-3325	48	25	and	and	CCONJ
dpc-3325	48	26	pregnant	pregnant	ADJ
dpc-3325	48	27	women	woman	NOUN
dpc-3325	48	28	were	be	AUX
dpc-3325	48	29	excluded	exclude	VERB
dpc-3325	48	30	from	from	ADP
dpc-3325	48	31	the	the	DET
dpc-3325	48	32	study	study	NOUN
dpc-3325	48	33	.	.	PUNCT
dpc-3325	49	1	hemogram	hemogram	PROPN
dpc-3325	49	2	,	,	PUNCT
dpc-3325	49	3	c	c	NOUN
dpc-3325	49	4	-	-	PUNCT
dpc-3325	49	5	reactive	reactive	ADJ
dpc-3325	49	6	protein	protein	NOUN
dpc-3325	49	7	(	(	PUNCT
dpc-3325	49	8	crp	crp	PROPN
dpc-3325	49	9	)	)	PUNCT
dpc-3325	49	10	,	,	PUNCT
dpc-3325	49	11	erythrocyte	erythrocyte	NOUN
dpc-3325	49	12	sedimentation	sedimentation	NOUN
dpc-3325	49	13	rate	rate	NOUN
dpc-3325	49	14	(	(	PUNCT
dpc-3325	49	15	esr	esr	PROPN
dpc-3325	49	16	)	)	PUNCT
dpc-3325	49	17	,	,	PUNCT
dpc-3325	49	18	d	d	X
dpc-3325	49	19	-	-	PUNCT
dpc-3325	49	20	dimer	dimer	ADJ
dpc-3325	49	21	,	,	PUNCT
dpc-3325	49	22	thyroid	thyroid	NOUN
dpc-3325	49	23	stimulating	stimulate	VERB
dpc-3325	49	24	hormone	hormone	NOUN
dpc-3325	49	25	(	(	PUNCT
dpc-3325	49	26	tsh	tsh	NOUN
dpc-3325	49	27	)	)	PUNCT
dpc-3325	49	28	,	,	PUNCT
dpc-3325	49	29	anti	anti	ADJ
dpc-3325	49	30	-	-	ADJ
dpc-3325	49	31	tpo	tpo	NOUN
dpc-3325	49	32	,	,	PUNCT
dpc-3325	49	33	liver	liver	NOUN
dpc-3325	49	34	,	,	PUNCT
dpc-3325	49	35	and	and	CCONJ
dpc-3325	49	36	kidney	kidney	NOUN
dpc-3325	49	37	function	function	NOUN
dpc-3325	49	38	tests	test	NOUN
dpc-3325	49	39	were	be	AUX
dpc-3325	49	40	performed	perform	VERB
dpc-3325	49	41	on	on	ADP
dpc-3325	49	42	each	each	DET
dpc-3325	49	43	patient	patient	NOUN
dpc-3325	49	44	.	.	PUNCT
dpc-3325	50	1	omalizumab	omalizumab	NOUN
dpc-3325	50	2	was	be	AUX
dpc-3325	50	3	administered	administer	VERB
dpc-3325	50	4	subcutaneously	subcutaneously	ADV
dpc-3325	50	5	at	at	ADP
dpc-3325	50	6	300	300	NUM
dpc-3325	50	7	mg	mg	NOUN
dpc-3325	50	8	once	once	ADV
dpc-3325	50	9	a	a	DET
dpc-3325	50	10	month	month	NOUN
dpc-3325	50	11	for	for	ADP
dpc-3325	50	12	the	the	DET
dpc-3325	50	13	indication	indication	NOUN
dpc-3325	50	14	of	of	ADP
dpc-3325	50	15	chronic	chronic	ADJ
dpc-3325	50	16	urticaria	urticaria	NOUN
dpc-3325	50	17	in	in	ADP
dpc-3325	50	18	patients	patient	NOUN
dpc-3325	50	19	whose	whose	DET
dpc-3325	50	20	symptoms	symptom	NOUN
dpc-3325	50	21	have	have	AUX
dpc-3325	50	22	not	not	PART
dpc-3325	50	23	been	be	AUX
dpc-3325	50	24	controlled	control	VERB
dpc-3325	50	25	with	with	ADP
dpc-3325	50	26	antihistamines	antihistamine	NOUN
dpc-3325	50	27	as	as	SCONJ
dpc-3325	50	28	stated	state	VERB
dpc-3325	50	29	in	in	ADP
dpc-3325	50	30	the	the	DET
dpc-3325	50	31	guidelines	guideline	NOUN
dpc-3325	50	32	[	[	X
dpc-3325	50	33	1	1	NUM
dpc-3325	50	34	]	]	PUNCT
dpc-3325	50	35	.	.	PUNCT
dpc-3325	51	1	patients	patient	NOUN
dpc-3325	51	2	were	be	AUX
dpc-3325	51	3	analyzed	analyze	VERB
dpc-3325	51	4	according	accord	VERB
dpc-3325	51	5	to	to	ADP
dpc-3325	51	6	their	their	PRON
dpc-3325	51	7	omalizumab	omalizumab	NOUN
dpc-3325	51	8	treatment	treatment	NOUN
dpc-3325	51	9	status	status	NOUN
dpc-3325	51	10	by	by	ADP
dpc-3325	51	11	dividing	divide	VERB
dpc-3325	51	12	them	they	PRON
dpc-3325	51	13	into	into	ADP
dpc-3325	51	14	two	two	NUM
dpc-3325	51	15	groups	group	NOUN
dpc-3325	51	16	,	,	PUNCT
dpc-3325	51	17	as	as	ADP
dpc-3325	51	18	those	those	PRON
dpc-3325	51	19	who	who	PRON
dpc-3325	51	20	received	receive	VERB
dpc-3325	51	21	omalizumab	omalizumab	NOUN
dpc-3325	51	22	and	and	CCONJ
dpc-3325	51	23	those	those	PRON
dpc-3325	51	24	who	who	PRON
dpc-3325	51	25	did	do	VERB
dpc-3325	51	26	not	not	PART
dpc-3325	51	27	.	.	PUNCT
dpc-3325	52	1	in	in	ADP
dpc-3325	52	2	order	order	NOUN
dpc-3325	52	3	to	to	PART
dpc-3325	52	4	evaluate	evaluate	VERB
dpc-3325	52	5	the	the	DET
dpc-3325	52	6	effectiveness	effectiveness	NOUN
dpc-3325	52	7	of	of	ADP
dpc-3325	52	8	the	the	DET
dpc-3325	52	9	treatment	treatment	NOUN
dpc-3325	52	10	for	for	ADP
dpc-3325	52	11	the	the	DET
dpc-3325	52	12	omalizumab	omalizumab	NOUN
dpc-3325	52	13	group	group	NOUN
dpc-3325	52	14	,	,	PUNCT
dpc-3325	52	15	patients	patient	NOUN
dpc-3325	52	16	who	who	PRON
dpc-3325	52	17	had	have	AUX
dpc-3325	52	18	been	be	AUX
dpc-3325	52	19	receiving	receive	VERB
dpc-3325	52	20	omalizumab	omalizumab	NOUN
dpc-3325	52	21	therapy	therapy	NOUN
dpc-3325	52	22	for	for	ADP
dpc-3325	52	23	at	at	ADV
dpc-3325	52	24	least	least	ADV
dpc-3325	52	25	4	4	NUM
dpc-3325	52	26	months	month	NOUN
dpc-3325	52	27	were	be	AUX
dpc-3325	52	28	included	include	VERB
dpc-3325	52	29	.	.	PUNCT
dpc-3325	53	1	ageand	ageand	NOUN
dpc-3325	53	2	gender	gender	NOUN
dpc-3325	53	3	-	-	PUNCT
dpc-3325	53	4	matched	match	VERB
dpc-3325	53	5	healthy	healthy	ADJ
dpc-3325	53	6	volunteer	volunteer	NOUN
dpc-3325	53	7	participants	participant	NOUN
dpc-3325	53	8	were	be	AUX
dpc-3325	53	9	recruited	recruit	VERB
dpc-3325	53	10	as	as	ADP
dpc-3325	53	11	the	the	DET
dpc-3325	53	12	control	control	NOUN
dpc-3325	53	13	group	group	NOUN
dpc-3325	53	14	after	after	ADP
dpc-3325	53	15	being	be	AUX
dpc-3325	53	16	informed	inform	VERB
dpc-3325	53	17	about	about	ADP
dpc-3325	53	18	the	the	DET
dpc-3325	53	19	procedures	procedure	NOUN
dpc-3325	53	20	and	and	CCONJ
dpc-3325	53	21	purpose	purpose	NOUN
dpc-3325	53	22	of	of	ADP
dpc-3325	53	23	the	the	DET
dpc-3325	53	24	study	study	NOUN
dpc-3325	53	25	.	.	PUNCT
dpc-3325	54	1	venous	venous	ADJ
dpc-3325	54	2	blood	blood	NOUN
dpc-3325	54	3	samples	sample	NOUN
dpc-3325	54	4	(	(	PUNCT
dpc-3325	54	5	10	10	NUM
dpc-3325	54	6	ml	ml	NOUN
dpc-3325	54	7	)	)	PUNCT
dpc-3325	54	8	from	from	ADP
dpc-3325	54	9	patients	patient	NOUN
dpc-3325	54	10	and	and	CCONJ
dpc-3325	54	11	controls	control	NOUN
dpc-3325	54	12	were	be	AUX
dpc-3325	54	13	centrifuged	centrifuge	VERB
dpc-3325	54	14	at	at	ADP
dpc-3325	54	15	1500	1500	NUM
dpc-3325	54	16	g	g	NOUN
dpc-3325	54	17	for	for	ADP
dpc-3325	54	18	10	10	NUM
dpc-3325	54	19	minutes	minute	NOUN
dpc-3325	54	20	,	,	PUNCT
dpc-3325	54	21	and	and	CCONJ
dpc-3325	54	22	samples	sample	NOUN
dpc-3325	54	23	were	be	AUX
dpc-3325	54	24	aliquoted	aliquote	VERB
dpc-3325	54	25	and	and	CCONJ
dpc-3325	54	26	stored	store	VERB
dpc-3325	54	27	at	at	ADP
dpc-3325	54	28	-80	-80	NOUN
dpc-3325	54	29	°	°	NOUN
dpc-3325	54	30	c	c	NOUN
dpc-3325	54	31	.	.	PUNCT
dpc-3325	55	1	conclusions	conclusion	NOUN
dpc-3325	55	2	:	:	PUNCT
dpc-3325	55	3	the	the	DET
dpc-3325	55	4	investigated	investigate	VERB
dpc-3325	55	5	cytokine	cytokine	NOUN
dpc-3325	55	6	profile	profile	NOUN
dpc-3325	55	7	in	in	ADP
dpc-3325	55	8	csu	csu	PROPN
dpc-3325	55	9	patients	patient	NOUN
dpc-3325	55	10	may	may	AUX
dpc-3325	55	11	differ	differ	VERB
dpc-3325	55	12	from	from	ADP
dpc-3325	55	13	healthy	healthy	ADJ
dpc-3325	55	14	controls	control	NOUN
dpc-3325	55	15	,	,	PUNCT
dpc-3325	55	16	particularly	particularly	ADV
dpc-3325	55	17	with	with	ADP
dpc-3325	55	18	the	the	DET
dpc-3325	55	19	higher	high	ADJ
dpc-3325	55	20	levels	level	NOUN
dpc-3325	55	21	of	of	ADP
dpc-3325	55	22	rantes	rante	NOUN
dpc-3325	55	23	and	and	CCONJ
dpc-3325	55	24	tnf	tnf	PROPN
dpc-3325	55	25	-	-	PUNCT
dpc-3325	55	26	α	α	PROPN
dpc-3325	55	27	,	,	PUNCT
dpc-3325	55	28	and	and	CCONJ
dpc-3325	55	29	omalizumab	omalizumab	NOUN
dpc-3325	55	30	treatment	treatment	NOUN
dpc-3325	55	31	does	do	AUX
dpc-3325	55	32	not	not	PART
dpc-3325	55	33	seem	seem	VERB
dpc-3325	55	34	to	to	PART
dpc-3325	55	35	affect	affect	VERB
dpc-3325	55	36	that	that	DET
dpc-3325	55	37	profile	profile	NOUN
dpc-3325	55	38	in	in	ADP
dpc-3325	55	39	csu	csu	PROPN
dpc-3325	55	40	patients	patient	NOUN
dpc-3325	55	41	.	.	PUNCT
dpc-3325	56	1	original	original	ADJ
dpc-3325	56	2	article	article	NOUN
dpc-3325	56	3	|	|	ADV
dpc-3325	56	4	dermatol	dermatol	ADJ
dpc-3325	56	5	pract	pract	NOUN
dpc-3325	56	6	concept	concept	NOUN
dpc-3325	56	7	.	.	PUNCT
dpc-3325	57	1	2023;13(4):e2023272	2023;13(4):e2023272	NUM
dpc-3325	57	2	3	3	NUM
dpc-3325	57	3	assessment	assessment	NOUN
dpc-3325	57	4	of	of	ADP
dpc-3325	57	5	urticaria	urticaria	ADJ
dpc-3325	57	6	activity	activity	NOUN
dpc-3325	57	7	to	to	PART
dpc-3325	57	8	evaluate	evaluate	VERB
dpc-3325	57	9	urticaria	urticaria	NOUN
dpc-3325	57	10	activity	activity	NOUN
dpc-3325	57	11	,	,	PUNCT
dpc-3325	57	12	the	the	DET
dpc-3325	57	13	7	7	NUM
dpc-3325	57	14	-	-	PUNCT
dpc-3325	57	15	day	day	NOUN
dpc-3325	57	16	-	-	PUNCT
dpc-3325	57	17	urticaria	urticaria	NOUN
dpc-3325	57	18	activity	activity	NOUN
dpc-3325	57	19	score	score	NOUN
dpc-3325	57	20	(	(	PUNCT
dpc-3325	57	21	uas-7	uas-7	NUM
dpc-3325	57	22	)	)	PUNCT
dpc-3325	57	23	,	,	PUNCT
dpc-3325	57	24	urticaria	urticaria	PROPN
dpc-3325	57	25	control	control	PROPN
dpc-3325	57	26	test	test	PROPN
dpc-3325	57	27	(	(	PUNCT
dpc-3325	57	28	uct	uct	PROPN
dpc-3325	57	29	)	)	PUNCT
dpc-3325	57	30	scores	score	NOUN
dpc-3325	57	31	,	,	PUNCT
dpc-3325	57	32	and	and	CCONJ
dpc-3325	57	33	chronic	chronic	ADJ
dpc-3325	57	34	urticaria	urticaria	NOUN
dpc-3325	57	35	quality	quality	NOUN
dpc-3325	57	36	of	of	ADP
dpc-3325	57	37	life	life	NOUN
dpc-3325	57	38	questionnaire	questionnaire	NOUN
dpc-3325	57	39	(	(	PUNCT
dpc-3325	57	40	cu	cu	NOUN
dpc-3325	57	41	-	-	PUNCT
dpc-3325	57	42	qol	qol	PROPN
dpc-3325	57	43	)	)	PUNCT
dpc-3325	57	44	were	be	AUX
dpc-3325	57	45	filled	fill	VERB
dpc-3325	57	46	out	out	ADP
dpc-3325	57	47	[	[	PUNCT
dpc-3325	57	48	20	20	NUM
dpc-3325	57	49	-	-	SYM
dpc-3325	57	50	23	23	NUM
dpc-3325	57	51	]	]	PUNCT
dpc-3325	57	52	.	.	PUNCT
dpc-3325	58	1	protein	protein	NOUN
dpc-3325	58	2	assessment	assessment	NOUN
dpc-3325	58	3	by	by	ADP
dpc-3325	58	4	enzyme	enzyme	NOUN
dpc-3325	58	5	-	-	PUNCT
dpc-3325	58	6	linked	link	VERB
dpc-3325	58	7	immunosorbent	immunosorbent	NOUN
dpc-3325	58	8	assay	assay	PROPN
dpc-3325	58	9	(	(	PUNCT
dpc-3325	58	10	elisa	elisa	NOUN
dpc-3325	58	11	)	)	PUNCT
dpc-3325	58	12	serum	serum	NOUN
dpc-3325	58	13	levels	level	NOUN
dpc-3325	58	14	of	of	ADP
dpc-3325	58	15	il-6	il-6	NOUN
dpc-3325	58	16	,	,	PUNCT
dpc-3325	58	17	il-8	il-8	NOUN
dpc-3325	58	18	,	,	PUNCT
dpc-3325	58	19	il-17	il-17	X
dpc-3325	58	20	,	,	PUNCT
dpc-3325	58	21	il-25	il-25	NOUN
dpc-3325	58	22	,	,	PUNCT
dpc-3325	58	23	il-31	il-31	X
dpc-3325	58	24	,	,	PUNCT
dpc-3325	58	25	il-33	il-33	X
dpc-3325	58	26	,	,	PUNCT
dpc-3325	58	27	eotaxin	eotaxin	PROPN
dpc-3325	58	28	,	,	PUNCT
dpc-3325	58	29	rantes	rante	NOUN
dpc-3325	58	30	,	,	PUNCT
dpc-3325	58	31	gm	gm	PROPN
dpc-3325	58	32	-	-	PUNCT
dpc-3325	58	33	csf	csf	PROPN
dpc-3325	58	34	,	,	PUNCT
dpc-3325	58	35	tnf	tnf	PROPN
dpc-3325	58	36	-	-	PUNCT
dpc-3325	58	37	α	α	PROPN
dpc-3325	58	38	,	,	PUNCT
dpc-3325	58	39	tslp	tslp	PROPN
dpc-3325	58	40	were	be	AUX
dpc-3325	58	41	analyzed	analyze	VERB
dpc-3325	58	42	in	in	ADP
dpc-3325	58	43	triplicate	triplicate	NOUN
dpc-3325	58	44	by	by	ADP
dpc-3325	58	45	elisa	elisa	NOUN
dpc-3325	58	46	using	use	VERB
dpc-3325	58	47	a	a	DET
dpc-3325	58	48	commercial	commercial	ADJ
dpc-3325	58	49	kit	kit	NOUN
dpc-3325	58	50	(	(	PUNCT
dpc-3325	58	51	il-6	il-6	NOUN
dpc-3325	58	52	:	:	PUNCT
dpc-3325	58	53	abcam	abcam	VERB
dpc-3325	58	54	;	;	PUNCT
dpc-3325	58	55	il-8	il-8	NOUN
dpc-3325	58	56	,	,	PUNCT
dpc-3325	58	57	il-17	il-17	X
dpc-3325	58	58	,	,	PUNCT
dpc-3325	58	59	il-25	il-25	NOUN
dpc-3325	58	60	,	,	PUNCT
dpc-3325	58	61	il-31	il-31	X
dpc-3325	58	62	,	,	PUNCT
dpc-3325	58	63	il-33	il-33	X
dpc-3325	58	64	,	,	PUNCT
dpc-3325	58	65	eotaxin	eotaxin	PROPN
dpc-3325	58	66	,	,	PUNCT
dpc-3325	58	67	rantes	rante	NOUN
dpc-3325	58	68	,	,	PUNCT
dpc-3325	58	69	gmcsf	gmcsf	PROPN
dpc-3325	58	70	,	,	PUNCT
dpc-3325	58	71	tslp	tslp	ADJ
dpc-3325	58	72	:	:	PUNCT
dpc-3325	58	73	r&d	r&d	NOUN
dpc-3325	58	74	systems	system	NOUN
dpc-3325	58	75	;	;	PUNCT
dpc-3325	58	76	tnf	tnf	PROPN
dpc-3325	58	77	-	-	PUNCT
dpc-3325	58	78	α	α	NOUN
dpc-3325	58	79	:	:	PUNCT
dpc-3325	58	80	mabtech	mabtech	NOUN
dpc-3325	58	81	)	)	PUNCT
dpc-3325	58	82	using	use	VERB
dpc-3325	58	83	the	the	DET
dpc-3325	58	84	ensight	ensight	NOUN
dpc-3325	58	85	multimode	multimode	ADJ
dpc-3325	58	86	plate	plate	NOUN
dpc-3325	58	87	reader	reader	NOUN
dpc-3325	58	88	(	(	PUNCT
dpc-3325	58	89	perkinelmer	perkinelmer	NOUN
dpc-3325	58	90	)	)	PUNCT
dpc-3325	58	91	according	accord	VERB
dpc-3325	58	92	to	to	ADP
dpc-3325	58	93	the	the	DET
dpc-3325	58	94	manufacturer	manufacturer	NOUN
dpc-3325	58	95	guidelines	guideline	NOUN
dpc-3325	58	96	.	.	PUNCT
dpc-3325	59	1	statistical	statistical	ADJ
dpc-3325	59	2	analysis	analysis	NOUN
dpc-3325	59	3	ibm	ibm	PROPN
dpc-3325	59	4	spss	spss	PROPN
dpc-3325	59	5	statistics	statistic	NOUN
dpc-3325	59	6	,	,	PUNCT
dpc-3325	59	7	version	version	NOUN
dpc-3325	59	8	25.0	25.0	NUM
dpc-3325	59	9	software	software	NOUN
dpc-3325	59	10	(	(	PUNCT
dpc-3325	59	11	ibm	ibm	PROPN
dpc-3325	59	12	corp	corp	PROPN
dpc-3325	59	13	.	.	PROPN
dpc-3325	59	14	)	)	PUNCT
dpc-3325	59	15	,	,	PUNCT
dpc-3325	59	16	was	be	AUX
dpc-3325	59	17	utilized	utilize	VERB
dpc-3325	59	18	for	for	ADP
dpc-3325	59	19	the	the	DET
dpc-3325	59	20	statistical	statistical	ADJ
dpc-3325	59	21	analyses	analysis	NOUN
dpc-3325	59	22	.	.	PUNCT
dpc-3325	60	1	the	the	DET
dpc-3325	60	2	normal	normal	ADJ
dpc-3325	60	3	distribution	distribution	NOUN
dpc-3325	60	4	of	of	ADP
dpc-3325	60	5	continuous	continuous	ADJ
dpc-3325	60	6	variables	variable	NOUN
dpc-3325	60	7	was	be	AUX
dpc-3325	60	8	checked	check	VERB
dpc-3325	60	9	via	via	ADP
dpc-3325	60	10	the	the	DET
dpc-3325	60	11	kolmogorov	kolmogorov	ADJ
dpc-3325	60	12	-	-	PUNCT
dpc-3325	60	13	smirnov	smirnov	ADJ
dpc-3325	60	14	test	test	NOUN
dpc-3325	60	15	and	and	CCONJ
dpc-3325	60	16	analyzed	analyze	VERB
dpc-3325	60	17	as	as	ADP
dpc-3325	60	18	mean	mean	NOUN
dpc-3325	60	19	±	±	NUM
dpc-3325	60	20	standard	standard	ADJ
dpc-3325	60	21	deviation	deviation	NOUN
dpc-3325	60	22	(	(	PUNCT
dpc-3325	60	23	sd	sd	NOUN
dpc-3325	60	24	)	)	PUNCT
dpc-3325	60	25	in	in	ADP
dpc-3325	60	26	a	a	DET
dpc-3325	60	27	normal	normal	ADJ
dpc-3325	60	28	distribution	distribution	NOUN
dpc-3325	60	29	,	,	PUNCT
dpc-3325	60	30	otherwise	otherwise	ADV
dpc-3325	60	31	as	as	ADP
dpc-3325	60	32	median	median	NOUN
dpc-3325	60	33	[	[	PUNCT
dpc-3325	60	34	lower	low	ADJ
dpc-3325	60	35	-	-	PUNCT
dpc-3325	60	36	upper	upper	ADJ
dpc-3325	60	37	quartile	quartile	NOUN
dpc-3325	60	38	]	]	PUNCT
dpc-3325	60	39	values	value	NOUN
dpc-3325	60	40	.	.	PUNCT
dpc-3325	61	1	patient	patient	ADJ
dpc-3325	61	2	demographics	demographic	NOUN
dpc-3325	61	3	were	be	AUX
dpc-3325	61	4	analyzed	analyze	VERB
dpc-3325	61	5	using	use	VERB
dpc-3325	61	6	the	the	DET
dpc-3325	61	7	chi	chi	ADJ
dpc-3325	61	8	-	-	PUNCT
dpc-3325	61	9	square	square	ADJ
dpc-3325	61	10	test	test	NOUN
dpc-3325	61	11	to	to	PART
dpc-3325	61	12	compare	compare	VERB
dpc-3325	61	13	distributions	distribution	NOUN
dpc-3325	61	14	of	of	ADP
dpc-3325	61	15	gender	gender	NOUN
dpc-3325	61	16	and	and	CCONJ
dpc-3325	61	17	comorbidities	comorbiditie	NOUN
dpc-3325	61	18	,	,	PUNCT
dpc-3325	61	19	and	and	CCONJ
dpc-3325	61	20	the	the	DET
dpc-3325	61	21	mann	mann	PROPN
dpc-3325	61	22	-	-	PUNCT
dpc-3325	61	23	whitney	whitney	PROPN
dpc-3325	61	24	u	u	PROPN
dpc-3325	61	25	test	test	NOUN
dpc-3325	61	26	to	to	PART
dpc-3325	61	27	compare	compare	VERB
dpc-3325	61	28	the	the	DET
dpc-3325	61	29	uct	uct	NOUN
dpc-3325	61	30	,	,	PUNCT
dpc-3325	61	31	uas-7	uas-7	X
dpc-3325	61	32	,	,	PUNCT
dpc-3325	61	33	cu	cu	PROPN
dpc-3325	61	34	-	-	PUNCT
dpc-3325	61	35	qol	qol	PROPN
dpc-3325	61	36	scores	score	NOUN
dpc-3325	61	37	,	,	PUNCT
dpc-3325	61	38	and	and	CCONJ
dpc-3325	61	39	csu	csu	VERB
dpc-3325	61	40	duration	duration	NOUN
dpc-3325	61	41	in	in	ADP
dpc-3325	61	42	both	both	DET
dpc-3325	61	43	groups	group	NOUN
dpc-3325	61	44	.	.	PUNCT
dpc-3325	62	1	spearman	spearman	NOUN
dpc-3325	62	2	's	's	PART
dpc-3325	62	3	rank	rank	NOUN
dpc-3325	62	4	correlation	correlation	NOUN
dpc-3325	62	5	test	test	NOUN
dpc-3325	62	6	was	be	AUX
dpc-3325	62	7	applied	apply	VERB
dpc-3325	62	8	for	for	ADP
dpc-3325	62	9	correlation	correlation	NOUN
dpc-3325	62	10	analysis	analysis	NOUN
dpc-3325	62	11	.	.	PUNCT
dpc-3325	63	1	the	the	DET
dpc-3325	63	2	kruskal	kruskal	PROPN
dpc-3325	63	3	-	-	PUNCT
dpc-3325	63	4	wallis	wallis	PROPN
dpc-3325	63	5	with	with	ADP
dpc-3325	63	6	dunn	dunn	PROPN
dpc-3325	63	7	test	test	NOUN
dpc-3325	63	8	was	be	AUX
dpc-3325	63	9	used	use	VERB
dpc-3325	63	10	to	to	PART
dpc-3325	63	11	compare	compare	VERB
dpc-3325	63	12	the	the	DET
dpc-3325	63	13	biomarkers	biomarker	NOUN
dpc-3325	63	14	of	of	ADP
dpc-3325	63	15	csu	csu	PROPN
dpc-3325	63	16	patients	patient	NOUN
dpc-3325	63	17	who	who	PRON
dpc-3325	63	18	received	receive	VERB
dpc-3325	63	19	omalizumab	omalizumab	NOUN
dpc-3325	63	20	and	and	CCONJ
dpc-3325	63	21	those	those	PRON
dpc-3325	63	22	who	who	PRON
dpc-3325	63	23	did	do	AUX
dpc-3325	63	24	not	not	PART
dpc-3325	63	25	receive	receive	VERB
dpc-3325	63	26	omalizumab	omalizumab	NOUN
dpc-3325	63	27	with	with	ADP
dpc-3325	63	28	those	those	PRON
dpc-3325	63	29	of	of	ADP
dpc-3325	63	30	the	the	DET
dpc-3325	63	31	control	control	NOUN
dpc-3325	63	32	group	group	NOUN
dpc-3325	63	33	.	.	PUNCT
dpc-3325	64	1	values	value	NOUN
dpc-3325	64	2	of	of	ADP
dpc-3325	64	3	p	p	NOUN
dpc-3325	64	4	<	<	X
dpc-3325	64	5	0.05	0.05	NUM
dpc-3325	64	6	were	be	AUX
dpc-3325	64	7	interpreted	interpret	VERB
dpc-3325	64	8	as	as	ADP
dpc-3325	64	9	statistically	statistically	ADV
dpc-3325	64	10	significant	significant	ADJ
dpc-3325	64	11	.	.	PUNCT
dpc-3325	65	1	the	the	DET
dpc-3325	65	2	study	study	NOUN
dpc-3325	65	3	was	be	AUX
dpc-3325	65	4	approved	approve	VERB
dpc-3325	65	5	by	by	ADP
dpc-3325	65	6	the	the	DET
dpc-3325	65	7	ethics	ethic	NOUN
dpc-3325	65	8	committee	committee	PROPN
dpc-3325	65	9	of	of	ADP
dpc-3325	65	10	hacettepe	hacettepe	PROPN
dpc-3325	65	11	university	university	NOUN
dpc-3325	65	12	hospital	hospital	NOUN
dpc-3325	65	13	(	(	PUNCT
dpc-3325	65	14	approval	approval	NOUN
dpc-3325	65	15	no	no	INTJ
dpc-3325	65	16	:	:	PUNCT
dpc-3325	65	17	go-19/1032	go-19/1032	NOUN
dpc-3325	65	18	)	)	PUNCT
dpc-3325	65	19	and	and	CCONJ
dpc-3325	65	20	all	all	DET
dpc-3325	65	21	participants	participant	NOUN
dpc-3325	65	22	gave	give	VERB
dpc-3325	65	23	written	write	VERB
dpc-3325	65	24	consent	consent	NOUN
dpc-3325	65	25	before	before	ADP
dpc-3325	65	26	the	the	DET
dpc-3325	65	27	study	study	NOUN
dpc-3325	65	28	procedures	procedure	NOUN
dpc-3325	65	29	.	.	PUNCT
dpc-3325	66	1	results	result	VERB
dpc-3325	66	2	the	the	DET
dpc-3325	66	3	study	study	NOUN
dpc-3325	66	4	included	include	VERB
dpc-3325	66	5	78	78	NUM
dpc-3325	66	6	patients	patient	NOUN
dpc-3325	66	7	with	with	ADP
dpc-3325	66	8	a	a	DET
dpc-3325	66	9	diagnosis	diagnosis	NOUN
dpc-3325	66	10	of	of	ADP
dpc-3325	66	11	csu	csu	PROPN
dpc-3325	66	12	followed	follow	VERB
dpc-3325	66	13	in	in	ADP
dpc-3325	66	14	the	the	DET
dpc-3325	66	15	hacettepe	hacettepe	PROPN
dpc-3325	66	16	university	university	NOUN
dpc-3325	66	17	adult	adult	NOUN
dpc-3325	66	18	allergy	allergy	NOUN
dpc-3325	66	19	and	and	CCONJ
dpc-3325	66	20	immunology	immunology	NOUN
dpc-3325	66	21	clinic	clinic	NOUN
dpc-3325	66	22	and	and	CCONJ
dpc-3325	66	23	18	18	NUM
dpc-3325	66	24	healthy	healthy	ADJ
dpc-3325	66	25	participants	participant	NOUN
dpc-3325	66	26	.	.	PUNCT
dpc-3325	67	1	the	the	DET
dpc-3325	67	2	mean	mean	ADJ
dpc-3325	67	3	age	age	NOUN
dpc-3325	67	4	of	of	ADP
dpc-3325	67	5	csu	csu	PROPN
dpc-3325	67	6	patients	patient	NOUN
dpc-3325	67	7	was	be	AUX
dpc-3325	67	8	40.2	40.2	NUM
dpc-3325	67	9	±	±	NUM
dpc-3325	67	10	12.5	12.5	NUM
dpc-3325	67	11	years	year	NOUN
dpc-3325	67	12	and	and	CCONJ
dpc-3325	67	13	57	57	NUM
dpc-3325	67	14	(	(	PUNCT
dpc-3325	67	15	73.1	73.1	NUM
dpc-3325	67	16	%	%	NOUN
dpc-3325	67	17	)	)	PUNCT
dpc-3325	67	18	of	of	ADP
dpc-3325	67	19	them	they	PRON
dpc-3325	67	20	were	be	AUX
dpc-3325	67	21	female	female	ADJ
dpc-3325	67	22	(	(	PUNCT
dpc-3325	67	23	table	table	NOUN
dpc-3325	67	24	1	1	NUM
dpc-3325	67	25	)	)	PUNCT
dpc-3325	67	26	.	.	PUNCT
dpc-3325	68	1	the	the	DET
dpc-3325	68	2	median	median	PROPN
dpc-3325	68	3	csu	csu	PROPN
dpc-3325	68	4	duration	duration	NOUN
dpc-3325	68	5	of	of	ADP
dpc-3325	68	6	the	the	DET
dpc-3325	68	7	patients	patient	NOUN
dpc-3325	68	8	was	be	AUX
dpc-3325	68	9	48	48	NUM
dpc-3325	68	10	(	(	PUNCT
dpc-3325	68	11	iqr	iqr	NOUN
dpc-3325	68	12	:	:	PUNCT
dpc-3325	68	13	15	15	NUM
dpc-3325	68	14	-	-	SYM
dpc-3325	68	15	120	120	NUM
dpc-3325	68	16	)	)	PUNCT
dpc-3325	68	17	months	month	NOUN
dpc-3325	68	18	.	.	PUNCT
dpc-3325	69	1	comorbidities	comorbiditie	NOUN
dpc-3325	69	2	were	be	AUX
dpc-3325	69	3	determined	determine	VERB
dpc-3325	69	4	as	as	ADP
dpc-3325	69	5	,	,	PUNCT
dpc-3325	69	6	12	12	NUM
dpc-3325	69	7	(	(	PUNCT
dpc-3325	69	8	15.4	15.4	NUM
dpc-3325	69	9	%	%	NOUN
dpc-3325	69	10	)	)	PUNCT
dpc-3325	70	1	asthma	asthma	NOUN
dpc-3325	70	2	,	,	PUNCT
dpc-3325	70	3	11	11	NUM
dpc-3325	70	4	(	(	PUNCT
dpc-3325	70	5	14.1	14.1	NUM
dpc-3325	70	6	%	%	NOUN
dpc-3325	70	7	)	)	PUNCT
dpc-3325	70	8	allergic	allergic	ADJ
dpc-3325	70	9	rhinitis	rhinitis	NOUN
dpc-3325	70	10	,	,	PUNCT
dpc-3325	70	11	8	8	NUM
dpc-3325	70	12	(	(	PUNCT
dpc-3325	70	13	10.3	10.3	NUM
dpc-3325	70	14	%	%	NOUN
dpc-3325	70	15	)	)	PUNCT
dpc-3325	70	16	hypertension	hypertension	NOUN
dpc-3325	70	17	,	,	PUNCT
dpc-3325	70	18	5	5	NUM
dpc-3325	70	19	(	(	PUNCT
dpc-3325	70	20	6.4	6.4	NUM
dpc-3325	70	21	%	%	NOUN
dpc-3325	70	22	)	)	PUNCT
dpc-3325	70	23	diabetes	diabetes	NOUN
dpc-3325	70	24	mellitus	mellitus	NOUN
dpc-3325	70	25	,	,	PUNCT
dpc-3325	70	26	10	10	NUM
dpc-3325	70	27	(	(	PUNCT
dpc-3325	70	28	12.8	12.8	NUM
dpc-3325	70	29	%	%	NOUN
dpc-3325	70	30	)	)	PUNCT
dpc-3325	70	31	hypothyroidism	hypothyroidism	NOUN
dpc-3325	70	32	,	,	PUNCT
dpc-3325	70	33	5	5	NUM
dpc-3325	70	34	(	(	PUNCT
dpc-3325	70	35	6.4	6.4	NUM
dpc-3325	70	36	%	%	NOUN
dpc-3325	70	37	)	)	PUNCT
dpc-3325	70	38	rheumatological	rheumatological	NOUN
dpc-3325	70	39	,	,	PUNCT
dpc-3325	70	40	4	4	NUM
dpc-3325	70	41	(	(	PUNCT
dpc-3325	70	42	5.1	5.1	NUM
dpc-3325	70	43	%	%	NOUN
dpc-3325	70	44	)	)	PUNCT
dpc-3325	70	45	cardiac	cardiac	ADJ
dpc-3325	70	46	,	,	PUNCT
dpc-3325	70	47	3	3	NUM
dpc-3325	70	48	(	(	PUNCT
dpc-3325	70	49	2.6	2.6	NUM
dpc-3325	70	50	%	%	NOUN
dpc-3325	70	51	)	)	PUNCT
dpc-3325	70	52	renal	renal	ADJ
dpc-3325	70	53	,	,	PUNCT
dpc-3325	70	54	and	and	CCONJ
dpc-3325	70	55	1	1	NUM
dpc-3325	70	56	(	(	PUNCT
dpc-3325	70	57	1.3	1.3	NUM
dpc-3325	70	58	%	%	NOUN
dpc-3325	70	59	)	)	PUNCT
dpc-3325	70	60	psychiatric	psychiatric	ADJ
dpc-3325	70	61	disorder	disorder	NOUN
dpc-3325	70	62	.	.	PUNCT
dpc-3325	71	1	there	there	PRON
dpc-3325	71	2	was	be	VERB
dpc-3325	71	3	no	no	DET
dpc-3325	71	4	difference	difference	NOUN
dpc-3325	71	5	in	in	ADP
dpc-3325	71	6	comorbidities	comorbiditie	NOUN
dpc-3325	71	7	between	between	ADP
dpc-3325	71	8	the	the	DET
dpc-3325	71	9	two	two	NUM
dpc-3325	71	10	groups	group	NOUN
dpc-3325	71	11	receiving	receive	VERB
dpc-3325	71	12	and	and	CCONJ
dpc-3325	71	13	not	not	PART
dpc-3325	71	14	receiving	receive	VERB
dpc-3325	71	15	omalizumab	omalizumab	NOUN
dpc-3325	71	16	.	.	PUNCT
dpc-3325	72	1	of	of	ADP
dpc-3325	72	2	the	the	DET
dpc-3325	72	3	patients	patient	NOUN
dpc-3325	72	4	,	,	PUNCT
dpc-3325	72	5	42	42	NUM
dpc-3325	72	6	(	(	PUNCT
dpc-3325	72	7	53.8	53.8	NUM
dpc-3325	72	8	%	%	NOUN
dpc-3325	72	9	)	)	PUNCT
dpc-3325	72	10	were	be	AUX
dpc-3325	72	11	receiving	receive	VERB
dpc-3325	72	12	omalizumab	omalizumab	NOUN
dpc-3325	72	13	,	,	PUNCT
dpc-3325	72	14	with	with	ADP
dpc-3325	72	15	a	a	DET
dpc-3325	72	16	median	median	ADJ
dpc-3325	72	17	duration	duration	NOUN
dpc-3325	72	18	of	of	ADP
dpc-3325	72	19	18	18	NUM
dpc-3325	72	20	months	month	NOUN
dpc-3325	72	21	(	(	PUNCT
dpc-3325	72	22	9	9	NUM
dpc-3325	72	23	-	-	SYM
dpc-3325	72	24	30	30	NUM
dpc-3325	72	25	)	)	PUNCT
dpc-3325	72	26	and	and	CCONJ
dpc-3325	72	27	a	a	DET
dpc-3325	72	28	csu	csu	ADJ
dpc-3325	72	29	duration	duration	NOUN
dpc-3325	72	30	of	of	ADP
dpc-3325	72	31	66	66	NUM
dpc-3325	72	32	(	(	PUNCT
dpc-3325	72	33	31.2	31.2	NUM
dpc-3325	72	34	-	-	SYM
dpc-3325	72	35	138	138	NUM
dpc-3325	72	36	)	)	PUNCT
dpc-3325	72	37	months	month	NOUN
dpc-3325	72	38	.	.	PUNCT
dpc-3325	73	1	the	the	DET
dpc-3325	73	2	median	median	PROPN
dpc-3325	73	3	uct	uct	PROPN
dpc-3325	73	4	score	score	NOUN
dpc-3325	73	5	of	of	ADP
dpc-3325	73	6	the	the	DET
dpc-3325	73	7	patients	patient	NOUN
dpc-3325	73	8	was	be	AUX
dpc-3325	73	9	10	10	NUM
dpc-3325	73	10	(	(	PUNCT
dpc-3325	73	11	5	5	NUM
dpc-3325	73	12	-	-	SYM
dpc-3325	73	13	13	13	NUM
dpc-3325	73	14	)	)	PUNCT
dpc-3325	73	15	,	,	PUNCT
dpc-3325	73	16	and	and	CCONJ
dpc-3325	73	17	the	the	DET
dpc-3325	73	18	median	median	NOUN
dpc-3325	73	19	uas-7	uas-7	PRON
dpc-3325	73	20	score	score	NOUN
dpc-3325	73	21	was	be	AUX
dpc-3325	73	22	15	15	NUM
dpc-3325	73	23	(	(	PUNCT
dpc-3325	73	24	4	4	NUM
dpc-3325	73	25	-	-	NUM
dpc-3325	73	26	27	27	NUM
dpc-3325	73	27	)	)	PUNCT
dpc-3325	73	28	.	.	PUNCT
dpc-3325	74	1	uct	uct	PROPN
dpc-3325	74	2	scores	score	NOUN
dpc-3325	74	3	were	be	AUX
dpc-3325	74	4	table	table	NOUN
dpc-3325	74	5	1	1	NUM
dpc-3325	74	6	.	.	PUNCT
dpc-3325	74	7	comparisons	comparison	NOUN
dpc-3325	74	8	of	of	ADP
dpc-3325	74	9	the	the	DET
dpc-3325	74	10	patient	patient	ADJ
dpc-3325	74	11	characteristics	characteristic	NOUN
dpc-3325	74	12	according	accord	VERB
dpc-3325	74	13	to	to	ADP
dpc-3325	74	14	the	the	DET
dpc-3325	74	15	status	status	NOUN
dpc-3325	74	16	of	of	ADP
dpc-3325	74	17	omalizumab	omalizumab	NOUN
dpc-3325	74	18	therapy	therapy	NOUN
dpc-3325	74	19	.	.	PUNCT
dpc-3325	75	1	variables	variable	NOUN
dpc-3325	75	2	total	total	VERB
dpc-3325	75	3	(	(	PUNCT
dpc-3325	75	4	n	n	NOUN
dpc-3325	75	5	=	=	SYM
dpc-3325	75	6	78	78	NUM
dpc-3325	75	7	)	)	PUNCT
dpc-3325	75	8	omalizumab	omalizumab	NOUN
dpc-3325	75	9	group	group	NOUN
dpc-3325	75	10	(	(	PUNCT
dpc-3325	75	11	n	n	NOUN
dpc-3325	75	12	=	=	SYM
dpc-3325	75	13	42	42	NUM
dpc-3325	75	14	)	)	PUNCT
dpc-3325	75	15	non	non	ADJ
dpc-3325	75	16	-	-	ADJ
dpc-3325	75	17	omalizumab	omalizumab	ADJ
dpc-3325	75	18	group	group	NOUN
dpc-3325	75	19	(	(	PUNCT
dpc-3325	75	20	n	n	NOUN
dpc-3325	75	21	=	=	SYM
dpc-3325	75	22	36	36	NUM
dpc-3325	75	23	)	)	PUNCT
dpc-3325	75	24	p	p	NOUN
dpc-3325	75	25	value	value	NOUN
dpc-3325	75	26	age	age	NOUN
dpc-3325	75	27	,	,	PUNCT
dpc-3325	75	28	mean	mean	VERB
dpc-3325	75	29	±	±	NUM
dpc-3325	75	30	sd	sd	NOUN
dpc-3325	75	31	,	,	PUNCT
dpc-3325	75	32	years	year	NOUN
dpc-3325	75	33	40.2	40.2	NUM
dpc-3325	75	34	±	±	NUM
dpc-3325	75	35	12.5	12.5	NUM
dpc-3325	75	36	42.4	42.4	NUM
dpc-3325	75	37	±	±	NUM
dpc-3325	75	38	13.7	13.7	NUM
dpc-3325	75	39	38.5	38.5	NUM
dpc-3325	75	40	±	±	NUM
dpc-3325	75	41	11.9	11.9	NUM
dpc-3325	75	42	0.19	0.19	NUM
dpc-3325	75	43	female	female	ADJ
dpc-3325	75	44	gender	gender	NOUN
dpc-3325	75	45	,	,	PUNCT
dpc-3325	75	46	n	n	CCONJ
dpc-3325	75	47	(	(	PUNCT
dpc-3325	75	48	%	%	INTJ
dpc-3325	75	49	)	)	PUNCT
dpc-3325	75	50	57	57	NUM
dpc-3325	75	51	(	(	PUNCT
dpc-3325	75	52	73.1	73.1	NUM
dpc-3325	75	53	)	)	PUNCT
dpc-3325	75	54	33	33	NUM
dpc-3325	75	55	(	(	PUNCT
dpc-3325	75	56	78.6	78.6	NUM
dpc-3325	75	57	)	)	PUNCT
dpc-3325	75	58	24	24	NUM
dpc-3325	75	59	(	(	PUNCT
dpc-3325	75	60	66.7	66.7	NUM
dpc-3325	75	61	)	)	PUNCT
dpc-3325	75	62	0.30	0.30	NUM
dpc-3325	75	63	csu	csu	NOUN
dpc-3325	75	64	duration	duration	NOUN
dpc-3325	75	65	,	,	PUNCT
dpc-3325	75	66	median	median	PROPN
dpc-3325	75	67	(	(	PUNCT
dpc-3325	75	68	iqr	iqr	NOUN
dpc-3325	75	69	)	)	PUNCT
dpc-3325	75	70	,	,	PUNCT
dpc-3325	75	71	months	month	NOUN
dpc-3325	75	72	48	48	NUM
dpc-3325	75	73	(	(	PUNCT
dpc-3325	75	74	15	15	NUM
dpc-3325	75	75	-	-	SYM
dpc-3325	75	76	120	120	NUM
dpc-3325	75	77	)	)	PUNCT
dpc-3325	75	78	66	66	NUM
dpc-3325	75	79	(	(	PUNCT
dpc-3325	75	80	31.2	31.2	NUM
dpc-3325	75	81	-	-	SYM
dpc-3325	75	82	138	138	NUM
dpc-3325	75	83	)	)	PUNCT
dpc-3325	75	84	24	24	NUM
dpc-3325	75	85	(	(	PUNCT
dpc-3325	75	86	2	2	NUM
dpc-3325	75	87	-	-	SYM
dpc-3325	75	88	96	96	NUM
dpc-3325	75	89	)	)	PUNCT
dpc-3325	75	90	0.001	0.001	NUM
dpc-3325	75	91	comorbidities	comorbiditie	NOUN
dpc-3325	75	92	,	,	PUNCT
dpc-3325	75	93	n	n	CCONJ
dpc-3325	75	94	(	(	PUNCT
dpc-3325	75	95	%	%	INTJ
dpc-3325	75	96	)	)	PUNCT
dpc-3325	75	97	asthma	asthma	NOUN
dpc-3325	75	98	rhinitis	rhinitis	ADJ
dpc-3325	75	99	hypertension	hypertension	NOUN
dpc-3325	75	100	diabetes	diabetes	NOUN
dpc-3325	75	101	mellitus	mellitus	PROPN
dpc-3325	75	102	hypothyroidism	hypothyroidism	NOUN
dpc-3325	75	103	rheumatologic	rheumatologic	NOUN
dpc-3325	75	104	disorders	disorder	NOUN
dpc-3325	75	105	cardiac	cardiac	ADJ
dpc-3325	75	106	disorders	disorder	NOUN
dpc-3325	75	107	renal	renal	ADJ
dpc-3325	75	108	disorders	disorder	NOUN
dpc-3325	75	109	psychiatric	psychiatric	ADJ
dpc-3325	75	110	disorders	disorder	NOUN
dpc-3325	75	111	12	12	NUM
dpc-3325	75	112	(	(	PUNCT
dpc-3325	75	113	15.4	15.4	NUM
dpc-3325	75	114	)	)	PUNCT
dpc-3325	75	115	11	11	NUM
dpc-3325	75	116	(	(	PUNCT
dpc-3325	75	117	14.1	14.1	NUM
dpc-3325	75	118	)	)	PUNCT
dpc-3325	75	119	8	8	NUM
dpc-3325	75	120	(	(	PUNCT
dpc-3325	75	121	10.3	10.3	NUM
dpc-3325	75	122	)	)	PUNCT
dpc-3325	75	123	5	5	NUM
dpc-3325	75	124	(	(	PUNCT
dpc-3325	75	125	6.4	6.4	NUM
dpc-3325	75	126	)	)	PUNCT
dpc-3325	75	127	10	10	NUM
dpc-3325	75	128	(	(	PUNCT
dpc-3325	75	129	12.8	12.8	NUM
dpc-3325	75	130	)	)	PUNCT
dpc-3325	75	131	5	5	NUM
dpc-3325	75	132	(	(	PUNCT
dpc-3325	75	133	6.4	6.4	NUM
dpc-3325	75	134	)	)	PUNCT
dpc-3325	75	135	4	4	NUM
dpc-3325	75	136	(	(	PUNCT
dpc-3325	75	137	5.1	5.1	NUM
dpc-3325	75	138	)	)	SYM
dpc-3325	75	139	2	2	NUM
dpc-3325	75	140	(	(	PUNCT
dpc-3325	75	141	2.6	2.6	NUM
dpc-3325	75	142	)	)	PUNCT
dpc-3325	75	143	1	1	NUM
dpc-3325	75	144	(	(	PUNCT
dpc-3325	75	145	1.3	1.3	NUM
dpc-3325	75	146	)	)	PUNCT
dpc-3325	75	147	9	9	NUM
dpc-3325	75	148	(	(	PUNCT
dpc-3325	75	149	21.4	21.4	NUM
dpc-3325	75	150	)	)	PUNCT
dpc-3325	75	151	5	5	NUM
dpc-3325	75	152	(	(	PUNCT
dpc-3325	75	153	11.9	11.9	NUM
dpc-3325	75	154	)	)	PUNCT
dpc-3325	75	155	6	6	NUM
dpc-3325	75	156	(	(	PUNCT
dpc-3325	75	157	14.3	14.3	NUM
dpc-3325	75	158	)	)	PUNCT
dpc-3325	75	159	4	4	NUM
dpc-3325	75	160	(	(	PUNCT
dpc-3325	75	161	9.5	9.5	NUM
dpc-3325	75	162	)	)	PUNCT
dpc-3325	75	163	6	6	NUM
dpc-3325	75	164	(	(	PUNCT
dpc-3325	75	165	14.3	14.3	NUM
dpc-3325	75	166	)	)	PUNCT
dpc-3325	75	167	3	3	NUM
dpc-3325	75	168	(	(	PUNCT
dpc-3325	75	169	7.1	7.1	NUM
dpc-3325	75	170	)	)	SYM
dpc-3325	75	171	2	2	NUM
dpc-3325	75	172	(	(	PUNCT
dpc-3325	75	173	4.8	4.8	NUM
dpc-3325	75	174	)	)	PUNCT
dpc-3325	75	175	1	1	NUM
dpc-3325	75	176	(	(	PUNCT
dpc-3325	75	177	2.4	2.4	NUM
dpc-3325	75	178	)	)	SYM
dpc-3325	75	179	1	1	NUM
dpc-3325	75	180	(	(	PUNCT
dpc-3325	75	181	2.4	2.4	NUM
dpc-3325	75	182	)	)	PUNCT
dpc-3325	75	183	3	3	NUM
dpc-3325	75	184	(	(	PUNCT
dpc-3325	75	185	8.6	8.6	NUM
dpc-3325	75	186	)	)	PUNCT
dpc-3325	75	187	6	6	NUM
dpc-3325	75	188	(	(	PUNCT
dpc-3325	75	189	17.1	17.1	NUM
dpc-3325	75	190	)	)	SYM
dpc-3325	75	191	2	2	NUM
dpc-3325	75	192	(	(	PUNCT
dpc-3325	75	193	5.6	5.6	NUM
dpc-3325	75	194	)	)	SYM
dpc-3325	75	195	1	1	NUM
dpc-3325	75	196	(	(	PUNCT
dpc-3325	75	197	2.8	2.8	NUM
dpc-3325	75	198	)	)	PUNCT
dpc-3325	75	199	4	4	NUM
dpc-3325	75	200	(	(	PUNCT
dpc-3325	75	201	11.1	11.1	NUM
dpc-3325	75	202	)	)	SYM
dpc-3325	75	203	2	2	NUM
dpc-3325	75	204	(	(	PUNCT
dpc-3325	75	205	5.6	5.6	NUM
dpc-3325	75	206	)	)	SYM
dpc-3325	75	207	2	2	NUM
dpc-3325	75	208	(	(	PUNCT
dpc-3325	75	209	5.6	5.6	NUM
dpc-3325	75	210	)	)	SYM
dpc-3325	75	211	1	1	NUM
dpc-3325	75	212	(	(	PUNCT
dpc-3325	75	213	2.8	2.8	NUM
dpc-3325	75	214	)	)	PUNCT
dpc-3325	75	215	0	0	NUM
dpc-3325	76	1	(	(	PUNCT
dpc-3325	76	2	0	0	NUM
dpc-3325	76	3	)	)	PUNCT
dpc-3325	76	4	0.20	0.20	NUM
dpc-3325	76	5	0.53	0.53	NUM
dpc-3325	76	6	0.18	0.18	NUM
dpc-3325	76	7	0.36	0.36	NUM
dpc-3325	76	8	0.74	0.74	NUM
dpc-3325	76	9	0.57	0.57	NUM
dpc-3325	76	10	0.63	0.63	NUM
dpc-3325	76	11	0.71	0.71	NUM
dpc-3325	76	12	n	n	CCONJ
dpc-3325	76	13	/	/	SYM
dpc-3325	76	14	a	a	DET
dpc-3325	76	15	uct	uct	PROPN
dpc-3325	76	16	score	score	NOUN
dpc-3325	76	17	,	,	PUNCT
dpc-3325	76	18	median	median	PROPN
dpc-3325	76	19	(	(	PUNCT
dpc-3325	76	20	iqr	iqr	NOUN
dpc-3325	76	21	)	)	PUNCT
dpc-3325	76	22	10	10	NUM
dpc-3325	76	23	(	(	PUNCT
dpc-3325	76	24	5	5	NUM
dpc-3325	76	25	-	-	SYM
dpc-3325	76	26	13	13	NUM
dpc-3325	76	27	)	)	PUNCT
dpc-3325	76	28	12	12	NUM
dpc-3325	76	29	(	(	PUNCT
dpc-3325	76	30	8	8	NUM
dpc-3325	76	31	-	-	SYM
dpc-3325	76	32	14	14	NUM
dpc-3325	76	33	)	)	PUNCT
dpc-3325	76	34	8	8	NUM
dpc-3325	76	35	(	(	PUNCT
dpc-3325	76	36	2	2	NUM
dpc-3325	76	37	-	-	SYM
dpc-3325	76	38	11	11	NUM
dpc-3325	76	39	)	)	PUNCT
dpc-3325	76	40	<	<	X
dpc-3325	76	41	0.001	0.001	NUM
dpc-3325	76	42	uas-7	uas-7	PRON
dpc-3325	76	43	score	score	NOUN
dpc-3325	76	44	,	,	PUNCT
dpc-3325	76	45	median	median	NOUN
dpc-3325	76	46	(	(	PUNCT
dpc-3325	76	47	iqr	iqr	NOUN
dpc-3325	76	48	)	)	PUNCT
dpc-3325	76	49	15	15	NUM
dpc-3325	76	50	(	(	PUNCT
dpc-3325	76	51	4	4	NUM
dpc-3325	76	52	-	-	SYM
dpc-3325	76	53	27	27	NUM
dpc-3325	76	54	)	)	PUNCT
dpc-3325	76	55	8.5	8.5	NUM
dpc-3325	76	56	(	(	PUNCT
dpc-3325	76	57	1	1	NUM
dpc-3325	76	58	-	-	SYM
dpc-3325	76	59	27	27	NUM
dpc-3325	76	60	)	)	PUNCT
dpc-3325	76	61	22	22	NUM
dpc-3325	76	62	(	(	PUNCT
dpc-3325	76	63	13	13	NUM
dpc-3325	76	64	-	-	SYM
dpc-3325	76	65	27	27	NUM
dpc-3325	76	66	)	)	PUNCT
dpc-3325	76	67	0.04	0.04	NUM
dpc-3325	76	68	cu	cu	PROPN
dpc-3325	76	69	-	-	PUNCT
dpc-3325	76	70	qol	qol	PROPN
dpc-3325	76	71	score	score	NOUN
dpc-3325	76	72	%	%	NOUN
dpc-3325	76	73	,	,	PUNCT
dpc-3325	76	74	median	median	PROPN
dpc-3325	76	75	(	(	PUNCT
dpc-3325	76	76	iqr	iqr	NOUN
dpc-3325	76	77	)	)	PUNCT
dpc-3325	76	78	27.1	27.1	NUM
dpc-3325	76	79	(	(	PUNCT
dpc-3325	76	80	15.2	15.2	NUM
dpc-3325	76	81	-	-	SYM
dpc-3325	76	82	45.7	45.7	NUM
dpc-3325	76	83	)	)	PUNCT
dpc-3325	76	84	22.8	22.8	NUM
dpc-3325	76	85	(	(	PUNCT
dpc-3325	76	86	14.4	14.4	NUM
dpc-3325	76	87	-	-	SYM
dpc-3325	76	88	45.3	45.3	NUM
dpc-3325	76	89	)	)	PUNCT
dpc-3325	76	90	33.6	33.6	NUM
dpc-3325	76	91	(	(	PUNCT
dpc-3325	76	92	17.3	17.3	NUM
dpc-3325	76	93	-	-	SYM
dpc-3325	76	94	56.5	56.5	NUM
dpc-3325	76	95	)	)	PUNCT
dpc-3325	76	96	0.14	0.14	NUM
dpc-3325	76	97	csu	csu	NOUN
dpc-3325	76	98	=	=	SYM
dpc-3325	76	99	chronic	chronic	ADJ
dpc-3325	76	100	spontaneous	spontaneous	ADJ
dpc-3325	76	101	urticaria	urticaria	NOUN
dpc-3325	76	102	;	;	PUNCT
dpc-3325	76	103	cu	cu	PROPN
dpc-3325	76	104	-	-	PUNCT
dpc-3325	76	105	qol	qol	NOUN
dpc-3325	76	106	=	=	SYM
dpc-3325	76	107	chronic	chronic	ADJ
dpc-3325	76	108	urticaria	urticaria	NOUN
dpc-3325	76	109	quality	quality	NOUN
dpc-3325	76	110	of	of	ADP
dpc-3325	76	111	life	life	NOUN
dpc-3325	76	112	;	;	PUNCT
dpc-3325	76	113	iqr	iqr	PROPN
dpc-3325	76	114	=	=	NOUN
dpc-3325	76	115	interquartile	interquartile	NOUN
dpc-3325	76	116	range	range	NOUN
dpc-3325	76	117	;	;	PUNCT
dpc-3325	76	118	n	n	CCONJ
dpc-3325	76	119	/	/	SYM
dpc-3325	76	120	a	a	DET
dpc-3325	76	121	=	=	X
dpc-3325	76	122	non	non	NOUN
dpc-3325	76	123	applicable	applicable	ADJ
dpc-3325	76	124	;	;	PUNCT
dpc-3325	76	125	sd	sd	NOUN
dpc-3325	76	126	=	=	SYM
dpc-3325	76	127	standard	standard	ADJ
dpc-3325	76	128	deviation	deviation	NOUN
dpc-3325	76	129	;	;	PUNCT
dpc-3325	76	130	uas-7	uas-7	X
dpc-3325	76	131	=	=	ADJ
dpc-3325	76	132	7	7	NUM
dpc-3325	76	133	-	-	PUNCT
dpc-3325	76	134	day	day	NOUN
dpc-3325	76	135	urticaria	urticaria	NOUN
dpc-3325	76	136	activity	activity	NOUN
dpc-3325	76	137	score	score	NOUN
dpc-3325	76	138	;	;	PUNCT
dpc-3325	76	139	uct	uct	PROPN
dpc-3325	76	140	=	=	PUNCT
dpc-3325	76	141	urticaria	urticaria	PROPN
dpc-3325	76	142	control	control	PROPN
dpc-3325	76	143	test	test	NOUN
dpc-3325	76	144	.	.	PUNCT
dpc-3325	77	1	4	4	NUM
dpc-3325	77	2	original	original	ADJ
dpc-3325	77	3	article	article	NOUN
dpc-3325	77	4	|	|	ADV
dpc-3325	77	5	dermatol	dermatol	ADJ
dpc-3325	77	6	pract	pract	NOUN
dpc-3325	77	7	concept	concept	NOUN
dpc-3325	77	8	.	.	PUNCT
dpc-3325	78	1	2023;13(4):e2023272	2023;13(4):e2023272	NUM
dpc-3325	78	2	(	(	PUNCT
dpc-3325	78	3	p	p	NOUN
dpc-3325	78	4	 	 	SPACE
dpc-3325	78	5	values	value	NOUN
dpc-3325	78	6	,	,	PUNCT
dpc-3325	78	7	respectively	respectively	ADV
dpc-3325	78	8	,	,	PUNCT
dpc-3325	78	9	0.001	0.001	NUM
dpc-3325	78	10	,	,	PUNCT
dpc-3325	78	11	0.06	0.06	NUM
dpc-3325	78	12	,	,	PUNCT
dpc-3325	78	13	0.02	0.02	NUM
dpc-3325	78	14	and	and	CCONJ
dpc-3325	78	15	<	<	X
dpc-3325	78	16	0.001	0.001	NUM
dpc-3325	78	17	)	)	PUNCT
dpc-3325	78	18	.	.	PUNCT
dpc-3325	79	1	among	among	ADP
dpc-3325	79	2	the	the	DET
dpc-3325	79	3	biomarkers	biomarker	NOUN
dpc-3325	79	4	,	,	PUNCT
dpc-3325	79	5	rantes	rante	NOUN
dpc-3325	79	6	and	and	CCONJ
dpc-3325	79	7	tnf	tnf	PROPN
dpc-3325	79	8	-	-	PUNCT
dpc-3325	79	9	α	α	PROPN
dpc-3325	79	10	levels	level	NOUN
dpc-3325	79	11	were	be	AUX
dpc-3325	79	12	more	more	ADV
dpc-3325	79	13	elevated	elevated	ADJ
dpc-3325	79	14	in	in	ADP
dpc-3325	79	15	csu	csu	PROPN
dpc-3325	79	16	patients	patient	NOUN
dpc-3325	79	17	(	(	PUNCT
dpc-3325	79	18	both	both	PRON
dpc-3325	79	19	p	p	ADJ
dpc-3325	79	20	values	value	NOUN
dpc-3325	79	21	<	<	X
dpc-3325	79	22	0,001	0,001	NUM
dpc-3325	79	23	)	)	PUNCT
dpc-3325	79	24	.	.	PUNCT
dpc-3325	80	1	the	the	DET
dpc-3325	80	2	eosinophil	eosinophil	ADJ
dpc-3325	80	3	counts	count	NOUN
dpc-3325	80	4	and	and	CCONJ
dpc-3325	80	5	percentages	percentage	NOUN
dpc-3325	80	6	,	,	PUNCT
dpc-3325	80	7	eotaxin	eotaxin	PROPN
dpc-3325	80	8	,	,	PUNCT
dpc-3325	80	9	il-6	il-6	PRON
dpc-3325	80	10	,	,	PUNCT
dpc-3325	80	11	tslp	tslp	VERB
dpc-3325	80	12	,	,	PUNCT
dpc-3325	80	13	il-17	il-17	ADV
dpc-3325	80	14	,	,	PUNCT
dpc-3325	80	15	and	and	CCONJ
dpc-3325	80	16	il31	il31	PROPN
dpc-3325	80	17	levels	level	NOUN
dpc-3325	80	18	were	be	AUX
dpc-3325	80	19	similar	similar	ADJ
dpc-3325	80	20	between	between	ADP
dpc-3325	80	21	the	the	DET
dpc-3325	80	22	csu	csu	PROPN
dpc-3325	80	23	and	and	CCONJ
dpc-3325	80	24	control	control	NOUN
dpc-3325	80	25	groups	group	NOUN
dpc-3325	80	26	(	(	PUNCT
dpc-3325	80	27	figure	figure	NOUN
dpc-3325	80	28	1	1	NUM
dpc-3325	80	29	)	)	PUNCT
dpc-3325	80	30	.	.	PUNCT
dpc-3325	81	1	there	there	PRON
dpc-3325	81	2	was	be	VERB
dpc-3325	81	3	no	no	DET
dpc-3325	81	4	significant	significant	ADJ
dpc-3325	81	5	difference	difference	NOUN
dpc-3325	81	6	in	in	ADP
dpc-3325	81	7	eosinophil	eosinophil	ADJ
dpc-3325	81	8	count	count	NOUN
dpc-3325	81	9	/	/	SYM
dpc-3325	81	10	percentage	percentage	NOUN
dpc-3325	81	11	,	,	PUNCT
dpc-3325	81	12	total	total	ADJ
dpc-3325	81	13	ige	ige	PROPN
dpc-3325	81	14	,	,	PUNCT
dpc-3325	81	15	erythrocyte	erythrocyte	NOUN
dpc-3325	81	16	sedimentation	sedimentation	NOUN
dpc-3325	81	17	rate	rate	NOUN
dpc-3325	81	18	,	,	PUNCT
dpc-3325	81	19	crp	crp	PROPN
dpc-3325	81	20	,	,	PUNCT
dpc-3325	81	21	eotaxin	eotaxin	PROPN
dpc-3325	81	22	,	,	PUNCT
dpc-3325	81	23	il-6	il-6	PRON
dpc-3325	81	24	,	,	PUNCT
dpc-3325	81	25	tslp	tslp	VERB
dpc-3325	81	26	,	,	PUNCT
dpc-3325	81	27	rantes	rante	NOUN
dpc-3325	81	28	,	,	PUNCT
dpc-3325	81	29	tnf	tnf	PROPN
dpc-3325	81	30	-	-	PUNCT
dpc-3325	81	31	α	α	PROPN
dpc-3325	81	32	,	,	PUNCT
dpc-3325	81	33	il-17	il-17	X
dpc-3325	81	34	,	,	PUNCT
dpc-3325	81	35	and	and	CCONJ
dpc-3325	81	36	higher	high	ADJ
dpc-3325	81	37	in	in	ADP
dpc-3325	81	38	the	the	DET
dpc-3325	81	39	group	group	NOUN
dpc-3325	81	40	receiving	receive	VERB
dpc-3325	81	41	omalizumab	omalizumab	NOUN
dpc-3325	81	42	(	(	PUNCT
dpc-3325	81	43	median	median	PROPN
dpc-3325	81	44	[	[	X
dpc-3325	81	45	iqr	iqr	X
dpc-3325	81	46	]	]	X
dpc-3325	81	47	:	:	PUNCT
dpc-3325	81	48	12	12	NUM
dpc-3325	81	49	[	[	SYM
dpc-3325	81	50	8	8	NUM
dpc-3325	81	51	-	-	SYM
dpc-3325	81	52	14	14	NUM
dpc-3325	81	53	]	]	PUNCT
dpc-3325	81	54	versus	versus	ADP
dpc-3325	81	55	8	8	NUM
dpc-3325	81	56	(	(	PUNCT
dpc-3325	81	57	2	2	NUM
dpc-3325	81	58	-	-	SYM
dpc-3325	81	59	11	11	NUM
dpc-3325	81	60	)	)	PUNCT
dpc-3325	81	61	,	,	PUNCT
dpc-3325	81	62	p	p	X
dpc-3325	81	63	<	<	X
dpc-3325	81	64	0.001	0.001	NUM
dpc-3325	81	65	)	)	PUNCT
dpc-3325	81	66	.	.	PUNCT
dpc-3325	82	1	uas-7	uas-7	X
dpc-3325	82	2	scores	score	NOUN
dpc-3325	82	3	were	be	AUX
dpc-3325	82	4	lower	low	ADJ
dpc-3325	82	5	in	in	ADP
dpc-3325	82	6	the	the	DET
dpc-3325	82	7	omalizumab	omalizumab	NOUN
dpc-3325	82	8	group	group	NOUN
dpc-3325	82	9	(	(	PUNCT
dpc-3325	82	10	8.5	8.5	NUM
dpc-3325	82	11	(	(	PUNCT
dpc-3325	82	12	1	1	NUM
dpc-3325	82	13	-	-	NUM
dpc-3325	82	14	27	27	NUM
dpc-3325	82	15	)	)	PUNCT
dpc-3325	82	16	versus	versus	ADP
dpc-3325	82	17	22	22	NUM
dpc-3325	83	1	[	[	SYM
dpc-3325	83	2	13	13	NUM
dpc-3325	83	3	-	-	SYM
dpc-3325	83	4	27	27	NUM
dpc-3325	83	5	]	]	PUNCT
dpc-3325	83	6	,	,	PUNCT
dpc-3325	83	7	p	p	X
dpc-3325	83	8	=	=	NOUN
dpc-3325	83	9	0.04	0.04	NUM
dpc-3325	83	10	)	)	PUNCT
dpc-3325	83	11	.	.	PUNCT
dpc-3325	84	1	there	there	PRON
dpc-3325	84	2	was	be	VERB
dpc-3325	84	3	no	no	DET
dpc-3325	84	4	significant	significant	ADJ
dpc-3325	84	5	difference	difference	NOUN
dpc-3325	84	6	between	between	ADP
dpc-3325	84	7	the	the	DET
dpc-3325	84	8	quality	quality	NOUN
dpc-3325	84	9	-	-	PUNCT
dpc-3325	84	10	of	of	ADP
dpc-3325	84	11	-	-	PUNCT
dpc-3325	84	12	life	life	NOUN
dpc-3325	84	13	scores	score	NOUN
dpc-3325	84	14	in	in	ADP
dpc-3325	84	15	both	both	DET
dpc-3325	84	16	groups	group	NOUN
dpc-3325	84	17	(	(	PUNCT
dpc-3325	84	18	table	table	NOUN
dpc-3325	84	19	1	1	NUM
dpc-3325	84	20	)	)	PUNCT
dpc-3325	84	21	.	.	PUNCT
dpc-3325	85	1	in	in	ADP
dpc-3325	85	2	the	the	DET
dpc-3325	85	3	comparison	comparison	NOUN
dpc-3325	85	4	of	of	ADP
dpc-3325	85	5	the	the	DET
dpc-3325	85	6	csu	csu	PROPN
dpc-3325	85	7	and	and	CCONJ
dpc-3325	85	8	control	control	NOUN
dpc-3325	85	9	groups	group	NOUN
dpc-3325	85	10	;	;	PUNCT
dpc-3325	85	11	crp	crp	PROPN
dpc-3325	85	12	,	,	PUNCT
dpc-3325	85	13	esr	esr	PROPN
dpc-3325	85	14	,	,	PUNCT
dpc-3325	85	15	d	d	NOUN
dpc-3325	85	16	-	-	PUNCT
dpc-3325	85	17	dimer	dimer	ADJ
dpc-3325	85	18	,	,	PUNCT
dpc-3325	85	19	and	and	CCONJ
dpc-3325	85	20	total	total	ADJ
dpc-3325	85	21	ige	ige	PROPN
dpc-3325	85	22	levels	level	NOUN
dpc-3325	85	23	were	be	AUX
dpc-3325	85	24	higher	high	ADJ
dpc-3325	85	25	in	in	ADP
dpc-3325	85	26	csu	csu	PROPN
dpc-3325	85	27	patients	patient	NOUN
dpc-3325	85	28	(	(	PUNCT
dpc-3325	85	29	n=78	n=78	NOUN
dpc-3325	85	30	)	)	PUNCT
dpc-3325	85	31	compared	compare	VERB
dpc-3325	85	32	to	to	ADP
dpc-3325	85	33	the	the	DET
dpc-3325	85	34	control	control	NOUN
dpc-3325	85	35	group	group	NOUN
dpc-3325	85	36	(	(	PUNCT
dpc-3325	85	37	n	n	NOUN
dpc-3325	85	38	=	=	SYM
dpc-3325	85	39	18	18	NUM
dpc-3325	85	40	)	)	PUNCT
dpc-3325	85	41	figure	figure	NOUN
dpc-3325	85	42	1	1	NUM
dpc-3325	85	43	.	.	PUNCT
dpc-3325	85	44	comparison	comparison	NOUN
dpc-3325	85	45	of	of	ADP
dpc-3325	85	46	biomarker	biomarker	NOUN
dpc-3325	85	47	levels	level	NOUN
dpc-3325	85	48	in	in	ADP
dpc-3325	85	49	chronic	chronic	ADJ
dpc-3325	85	50	spontaneous	spontaneous	ADJ
dpc-3325	85	51	urticaria	urticaria	NOUN
dpc-3325	85	52	and	and	CCONJ
dpc-3325	85	53	control	control	NOUN
dpc-3325	85	54	groups	group	NOUN
dpc-3325	85	55	csu	csu	NOUN
dpc-3325	85	56	=	=	SYM
dpc-3325	85	57	chronic	chronic	ADJ
dpc-3325	85	58	spontaneous	spontaneous	ADJ
dpc-3325	85	59	urticaria	urticaria	NOUN
dpc-3325	85	60	;	;	PUNCT
dpc-3325	85	61	oma	oma	PROPN
dpc-3325	85	62	=	=	PUNCT
dpc-3325	85	63	omalizumab	omalizumab	NOUN
dpc-3325	85	64	;	;	PUNCT
dpc-3325	85	65	ns	ns	NUM
dpc-3325	85	66	=	=	PROPN
dpc-3325	85	67	non	non	ADJ
dpc-3325	85	68	-	-	ADJ
dpc-3325	85	69	significant	significant	ADJ
dpc-3325	85	70	.	.	PUNCT
dpc-3325	86	1	original	original	ADJ
dpc-3325	86	2	article	article	NOUN
dpc-3325	86	3	|	|	ADV
dpc-3325	86	4	dermatol	dermatol	ADJ
dpc-3325	86	5	pract	pract	NOUN
dpc-3325	86	6	concept	concept	NOUN
dpc-3325	86	7	.	.	PUNCT
dpc-3325	87	1	2023;13(4):e2023272	2023;13(4):e2023272	NUM
dpc-3325	87	2	5	5	NUM
dpc-3325	87	3	table	table	NOUN
dpc-3325	87	4	2	2	NUM
dpc-3325	87	5	.	.	PUNCT
dpc-3325	87	6	comparisons	comparison	NOUN
dpc-3325	87	7	of	of	ADP
dpc-3325	87	8	biomarker	biomarker	NOUN
dpc-3325	87	9	profile	profile	NOUN
dpc-3325	87	10	by	by	ADP
dpc-3325	87	11	omalizumab	omalizumab	NOUN
dpc-3325	87	12	status	status	NOUN
dpc-3325	87	13	and	and	CCONJ
dpc-3325	87	14	control	control	NOUN
dpc-3325	87	15	.	.	PUNCT
dpc-3325	88	1	variables	variable	NOUN
dpc-3325	88	2	*	*	VERB
dpc-3325	88	3	csu	csu	PROPN
dpc-3325	88	4	/	/	SYM
dpc-3325	88	5	oma	oma	PROPN
dpc-3325	88	6	(	(	PUNCT
dpc-3325	88	7	n	n	NOUN
dpc-3325	88	8	=	=	SYM
dpc-3325	88	9	42	42	NUM
dpc-3325	88	10	)	)	PUNCT
dpc-3325	88	11	csu	csu	PROPN
dpc-3325	88	12	/	/	SYM
dpc-3325	88	13	non	non	ADJ
dpc-3325	88	14	-	-	ADJ
dpc-3325	88	15	oma	oma	ADJ
dpc-3325	88	16	(	(	PUNCT
dpc-3325	88	17	n	n	NOUN
dpc-3325	88	18	=	=	SYM
dpc-3325	88	19	36	36	NUM
dpc-3325	88	20	)	)	PUNCT
dpc-3325	88	21	control	control	NOUN
dpc-3325	88	22	(	(	PUNCT
dpc-3325	88	23	n	n	NOUN
dpc-3325	88	24	=	=	SYM
dpc-3325	88	25	18	18	NUM
dpc-3325	88	26	)	)	PUNCT
dpc-3325	88	27	pa	pa	PROPN
dpc-3325	88	28	pb	pb	ADP
dpc-3325	88	29	oma	oma	PROPN
dpc-3325	88	30	vs	vs	ADP
dpc-3325	88	31	control	control	PROPN
dpc-3325	88	32	non	non	PROPN
dpc-3325	88	33	-	-	NOUN
dpc-3325	88	34	oma	oma	ADJ
dpc-3325	88	35	vs	vs	ADP
dpc-3325	88	36	control	control	PROPN
dpc-3325	88	37	oma	oma	PROPN
dpc-3325	88	38	vs	vs	ADP
dpc-3325	88	39	non	non	ADJ
dpc-3325	88	40	-	-	ADJ
dpc-3325	88	41	oma	oma	ADJ
dpc-3325	88	42	age	age	NOUN
dpc-3325	88	43	,	,	PUNCT
dpc-3325	88	44	years	year	NOUN
dpc-3325	88	45	female	female	ADJ
dpc-3325	88	46	gender	gender	NOUN
dpc-3325	88	47	,	,	PUNCT
dpc-3325	88	48	n	n	CCONJ
dpc-3325	88	49	(	(	PUNCT
dpc-3325	88	50	%	%	INTJ
dpc-3325	88	51	)	)	PUNCT
dpc-3325	88	52	eosinophils	eosinophil	NOUN
dpc-3325	88	53	,	,	PUNCT
dpc-3325	88	54	cells	cell	NOUN
dpc-3325	88	55	/	/	SYM
dpc-3325	88	56	μl	μl	NUM
dpc-3325	88	57	eosinophils	eosinophil	NOUN
dpc-3325	88	58	,	,	PUNCT
dpc-3325	88	59	%	%	NOUN
dpc-3325	88	60	d	d	X
dpc-3325	88	61	-	-	PUNCT
dpc-3325	88	62	dimer	dimer	ADJ
dpc-3325	88	63	,	,	PUNCT
dpc-3325	88	64	µg	µg	ADJ
dpc-3325	88	65	/	/	SYM
dpc-3325	88	66	ml	ml	PROPN
dpc-3325	88	67	total	total	ADJ
dpc-3325	88	68	ige	ige	PROPN
dpc-3325	88	69	,	,	PUNCT
dpc-3325	88	70	iu	iu	ADJ
dpc-3325	88	71	/	/	SYM
dpc-3325	88	72	ml	ml	X
dpc-3325	88	73	esr	esr	PROPN
dpc-3325	88	74	,	,	PUNCT
dpc-3325	88	75	mm	mm	PROPN
dpc-3325	88	76	/	/	SYM
dpc-3325	88	77	h	h	PROPN
dpc-3325	88	78	crp	crp	PROPN
dpc-3325	88	79	,	,	PUNCT
dpc-3325	88	80	mg	mg	PROPN
dpc-3325	88	81	/	/	SYM
dpc-3325	88	82	l	l	NOUN
dpc-3325	88	83	eotaxin	eotaxin	PROPN
dpc-3325	88	84	,	,	PUNCT
dpc-3325	88	85	pg	pg	NOUN
dpc-3325	88	86	/	/	SYM
dpc-3325	88	87	ml	ml	ADP
dpc-3325	88	88	il-6	il-6	NOUN
dpc-3325	88	89	,	,	PUNCT
dpc-3325	88	90	pg	pg	VERB
dpc-3325	88	91	/	/	SYM
dpc-3325	88	92	ml	ml	VERB
dpc-3325	88	93	tslp	tslp	VERB
dpc-3325	88	94	,	,	PUNCT
dpc-3325	88	95	pg	pg	INTJ
dpc-3325	88	96	/	/	SYM
dpc-3325	88	97	ml	ml	NOUN
dpc-3325	88	98	rantes	rante	NOUN
dpc-3325	88	99	,	,	PUNCT
dpc-3325	88	100	pg	pg	PROPN
dpc-3325	88	101	/	/	SYM
dpc-3325	88	102	ml	ml	ADP
dpc-3325	88	103	tnf	tnf	PROPN
dpc-3325	88	104	-	-	PUNCT
dpc-3325	88	105	α	α	PROPN
dpc-3325	88	106	,	,	PUNCT
dpc-3325	88	107	pg	pg	NOUN
dpc-3325	88	108	/	/	SYM
dpc-3325	88	109	ml	ml	NOUN
dpc-3325	88	110	il-17	il-17	ADV
dpc-3325	88	111	,	,	PUNCT
dpc-3325	88	112	pg	pg	VERB
dpc-3325	88	113	/	/	SYM
dpc-3325	88	114	ml	ml	NOUN
dpc-3325	88	115	il-31	il-31	PRON
dpc-3325	88	116	,	,	PUNCT
dpc-3325	88	117	pg	pg	PROPN
dpc-3325	88	118	/	/	SYM
dpc-3325	88	119	ml	ml	PROPN
dpc-3325	88	120	42.4	42.4	NUM
dpc-3325	88	121	±	±	NUM
dpc-3325	88	122	13.7	13.7	NUM
dpc-3325	88	123	33	33	NUM
dpc-3325	88	124	(	(	PUNCT
dpc-3325	88	125	78.6	78.6	NUM
dpc-3325	88	126	)	)	PUNCT
dpc-3325	88	127	100	100	NUM
dpc-3325	88	128	(	(	PUNCT
dpc-3325	88	129	100	100	NUM
dpc-3325	88	130	-	-	NUM
dpc-3325	88	131	215	215	NUM
dpc-3325	88	132	)	)	PUNCT
dpc-3325	88	133	1.60	1.60	NUM
dpc-3325	88	134	(	(	PUNCT
dpc-3325	88	135	0.82	0.82	NUM
dpc-3325	88	136	-	-	SYM
dpc-3325	88	137	2.62	2.62	NUM
dpc-3325	88	138	)	)	PUNCT
dpc-3325	88	139	0.35	0.35	NUM
dpc-3325	88	140	(	(	PUNCT
dpc-3325	88	141	0.24	0.24	NUM
dpc-3325	88	142	-	-	SYM
dpc-3325	88	143	0.51	0.51	NUM
dpc-3325	88	144	)	)	PUNCT
dpc-3325	88	145	232	232	NUM
dpc-3325	88	146	(	(	PUNCT
dpc-3325	88	147	87.1	87.1	NUM
dpc-3325	88	148	-	-	NUM
dpc-3325	88	149	358	358	NUM
dpc-3325	88	150	)	)	PUNCT
dpc-3325	88	151	10.5	10.5	NUM
dpc-3325	88	152	(	(	PUNCT
dpc-3325	88	153	6	6	NUM
dpc-3325	88	154	-	-	SYM
dpc-3325	88	155	20	20	NUM
dpc-3325	88	156	)	)	PUNCT
dpc-3325	88	157	0.43	0.43	NUM
dpc-3325	88	158	(	(	PUNCT
dpc-3325	88	159	0,29	0,29	NOUN
dpc-3325	88	160	-	-	PUNCT
dpc-3325	88	161	0.7	0.7	NUM
dpc-3325	88	162	)	)	PUNCT
dpc-3325	88	163	36.2	36.2	NUM
dpc-3325	88	164	(	(	PUNCT
dpc-3325	88	165	25.1	25.1	NUM
dpc-3325	88	166	-	-	NUM
dpc-3325	88	167	54.5	54.5	NUM
dpc-3325	88	168	)	)	PUNCT
dpc-3325	88	169	1.44	1.44	NUM
dpc-3325	88	170	(	(	PUNCT
dpc-3325	88	171	0.82	0.82	NUM
dpc-3325	88	172	-	-	SYM
dpc-3325	88	173	2.76	2.76	NUM
dpc-3325	88	174	)	)	PUNCT
dpc-3325	88	175	27.8	27.8	NUM
dpc-3325	88	176	(	(	PUNCT
dpc-3325	88	177	0.72	0.72	NUM
dpc-3325	88	178	-	-	SYM
dpc-3325	88	179	582.9	582.9	NUM
dpc-3325	88	180	)	)	PUNCT
dpc-3325	88	181	3548	3548	NUM
dpc-3325	88	182	(	(	PUNCT
dpc-3325	88	183	3108	3108	NUM
dpc-3325	88	184	-	-	SYM
dpc-3325	88	185	4003	4003	NUM
dpc-3325	88	186	)	)	PUNCT
dpc-3325	88	187	35.1	35.1	NUM
dpc-3325	88	188	(	(	PUNCT
dpc-3325	88	189	0.29	0.29	NUM
dpc-3325	88	190	-	-	SYM
dpc-3325	88	191	605.3	605.3	NUM
dpc-3325	88	192	)	)	PUNCT
dpc-3325	88	193	58.6	58.6	NUM
dpc-3325	88	194	(	(	PUNCT
dpc-3325	88	195	1.75	1.75	NUM
dpc-3325	88	196	-	-	SYM
dpc-3325	88	197	263.8	263.8	NUM
dpc-3325	88	198	)	)	PUNCT
dpc-3325	88	199	632.2	632.2	NUM
dpc-3325	88	200	(	(	PUNCT
dpc-3325	88	201	100.8	100.8	NUM
dpc-3325	88	202	-	-	PUNCT
dpc-3325	88	203	2498	2498	NUM
dpc-3325	88	204	)	)	PUNCT
dpc-3325	88	205	38.5	38.5	NUM
dpc-3325	88	206	±	±	NUM
dpc-3325	88	207	11.9	11.9	NUM
dpc-3325	88	208	24	24	NUM
dpc-3325	88	209	(	(	PUNCT
dpc-3325	88	210	66.7	66.7	NUM
dpc-3325	88	211	)	)	PUNCT
dpc-3325	88	212	100	100	NUM
dpc-3325	88	213	(	(	PUNCT
dpc-3325	88	214	100	100	NUM
dpc-3325	88	215	-	-	SYM
dpc-3325	88	216	200	200	NUM
dpc-3325	88	217	)	)	PUNCT
dpc-3325	88	218	1.55	1.55	NUM
dpc-3325	88	219	(	(	PUNCT
dpc-3325	88	220	1.02	1.02	NUM
dpc-3325	88	221	-	-	SYM
dpc-3325	88	222	2.67	2.67	NUM
dpc-3325	88	223	)	)	PUNCT
dpc-3325	88	224	0.41	0.41	NUM
dpc-3325	88	225	(	(	PUNCT
dpc-3325	88	226	0.23	0.23	NUM
dpc-3325	88	227	-	-	PUNCT
dpc-3325	88	228	0.69	0.69	NUM
dpc-3325	88	229	)	)	PUNCT
dpc-3325	88	230	105	105	NUM
dpc-3325	88	231	(	(	PUNCT
dpc-3325	88	232	37.4	37.4	NUM
dpc-3325	88	233	-	-	SYM
dpc-3325	88	234	248	248	NUM
dpc-3325	88	235	)	)	PUNCT
dpc-3325	88	236	10	10	NUM
dpc-3325	88	237	(	(	PUNCT
dpc-3325	88	238	4	4	NUM
dpc-3325	88	239	-	-	SYM
dpc-3325	88	240	15	15	NUM
dpc-3325	88	241	)	)	PUNCT
dpc-3325	88	242	0.54	0.54	NUM
dpc-3325	88	243	(	(	PUNCT
dpc-3325	88	244	0.27	0.27	NUM
dpc-3325	88	245	-	-	SYM
dpc-3325	88	246	1.03	1.03	NUM
dpc-3325	88	247	)	)	PUNCT
dpc-3325	88	248	35.7	35.7	NUM
dpc-3325	88	249	(	(	PUNCT
dpc-3325	88	250	19.4	19.4	NUM
dpc-3325	88	251	-	-	SYM
dpc-3325	88	252	50.5	50.5	NUM
dpc-3325	88	253	)	)	PUNCT
dpc-3325	88	254	1.37	1.37	NUM
dpc-3325	88	255	(	(	PUNCT
dpc-3325	88	256	0.90	0.90	NUM
dpc-3325	88	257	-	-	SYM
dpc-3325	88	258	3.93	3.93	NUM
dpc-3325	88	259	)	)	PUNCT
dpc-3325	88	260	12.2	12.2	NUM
dpc-3325	88	261	(	(	PUNCT
dpc-3325	88	262	0.32149.3	0.32149.3	NOUN
dpc-3325	88	263	)	)	PUNCT
dpc-3325	88	264	3483	3483	NUM
dpc-3325	88	265	(	(	PUNCT
dpc-3325	88	266	2950	2950	NUM
dpc-3325	88	267	-	-	SYM
dpc-3325	88	268	3894	3894	NUM
dpc-3325	88	269	)	)	PUNCT
dpc-3325	88	270	156.7	156.7	NUM
dpc-3325	88	271	(	(	PUNCT
dpc-3325	88	272	33.08	33.08	NUM
dpc-3325	88	273	-	-	SYM
dpc-3325	88	274	392	392	NUM
dpc-3325	88	275	)	)	PUNCT
dpc-3325	88	276	47.7	47.7	NUM
dpc-3325	88	277	(	(	PUNCT
dpc-3325	88	278	8.2	8.2	NUM
dpc-3325	88	279	-	-	SYM
dpc-3325	88	280	268.8	268.8	NUM
dpc-3325	88	281	)	)	PUNCT
dpc-3325	88	282	743.2	743.2	NUM
dpc-3325	88	283	(	(	PUNCT
dpc-3325	88	284	121.3	121.3	NUM
dpc-3325	88	285	-	-	SYM
dpc-3325	88	286	3447	3447	NUM
dpc-3325	88	287	)	)	PUNCT
dpc-3325	88	288	38	38	NUM
dpc-3325	88	289	(	(	PUNCT
dpc-3325	88	290	30	30	NUM
dpc-3325	88	291	-	-	SYM
dpc-3325	88	292	47	47	NUM
dpc-3325	88	293	)	)	PUNCT
dpc-3325	88	294	38	38	NUM
dpc-3325	88	295	(	(	PUNCT
dpc-3325	88	296	30	30	NUM
dpc-3325	88	297	-	-	SYM
dpc-3325	88	298	47	47	NUM
dpc-3325	88	299	)	)	PUNCT
dpc-3325	88	300	115	115	NUM
dpc-3325	88	301	(	(	PUNCT
dpc-3325	88	302	100	100	NUM
dpc-3325	88	303	-	-	SYM
dpc-3325	88	304	200	200	NUM
dpc-3325	88	305	)	)	PUNCT
dpc-3325	88	306	1.5	1.5	NUM
dpc-3325	88	307	(	(	PUNCT
dpc-3325	88	308	1.2	1.2	NUM
dpc-3325	88	309	-	-	SYM
dpc-3325	88	310	2.6	2.6	NUM
dpc-3325	88	311	)	)	PUNCT
dpc-3325	88	312	0.24	0.24	NUM
dpc-3325	88	313	(	(	PUNCT
dpc-3325	88	314	0.19	0.19	NUM
dpc-3325	88	315	-	-	SYM
dpc-3325	88	316	0.38	0.38	NUM
dpc-3325	88	317	)	)	PUNCT
dpc-3325	88	318	23.6	23.6	NUM
dpc-3325	88	319	(	(	PUNCT
dpc-3325	88	320	11.9	11.9	NUM
dpc-3325	88	321	-	-	SYM
dpc-3325	88	322	50.6	50.6	NUM
dpc-3325	88	323	)	)	PUNCT
dpc-3325	88	324	3	3	NUM
dpc-3325	88	325	(	(	PUNCT
dpc-3325	88	326	2	2	NUM
dpc-3325	88	327	-	-	SYM
dpc-3325	88	328	6	6	NUM
dpc-3325	88	329	)	)	PUNCT
dpc-3325	88	330	0.20	0.20	NUM
dpc-3325	88	331	(	(	PUNCT
dpc-3325	88	332	0.11	0.11	NUM
dpc-3325	88	333	-	-	NUM
dpc-3325	88	334	0.37	0.37	NUM
dpc-3325	88	335	)	)	PUNCT
dpc-3325	88	336	24.8	24.8	NUM
dpc-3325	88	337	(	(	PUNCT
dpc-3325	88	338	17	17	NUM
dpc-3325	88	339	-	-	SYM
dpc-3325	88	340	46.5	46.5	NUM
dpc-3325	88	341	)	)	PUNCT
dpc-3325	88	342	1.0	1.0	NUM
dpc-3325	88	343	(	(	PUNCT
dpc-3325	88	344	0.7	0.7	NUM
dpc-3325	88	345	-	-	SYM
dpc-3325	88	346	1.6	1.6	NUM
dpc-3325	88	347	)	)	PUNCT
dpc-3325	88	348	93.6	93.6	NUM
dpc-3325	88	349	(	(	PUNCT
dpc-3325	88	350	6.5	6.5	NUM
dpc-3325	88	351	-	-	SYM
dpc-3325	88	352	793.0	793.0	NUM
dpc-3325	88	353	)	)	PUNCT
dpc-3325	88	354	664.4	664.4	NUM
dpc-3325	88	355	(	(	PUNCT
dpc-3325	88	356	640	640	NUM
dpc-3325	88	357	-	-	NUM
dpc-3325	88	358	743	743	NUM
dpc-3325	88	359	)	)	PUNCT
dpc-3325	88	360	1.8	1.8	NUM
dpc-3325	88	361	(	(	PUNCT
dpc-3325	88	362	1.5	1.5	NUM
dpc-3325	88	363	-	-	SYM
dpc-3325	88	364	2.91	2.91	NUM
dpc-3325	88	365	)	)	PUNCT
dpc-3325	88	366	100	100	NUM
dpc-3325	88	367	(	(	PUNCT
dpc-3325	88	368	15.8	15.8	NUM
dpc-3325	88	369	-	-	NUM
dpc-3325	88	370	639	639	NUM
dpc-3325	88	371	)	)	PUNCT
dpc-3325	88	372	213.1	213.1	NUM
dpc-3325	88	373	(	(	PUNCT
dpc-3325	88	374	9	9	NUM
dpc-3325	88	375	-	-	SYM
dpc-3325	88	376	633.6	633.6	NUM
dpc-3325	88	377	)	)	PUNCT
dpc-3325	88	378	ns	ns	NUM
dpc-3325	88	379	ns	ns	NUM
dpc-3325	88	380	ns	ns	NUM
dpc-3325	89	1	ns	ns	NUM
dpc-3325	90	1	ns	ns	NUM
dpc-3325	90	2	<	<	PROPN
dpc-3325	90	3	0.01	0.01	NUM
dpc-3325	90	4	0.01	0.01	NUM
dpc-3325	90	5	0.01	0.01	NUM
dpc-3325	90	6	ns	ns	NUM
dpc-3325	90	7	ns	ns	NUM
dpc-3325	91	1	ns	ns	NUM
dpc-3325	91	2	<	<	PROPN
dpc-3325	91	3	0.01	0.01	NUM
dpc-3325	91	4	0.016	0.016	NUM
dpc-3325	91	5	ns	ns	NUM
dpc-3325	91	6	ns	ns	NUM
dpc-3325	91	7	ns	ns	NUM
dpc-3325	91	8	ns	ns	NUM
dpc-3325	91	9	ns	ns	NUM
dpc-3325	91	10	ns	ns	NUM
dpc-3325	91	11	ns	ns	PROPN
dpc-3325	91	12	<	<	PROPN
dpc-3325	91	13	0.01	0.01	NUM
dpc-3325	91	14	ns	ns	NUM
dpc-3325	91	15	<	<	PROPN
dpc-3325	91	16	0.01	0.01	NUM
dpc-3325	91	17	ns	ns	NUM
dpc-3325	91	18	ns	ns	NUM
dpc-3325	92	1	ns	ns	NUM
dpc-3325	92	2	<	<	X
dpc-3325	92	3	0.01	0.01	NUM
dpc-3325	92	4	<	<	NOUN
dpc-3325	92	5	0.01	0.01	NUM
dpc-3325	92	6	ns	ns	NUM
dpc-3325	92	7	ns	ns	NUM
dpc-3325	92	8	ns	ns	NUM
dpc-3325	92	9	ns	ns	NUM
dpc-3325	92	10	ns	ns	NUM
dpc-3325	92	11	ns	ns	NUM
dpc-3325	92	12	ns	ns	NUM
dpc-3325	92	13	ns	ns	NUM
dpc-3325	92	14	ns	ns	NUM
dpc-3325	92	15	ns	ns	NUM
dpc-3325	92	16	ns	ns	NUM
dpc-3325	92	17	ns	ns	NUM
dpc-3325	92	18	ns	ns	NUM
dpc-3325	92	19	ns	ns	NUM
dpc-3325	92	20	ns	ns	NUM
dpc-3325	92	21	ns	ns	NUM
dpc-3325	92	22	ns	ns	NUM
dpc-3325	92	23	0.37	0.37	NUM
dpc-3325	92	24	0.43	0.43	NUM
dpc-3325	92	25	0.88	0.88	NUM
dpc-3325	92	26	0.96	0.96	NUM
dpc-3325	92	27	0.05	0.05	NUM
dpc-3325	92	28	<	<	X
dpc-3325	92	29	0.01	0.01	NUM
dpc-3325	92	30	0.015	0.015	NUM
dpc-3325	92	31	<	<	X
dpc-3325	92	32	0.01	0.01	NUM
dpc-3325	92	33	0.37	0.37	NUM
dpc-3325	92	34	0.41	0.41	NUM
dpc-3325	92	35	0.41	0.41	NUM
dpc-3325	92	36	<	<	NOUN
dpc-3325	92	37	0.01	0.01	NUM
dpc-3325	92	38	<	<	X
dpc-3325	92	39	0.01	0.01	NUM
dpc-3325	92	40	0.31	0.31	NUM
dpc-3325	92	41	0.21	0.21	NUM
dpc-3325	92	42	was	be	AUX
dpc-3325	92	43	observed	observe	VERB
dpc-3325	92	44	only	only	ADV
dpc-3325	92	45	between	between	ADP
dpc-3325	92	46	the	the	DET
dpc-3325	92	47	csu	csu	NOUN
dpc-3325	92	48	-	-	PUNCT
dpc-3325	92	49	receiving	receive	VERB
dpc-3325	92	50	omalizumab	omalizumab	NOUN
dpc-3325	92	51	group	group	NOUN
dpc-3325	92	52	and	and	CCONJ
dpc-3325	92	53	the	the	DET
dpc-3325	92	54	control	control	NOUN
dpc-3325	92	55	group	group	NOUN
dpc-3325	92	56	(	(	PUNCT
dpc-3325	92	57	csu	csu	PROPN
dpc-3325	92	58	/	/	SYM
dpc-3325	92	59	oma	oma	PROPN
dpc-3325	92	60	versus	versus	ADP
dpc-3325	92	61	control	control	PROPN
dpc-3325	92	62	,	,	PUNCT
dpc-3325	92	63	p	p	X
dpc-3325	92	64	=	=	NOUN
dpc-3325	92	65	0.01	0.01	NUM
dpc-3325	92	66	)	)	PUNCT
dpc-3325	92	67	.	.	PUNCT
dpc-3325	93	1	d	d	X
dpc-3325	93	2	-	-	PUNCT
dpc-3325	93	3	dimer	dimer	ADJ
dpc-3325	93	4	levels	level	NOUN
dpc-3325	93	5	between	between	ADP
dpc-3325	93	6	patients	patient	NOUN
dpc-3325	93	7	and	and	CCONJ
dpc-3325	93	8	healthy	healthy	ADJ
dpc-3325	93	9	controls	control	NOUN
dpc-3325	93	10	were	be	AUX
dpc-3325	93	11	higher	high	ADJ
dpc-3325	93	12	in	in	ADP
dpc-3325	93	13	the	the	DET
dpc-3325	93	14	total	total	ADJ
dpc-3325	93	15	csu	csu	PROPN
dpc-3325	93	16	group	group	NOUN
dpc-3325	93	17	(	(	PUNCT
dpc-3325	93	18	p	p	X
dpc-3325	93	19	=	=	NOUN
dpc-3325	93	20	0.02	0.02	NUM
dpc-3325	93	21	)	)	PUNCT
dpc-3325	93	22	;	;	PUNCT
dpc-3325	93	23	however	however	ADV
dpc-3325	93	24	,	,	PUNCT
dpc-3325	93	25	this	this	PRON
dpc-3325	93	26	did	do	AUX
dpc-3325	93	27	not	not	PART
dpc-3325	93	28	constitute	constitute	VERB
dpc-3325	93	29	as	as	ADP
dpc-3325	93	30	evidence	evidence	NOUN
dpc-3325	93	31	for	for	ADP
dpc-3325	93	32	a	a	DET
dpc-3325	93	33	correlated	correlate	VERB
dpc-3325	93	34	association	association	NOUN
dpc-3325	93	35	and	and	CCONJ
dpc-3325	93	36	lost	lose	VERB
dpc-3325	93	37	significance	significance	NOUN
dpc-3325	93	38	in	in	ADP
dpc-3325	93	39	the	the	DET
dpc-3325	93	40	overall	overall	ADJ
dpc-3325	93	41	comparison	comparison	NOUN
dpc-3325	93	42	of	of	ADP
dpc-3325	93	43	the	the	DET
dpc-3325	93	44	three	three	NUM
dpc-3325	93	45	groups	group	NOUN
dpc-3325	93	46	(	(	PUNCT
dpc-3325	93	47	p	p	X
dpc-3325	93	48	=	=	NOUN
dpc-3325	93	49	0.05	0.05	NUM
dpc-3325	93	50	)	)	PUNCT
dpc-3325	93	51	.	.	PUNCT
dpc-3325	94	1	within	within	ADP
dpc-3325	94	2	the	the	DET
dpc-3325	94	3	csu	csu	PROPN
dpc-3325	94	4	patients	patient	NOUN
dpc-3325	94	5	,	,	PUNCT
dpc-3325	94	6	there	there	PRON
dpc-3325	94	7	was	be	VERB
dpc-3325	94	8	a	a	DET
dpc-3325	94	9	slight	slight	ADJ
dpc-3325	94	10	but	but	CCONJ
dpc-3325	94	11	significant	significant	ADJ
dpc-3325	94	12	correlation	correlation	NOUN
dpc-3325	94	13	between	between	ADP
dpc-3325	94	14	uct	uct	PROPN
dpc-3325	94	15	scores	score	NOUN
dpc-3325	94	16	and	and	CCONJ
dpc-3325	94	17	tnf	tnf	PROPN
dpc-3325	94	18	-	-	PUNCT
dpc-3325	94	19	α	α	PROPN
dpc-3325	94	20	(	(	PUNCT
dpc-3325	94	21	p	p	X
dpc-3325	94	22	=	=	NOUN
dpc-3325	94	23	0.008	0.008	NUM
dpc-3325	94	24	,	,	PUNCT
dpc-3325	94	25	r	r	NOUN
dpc-3325	94	26	=	=	NOUN
dpc-3325	94	27	0.32	0.32	NUM
dpc-3325	94	28	)	)	PUNCT
dpc-3325	94	29	and	and	CCONJ
dpc-3325	94	30	il-17	il-17	NUM
dpc-3325	94	31	(	(	PUNCT
dpc-3325	94	32	p	p	X
dpc-3325	94	33	=	=	PROPN
dpc-3325	94	34	0.06	0.06	NUM
dpc-3325	94	35	,	,	PUNCT
dpc-3325	94	36	r	r	NOUN
dpc-3325	94	37	=	=	SYM
dpc-3325	94	38	0.33	0.33	NUM
dpc-3325	94	39	)	)	PUNCT
dpc-3325	94	40	levels	level	NOUN
dpc-3325	94	41	(	(	PUNCT
dpc-3325	94	42	figure	figure	NOUN
dpc-3325	94	43	2	2	NUM
dpc-3325	94	44	)	)	PUNCT
dpc-3325	94	45	.	.	PUNCT
dpc-3325	95	1	serum	serum	NOUN
dpc-3325	95	2	levels	level	NOUN
dpc-3325	95	3	of	of	ADP
dpc-3325	95	4	il-8	il-8	NOUN
dpc-3325	95	5	,	,	PUNCT
dpc-3325	95	6	il-25	il-25	NOUN
dpc-3325	95	7	,	,	PUNCT
dpc-3325	95	8	il-33	il-33	X
dpc-3325	95	9	,	,	PUNCT
dpc-3325	95	10	and	and	CCONJ
dpc-3325	95	11	gm	gm	PROPN
dpc-3325	95	12	-	-	PUNCT
dpc-3325	95	13	csf	csf	PROPN
dpc-3325	95	14	were	be	AUX
dpc-3325	95	15	also	also	ADV
dpc-3325	95	16	analyzed	analyze	VERB
dpc-3325	95	17	by	by	ADP
dpc-3325	95	18	elisa	elisa	NOUN
dpc-3325	95	19	;	;	PUNCT
dpc-3325	95	20	however	however	ADV
dpc-3325	95	21	,	,	PUNCT
dpc-3325	95	22	their	their	PRON
dpc-3325	95	23	levels	level	NOUN
dpc-3325	95	24	were	be	AUX
dpc-3325	95	25	below	below	ADP
dpc-3325	95	26	the	the	DET
dpc-3325	95	27	detection	detection	NOUN
dpc-3325	95	28	ranges	range	VERB
dpc-3325	95	29	of	of	ADP
dpc-3325	95	30	the	the	DET
dpc-3325	95	31	kits	kit	NOUN
dpc-3325	95	32	.	.	PUNCT
dpc-3325	96	1	il-31	il-31	NOUN
dpc-3325	96	2	 	 	SPACE
dpc-3325	96	3	levels	level	NOUN
dpc-3325	96	4	between	between	ADP
dpc-3325	96	5	the	the	DET
dpc-3325	96	6	groups	group	NOUN
dpc-3325	96	7	that	that	PRON
dpc-3325	96	8	were	be	AUX
dpc-3325	96	9	receiving	receive	VERB
dpc-3325	96	10	and	and	CCONJ
dpc-3325	96	11	not	not	PART
dpc-3325	96	12	receiving	receive	VERB
dpc-3325	96	13	omalizumab	omalizumab	NOUN
dpc-3325	96	14	(	(	PUNCT
dpc-3325	96	15	figure	figure	NOUN
dpc-3325	96	16	1	1	NUM
dpc-3325	96	17	and	and	CCONJ
dpc-3325	96	18	table	table	NOUN
dpc-3325	96	19	2	2	NUM
dpc-3325	96	20	)	)	PUNCT
dpc-3325	96	21	.	.	PUNCT
dpc-3325	97	1	in	in	ADP
dpc-3325	97	2	the	the	DET
dpc-3325	97	3	overall	overall	ADJ
dpc-3325	97	4	comparison	comparison	NOUN
dpc-3325	97	5	of	of	ADP
dpc-3325	97	6	the	the	DET
dpc-3325	97	7	three	three	NUM
dpc-3325	97	8	groups	group	NOUN
dpc-3325	97	9	:	:	PUNCT
dpc-3325	97	10	csu	csu	NOUN
dpc-3325	97	11	-	-	PUNCT
dpc-3325	97	12	receiving	receive	VERB
dpc-3325	97	13	omalizumab	omalizumab	NOUN
dpc-3325	97	14	,	,	PUNCT
dpc-3325	97	15	csu	csu	VERB
dpc-3325	97	16	-	-	PUNCT
dpc-3325	97	17	not	not	PART
dpc-3325	97	18	receiving	receive	VERB
dpc-3325	97	19	omalizumab	omalizumab	NOUN
dpc-3325	97	20	,	,	PUNCT
dpc-3325	97	21	and	and	CCONJ
dpc-3325	97	22	control	control	NOUN
dpc-3325	97	23	groups	group	NOUN
dpc-3325	97	24	,	,	PUNCT
dpc-3325	97	25	total	total	ADJ
dpc-3325	97	26	ige	ige	PROPN
dpc-3325	97	27	,	,	PUNCT
dpc-3325	97	28	esr	esr	PROPN
dpc-3325	97	29	,	,	PUNCT
dpc-3325	97	30	crp	crp	PROPN
dpc-3325	97	31	,	,	PUNCT
dpc-3325	97	32	rantes	rante	NOUN
dpc-3325	97	33	,	,	PUNCT
dpc-3325	97	34	and	and	CCONJ
dpc-3325	97	35	tnf	tnf	PROPN
dpc-3325	97	36	-	-	PUNCT
dpc-3325	97	37	α	α	PROPN
dpc-3325	97	38	were	be	AUX
dpc-3325	97	39	significantly	significantly	ADV
dpc-3325	97	40	different	different	ADJ
dpc-3325	97	41	(	(	PUNCT
dpc-3325	97	42	p	p	X
dpc-3325	97	43	<	<	X
dpc-3325	97	44	0.01	0.01	NUM
dpc-3325	97	45	,	,	PUNCT
dpc-3325	97	46	0.015	0.015	NUM
dpc-3325	97	47	,	,	PUNCT
dpc-3325	97	48	<	<	X
dpc-3325	97	49	0.01	0.01	NUM
dpc-3325	97	50	,	,	PUNCT
dpc-3325	97	51	<	<	X
dpc-3325	97	52	0.01	0.01	NUM
dpc-3325	97	53	and	and	CCONJ
dpc-3325	97	54	<	<	X
dpc-3325	97	55	0.01	0.01	NUM
dpc-3325	97	56	respectively	respectively	ADV
dpc-3325	97	57	)	)	PUNCT
dpc-3325	97	58	.	.	PUNCT
dpc-3325	98	1	total	total	PROPN
dpc-3325	98	2	ige	ige	PROPN
dpc-3325	98	3	,	,	PUNCT
dpc-3325	98	4	crp	crp	PROPN
dpc-3325	98	5	,	,	PUNCT
dpc-3325	98	6	rantes	rante	NOUN
dpc-3325	98	7	,	,	PUNCT
dpc-3325	98	8	and	and	CCONJ
dpc-3325	98	9	tnf	tnf	PROPN
dpc-3325	98	10	-	-	PUNCT
dpc-3325	98	11	α	α	PROPN
dpc-3325	98	12	values	value	NOUN
dpc-3325	98	13	were	be	AUX
dpc-3325	98	14	similar	similar	ADJ
dpc-3325	98	15	between	between	ADP
dpc-3325	98	16	those	those	PRON
dpc-3325	98	17	who	who	PRON
dpc-3325	98	18	received	receive	VERB
dpc-3325	98	19	and	and	CCONJ
dpc-3325	98	20	did	do	AUX
dpc-3325	98	21	not	not	PART
dpc-3325	98	22	receive	receive	VERB
dpc-3325	98	23	omalizumab	omalizumab	NOUN
dpc-3325	98	24	,	,	PUNCT
dpc-3325	98	25	but	but	CCONJ
dpc-3325	98	26	both	both	DET
dpc-3325	98	27	groups	group	NOUN
dpc-3325	98	28	were	be	AUX
dpc-3325	98	29	significantly	significantly	ADV
dpc-3325	98	30	different	different	ADJ
dpc-3325	98	31	from	from	ADP
dpc-3325	98	32	the	the	DET
dpc-3325	98	33	control	control	NOUN
dpc-3325	98	34	group	group	NOUN
dpc-3325	98	35	in	in	ADP
dpc-3325	98	36	terms	term	NOUN
dpc-3325	98	37	of	of	ADP
dpc-3325	98	38	these	these	DET
dpc-3325	98	39	biomarkers	biomarker	NOUN
dpc-3325	98	40	.	.	PUNCT
dpc-3325	99	1	total	total	PROPN
dpc-3325	99	2	ige	ige	PROPN
dpc-3325	99	3	,	,	PUNCT
dpc-3325	99	4	crp	crp	PROPN
dpc-3325	99	5	,	,	PUNCT
dpc-3325	99	6	rantes	rante	NOUN
dpc-3325	99	7	,	,	PUNCT
dpc-3325	99	8	and	and	CCONJ
dpc-3325	99	9	tnf	tnf	PROPN
dpc-3325	99	10	-	-	PUNCT
dpc-3325	99	11	a	a	PROPN
dpc-3325	99	12	were	be	AUX
dpc-3325	99	13	higher	high	ADJ
dpc-3325	99	14	in	in	ADP
dpc-3325	99	15	patients	patient	NOUN
dpc-3325	99	16	receiving	receive	VERB
dpc-3325	99	17	and	and	CCONJ
dpc-3325	99	18	not	not	PART
dpc-3325	99	19	receiving	receive	VERB
dpc-3325	99	20	omalizumab	omalizumab	NOUN
dpc-3325	99	21	compared	compare	VERB
dpc-3325	99	22	to	to	ADP
dpc-3325	99	23	the	the	DET
dpc-3325	99	24	control	control	NOUN
dpc-3325	99	25	group	group	NOUN
dpc-3325	99	26	(	(	PUNCT
dpc-3325	99	27	table	table	NOUN
dpc-3325	99	28	2	2	NUM
dpc-3325	99	29	)	)	PUNCT
dpc-3325	99	30	.	.	PUNCT
dpc-3325	100	1	statistical	statistical	ADJ
dpc-3325	100	2	significance	significance	NOUN
dpc-3325	100	3	in	in	ADP
dpc-3325	100	4	esr	esr	PROPN
dpc-3325	100	5	figure	figure	NOUN
dpc-3325	100	6	2	2	NUM
dpc-3325	100	7	.	.	PUNCT
dpc-3325	100	8	correlation	correlation	NOUN
dpc-3325	100	9	graphs	graph	NOUN
dpc-3325	100	10	between	between	ADP
dpc-3325	100	11	urticaria	urticaria	PROPN
dpc-3325	100	12	control	control	PROPN
dpc-3325	100	13	test	test	NOUN
dpc-3325	100	14	and	and	CCONJ
dpc-3325	100	15	il-17	il-17	ADV
dpc-3325	100	16	/tnf	/tnf	NOUN
dpc-3325	100	17	-	-	PUNCT
dpc-3325	100	18	α	α	NUM
dpc-3325	100	19	levels	level	NOUN
dpc-3325	100	20	.	.	PUNCT
dpc-3325	101	1	*	*	PUNCT
dpc-3325	101	2	categorical	categorical	ADJ
dpc-3325	101	3	variables	variable	NOUN
dpc-3325	101	4	were	be	AUX
dpc-3325	101	5	presented	present	VERB
dpc-3325	101	6	with	with	ADP
dpc-3325	101	7	frequencies	frequency	NOUN
dpc-3325	101	8	and	and	CCONJ
dpc-3325	101	9	percentages	percentage	NOUN
dpc-3325	101	10	(	(	PUNCT
dpc-3325	101	11	%	%	INTJ
dpc-3325	101	12	)	)	PUNCT
dpc-3325	101	13	and	and	CCONJ
dpc-3325	101	14	continuous	continuous	ADJ
dpc-3325	101	15	variables	variable	NOUN
dpc-3325	101	16	as	as	ADP
dpc-3325	101	17	mean	mean	NOUN
dpc-3325	101	18	±	±	NUM
dpc-3325	101	19	standard	standard	ADJ
dpc-3325	101	20	deviation	deviation	NOUN
dpc-3325	101	21	or	or	CCONJ
dpc-3325	101	22	median	median	NOUN
dpc-3325	101	23	(	(	PUNCT
dpc-3325	101	24	iqr	iqr	NOUN
dpc-3325	101	25	)	)	PUNCT
dpc-3325	101	26	.	.	PUNCT
dpc-3325	102	1	csu	csu	PROPN
dpc-3325	102	2	;	;	PUNCT
dpc-3325	102	3	chronic	chronic	ADJ
dpc-3325	102	4	spontaneous	spontaneous	ADJ
dpc-3325	102	5	urticaria	urticaria	NOUN
dpc-3325	102	6	,	,	PUNCT
dpc-3325	102	7	oma	oma	PROPN
dpc-3325	102	8	:	:	PUNCT
dpc-3325	102	9	omalizumab	omalizumab	PROPN
dpc-3325	102	10	pa	pa	PROPN
dpc-3325	102	11	;	;	PUNCT
dpc-3325	102	12	pairwise	pairwise	NOUN
dpc-3325	102	13	comparisons	comparison	NOUN
dpc-3325	102	14	between	between	ADP
dpc-3325	102	15	the	the	DET
dpc-3325	102	16	groups	group	NOUN
dpc-3325	102	17	pb	pb	ADP
dpc-3325	102	18	;	;	PUNCT
dpc-3325	102	19	kruskal	kruskal	PROPN
dpc-3325	102	20	-	-	PUNCT
dpc-3325	102	21	wallis	wallis	PROPN
dpc-3325	102	22	test	test	NOUN
dpc-3325	102	23	for	for	ADP
dpc-3325	102	24	nonparametric	nonparametric	NOUN
dpc-3325	102	25	variables	variable	NOUN
dpc-3325	102	26	for	for	ADP
dpc-3325	102	27	the	the	DET
dpc-3325	102	28	comparison	comparison	NOUN
dpc-3325	102	29	of	of	ADP
dpc-3325	102	30	the	the	DET
dpc-3325	102	31	three	three	NUM
dpc-3325	102	32	groups	group	NOUN
dpc-3325	102	33	c	c	X
dpc-3325	102	34	;	;	PUNCT
dpc-3325	102	35	chi	chi	ADJ
dpc-3325	102	36	-	-	PUNCT
dpc-3325	102	37	square	square	ADJ
dpc-3325	102	38	test	test	NOUN
dpc-3325	102	39	ns	ns	NUM
dpc-3325	102	40	:	:	PUNCT
dpc-3325	102	41	non	non	ADJ
dpc-3325	102	42	-	-	ADJ
dpc-3325	102	43	significant	significant	ADJ
dpc-3325	102	44	6	6	NUM
dpc-3325	102	45	original	original	ADJ
dpc-3325	102	46	article	article	NOUN
dpc-3325	102	47	|	|	ADV
dpc-3325	102	48	dermatol	dermatol	ADJ
dpc-3325	102	49	pract	pract	NOUN
dpc-3325	102	50	concept	concept	NOUN
dpc-3325	102	51	.	.	PUNCT
dpc-3325	103	1	2023;13(4):e2023272	2023;13(4):e2023272	NUM
dpc-3325	103	2	therefore	therefore	ADV
dpc-3325	103	3	,	,	PUNCT
dpc-3325	103	4	pharmacological	pharmacological	ADJ
dpc-3325	103	5	inhibition	inhibition	NOUN
dpc-3325	103	6	of	of	ADP
dpc-3325	103	7	the	the	DET
dpc-3325	103	8	interaction	interaction	NOUN
dpc-3325	103	9	between	between	ADP
dpc-3325	103	10	tslp	tslp	PROPN
dpc-3325	103	11	and	and	CCONJ
dpc-3325	103	12	its	its	PRON
dpc-3325	103	13	receptor	receptor	NOUN
dpc-3325	103	14	or	or	CCONJ
dpc-3325	103	15	antibody	antibody	NOUN
dpc-3325	103	16	-	-	PUNCT
dpc-3325	103	17	mediated	mediate	VERB
dpc-3325	103	18	tslp	tslp	ADJ
dpc-3325	103	19	neutralization	neutralization	NOUN
dpc-3325	103	20	was	be	AUX
dpc-3325	103	21	discussed	discuss	VERB
dpc-3325	103	22	to	to	PART
dpc-3325	103	23	be	be	AUX
dpc-3325	103	24	a	a	DET
dpc-3325	103	25	possible	possible	ADJ
dpc-3325	103	26	option	option	NOUN
dpc-3325	103	27	in	in	ADP
dpc-3325	103	28	the	the	DET
dpc-3325	103	29	treatment	treatment	NOUN
dpc-3325	103	30	of	of	ADP
dpc-3325	103	31	csu	csu	PROPN
dpc-3325	103	32	patients	patient	NOUN
dpc-3325	103	33	[	[	X
dpc-3325	103	34	35	35	NUM
dpc-3325	103	35	]	]	PUNCT
dpc-3325	103	36	.	.	PUNCT
dpc-3325	104	1	however	however	ADV
dpc-3325	104	2	,	,	PUNCT
dpc-3325	104	3	the	the	DET
dpc-3325	104	4	number	number	NOUN
dpc-3325	104	5	of	of	ADP
dpc-3325	104	6	studies	study	NOUN
dpc-3325	104	7	examining	examine	VERB
dpc-3325	104	8	serum	serum	NOUN
dpc-3325	104	9	tslp	tslp	PROPN
dpc-3325	104	10	levels	level	NOUN
dpc-3325	104	11	in	in	ADP
dpc-3325	104	12	csu	csu	PROPN
dpc-3325	104	13	is	be	AUX
dpc-3325	104	14	limited	limited	ADJ
dpc-3325	104	15	.	.	PUNCT
dpc-3325	105	1	metz	metz	PROPN
dpc-3325	105	2	et	et	PROPN
dpc-3325	105	3	al	al	PROPN
dpc-3325	105	4	.	.	PROPN
dpc-3325	105	5	reported	report	VERB
dpc-3325	105	6	no	no	DET
dpc-3325	105	7	significant	significant	ADJ
dpc-3325	105	8	increase	increase	NOUN
dpc-3325	105	9	in	in	ADP
dpc-3325	105	10	tslp	tslp	ADJ
dpc-3325	105	11	levels	level	NOUN
dpc-3325	105	12	in	in	ADP
dpc-3325	105	13	csu	csu	PROPN
dpc-3325	105	14	patients	patient	NOUN
dpc-3325	105	15	[	[	X
dpc-3325	105	16	32	32	NUM
dpc-3325	105	17	]	]	PUNCT
dpc-3325	105	18	.	.	PUNCT
dpc-3325	106	1	in	in	ADP
dpc-3325	106	2	our	our	PRON
dpc-3325	106	3	study	study	NOUN
dpc-3325	106	4	,	,	PUNCT
dpc-3325	106	5	tslp	tslp	PROPN
dpc-3325	106	6	levels	level	NOUN
dpc-3325	106	7	showed	show	VERB
dpc-3325	106	8	variation	variation	NOUN
dpc-3325	106	9	in	in	ADP
dpc-3325	106	10	healthy	healthy	ADJ
dpc-3325	106	11	and	and	CCONJ
dpc-3325	106	12	csu	csu	NOUN
dpc-3325	106	13	samples	sample	NOUN
dpc-3325	106	14	,	,	PUNCT
dpc-3325	106	15	and	and	CCONJ
dpc-3325	106	16	no	no	DET
dpc-3325	106	17	significant	significant	ADJ
dpc-3325	106	18	difference	difference	NOUN
dpc-3325	106	19	was	be	AUX
dpc-3325	106	20	detected	detect	VERB
dpc-3325	106	21	between	between	ADP
dpc-3325	106	22	the	the	DET
dpc-3325	106	23	groups	group	NOUN
dpc-3325	106	24	.	.	PUNCT
dpc-3325	107	1	this	this	PRON
dpc-3325	107	2	suggests	suggest	VERB
dpc-3325	107	3	that	that	SCONJ
dpc-3325	107	4	since	since	SCONJ
dpc-3325	107	5	tslp	tslp	ADJ
dpc-3325	107	6	is	be	AUX
dpc-3325	107	7	a	a	DET
dpc-3325	107	8	more	more	ADV
dpc-3325	107	9	target	target	NOUN
dpc-3325	107	10	-	-	PUNCT
dpc-3325	107	11	oriented	orient	VERB
dpc-3325	107	12	molecule	molecule	NOUN
dpc-3325	107	13	,	,	PUNCT
dpc-3325	107	14	its	its	PRON
dpc-3325	107	15	levels	level	NOUN
dpc-3325	107	16	in	in	ADP
dpc-3325	107	17	csu	csu	PROPN
dpc-3325	107	18	patients	patient	NOUN
dpc-3325	107	19	may	may	AUX
dpc-3325	107	20	be	be	AUX
dpc-3325	107	21	more	more	ADV
dpc-3325	107	22	significant	significant	ADJ
dpc-3325	107	23	in	in	ADP
dpc-3325	107	24	assessing	assess	VERB
dpc-3325	107	25	lesioned	lesione	VERB
dpc-3325	107	26	skin	skin	NOUN
dpc-3325	107	27	rather	rather	ADV
dpc-3325	107	28	than	than	ADP
dpc-3325	107	29	as	as	ADP
dpc-3325	107	30	a	a	DET
dpc-3325	107	31	serum	serum	NOUN
dpc-3325	107	32	biomarker	biomarker	NOUN
dpc-3325	107	33	.	.	PUNCT
dpc-3325	108	1	it	it	PRON
dpc-3325	108	2	has	have	AUX
dpc-3325	108	3	been	be	AUX
dpc-3325	108	4	shown	show	VERB
dpc-3325	108	5	that	that	SCONJ
dpc-3325	108	6	il-31	il-31	ADV
dpc-3325	108	7	,	,	PUNCT
dpc-3325	108	8	mainly	mainly	ADV
dpc-3325	108	9	secreted	secrete	VERB
dpc-3325	108	10	by	by	ADP
dpc-3325	108	11	th2	th2	PROPN
dpc-3325	108	12	cells	cell	NOUN
dpc-3325	108	13	,	,	PUNCT
dpc-3325	108	14	causes	cause	VERB
dpc-3325	108	15	pruritus	pruritus	PROPN
dpc-3325	108	16	by	by	ADP
dpc-3325	108	17	activating	activate	VERB
dpc-3325	108	18	the	the	DET
dpc-3325	108	19	il-31	il-31	ADJ
dpc-3325	108	20	receptor	receptor	NOUN
dpc-3325	108	21	on	on	ADP
dpc-3325	108	22	sensorial	sensorial	ADJ
dpc-3325	108	23	neurons	neuron	NOUN
dpc-3325	108	24	,	,	PUNCT
dpc-3325	108	25	hence	hence	ADV
dpc-3325	108	26	,	,	PUNCT
dpc-3325	108	27	it	it	PRON
dpc-3325	108	28	is	be	AUX
dpc-3325	108	29	thought	think	VERB
dpc-3325	108	30	to	to	PART
dpc-3325	108	31	be	be	AUX
dpc-3325	108	32	an	an	DET
dpc-3325	108	33	important	important	ADJ
dpc-3325	108	34	interleukin	interleukin	NOUN
dpc-3325	108	35	in	in	ADP
dpc-3325	108	36	skin	skin	NOUN
dpc-3325	108	37	-	-	PUNCT
dpc-3325	108	38	related	relate	VERB
dpc-3325	108	39	inflammation	inflammation	NOUN
dpc-3325	108	40	such	such	ADJ
dpc-3325	108	41	as	as	ADP
dpc-3325	108	42	atopic	atopic	NOUN
dpc-3325	108	43	dermatitis	dermatitis	NOUN
dpc-3325	108	44	[	[	X
dpc-3325	108	45	36	36	NUM
dpc-3325	108	46	-	-	SYM
dpc-3325	108	47	38	38	NUM
dpc-3325	108	48	]	]	PUNCT
dpc-3325	108	49	.	.	PUNCT
dpc-3325	109	1	additionally	additionally	ADV
dpc-3325	109	2	,	,	PUNCT
dpc-3325	109	3	studies	study	NOUN
dpc-3325	109	4	have	have	AUX
dpc-3325	109	5	shown	show	VERB
dpc-3325	109	6	that	that	SCONJ
dpc-3325	109	7	anti	anti	ADJ
dpc-3325	109	8	-	-	ADJ
dpc-3325	109	9	il-31	il-31	ADJ
dpc-3325	109	10	treatment	treatment	NOUN
dpc-3325	109	11	significantly	significantly	ADV
dpc-3325	109	12	reduces	reduce	VERB
dpc-3325	109	13	/	/	SYM
dpc-3325	109	14	prevents	prevent	VERB
dpc-3325	109	15	itching	itching	NOUN
dpc-3325	110	1	[	[	X
dpc-3325	110	2	36,39	36,39	ADV
dpc-3325	110	3	-	-	SYM
dpc-3325	110	4	42	42	NUM
dpc-3325	110	5	]	]	PUNCT
dpc-3325	110	6	.	.	PUNCT
dpc-3325	111	1	moreover	moreover	ADV
dpc-3325	111	2	,	,	PUNCT
dpc-3325	111	3	in	in	ADP
dpc-3325	111	4	addition	addition	NOUN
dpc-3325	111	5	to	to	ADP
dpc-3325	111	6	the	the	DET
dpc-3325	111	7	lesioned	lesione	VERB
dpc-3325	111	8	skin	skin	NOUN
dpc-3325	111	9	samples	sample	NOUN
dpc-3325	111	10	of	of	ADP
dpc-3325	111	11	csu	csu	NOUN
dpc-3325	111	12	patients	patient	NOUN
dpc-3325	111	13	,	,	PUNCT
dpc-3325	111	14	high	high	ADJ
dpc-3325	111	15	levels	level	NOUN
dpc-3325	111	16	of	of	ADP
dpc-3325	111	17	il-31	il-31	PUNCT
dpc-3325	111	18	were	be	AUX
dpc-3325	111	19	also	also	ADV
dpc-3325	111	20	detected	detect	VERB
dpc-3325	111	21	in	in	ADP
dpc-3325	111	22	serum	serum	NOUN
dpc-3325	111	23	samples	sample	NOUN
dpc-3325	111	24	[	[	X
dpc-3325	111	25	38,43	38,43	NOUN
dpc-3325	111	26	]	]	PUNCT
dpc-3325	111	27	.	.	PUNCT
dpc-3325	112	1	besides	besides	SCONJ
dpc-3325	112	2	,	,	PUNCT
dpc-3325	112	3	in	in	ADP
dpc-3325	112	4	a	a	DET
dpc-3325	112	5	study	study	NOUN
dpc-3325	112	6	conducted	conduct	VERB
dpc-3325	112	7	with	with	ADP
dpc-3325	112	8	15	15	NUM
dpc-3325	112	9	csu	csu	NOUN
dpc-3325	112	10	patients	patient	NOUN
dpc-3325	112	11	who	who	PRON
dpc-3325	112	12	were	be	AUX
dpc-3325	112	13	highly	highly	ADV
dpc-3325	112	14	responsive	responsive	ADJ
dpc-3325	112	15	to	to	ADP
dpc-3325	112	16	omalizumab	omalizumab	NOUN
dpc-3325	112	17	treatment	treatment	NOUN
dpc-3325	112	18	,	,	PUNCT
dpc-3325	112	19	a	a	DET
dpc-3325	112	20	decrease	decrease	NOUN
dpc-3325	112	21	in	in	ADP
dpc-3325	112	22	il-31	il-31	ADJ
dpc-3325	112	23	levels	level	NOUN
dpc-3325	112	24	was	be	AUX
dpc-3325	112	25	observed	observe	VERB
dpc-3325	112	26	after	after	ADP
dpc-3325	112	27	treatment	treatment	NOUN
dpc-3325	112	28	 	 	SPACE
dpc-3325	113	1	[	[	X
dpc-3325	113	2	40	40	NUM
dpc-3325	113	3	]	]	PUNCT
dpc-3325	113	4	.	.	PUNCT
dpc-3325	114	1	in	in	ADP
dpc-3325	114	2	our	our	PRON
dpc-3325	114	3	current	current	ADJ
dpc-3325	114	4	study	study	NOUN
dpc-3325	114	5	,	,	PUNCT
dpc-3325	114	6	there	there	PRON
dpc-3325	114	7	was	be	VERB
dpc-3325	114	8	a	a	DET
dpc-3325	114	9	tendency	tendency	NOUN
dpc-3325	114	10	for	for	ADP
dpc-3325	114	11	higher	high	ADJ
dpc-3325	114	12	il-31	il-31	ADJ
dpc-3325	114	13	levels	level	NOUN
dpc-3325	114	14	in	in	ADP
dpc-3325	114	15	csu	csu	PROPN
dpc-3325	114	16	patients	patient	NOUN
dpc-3325	114	17	.	.	PUNCT
dpc-3325	115	1	if	if	SCONJ
dpc-3325	115	2	the	the	DET
dpc-3325	115	3	sample	sample	NOUN
dpc-3325	115	4	size	size	NOUN
dpc-3325	115	5	in	in	ADP
dpc-3325	115	6	the	the	DET
dpc-3325	115	7	control	control	NOUN
dpc-3325	115	8	group	group	NOUN
dpc-3325	115	9	was	be	AUX
dpc-3325	115	10	larger	large	ADJ
dpc-3325	115	11	,	,	PUNCT
dpc-3325	115	12	it	it	PRON
dpc-3325	115	13	is	be	AUX
dpc-3325	115	14	believed	believe	VERB
dpc-3325	115	15	that	that	SCONJ
dpc-3325	115	16	the	the	DET
dpc-3325	115	17	il-31	il-31	ADJ
dpc-3325	115	18	levels	level	NOUN
dpc-3325	115	19	between	between	ADP
dpc-3325	115	20	the	the	DET
dpc-3325	115	21	csu	csu	PROPN
dpc-3325	115	22	and	and	CCONJ
dpc-3325	115	23	control	control	NOUN
dpc-3325	115	24	groups	group	NOUN
dpc-3325	115	25	would	would	AUX
dpc-3325	115	26	have	have	AUX
dpc-3325	115	27	reached	reach	VERB
dpc-3325	115	28	a	a	DET
dpc-3325	115	29	significant	significant	ADJ
dpc-3325	115	30	difference	difference	NOUN
dpc-3325	115	31	.	.	PUNCT
dpc-3325	116	1	studies	study	NOUN
dpc-3325	116	2	investigating	investigate	VERB
dpc-3325	116	3	the	the	DET
dpc-3325	116	4	function	function	NOUN
dpc-3325	116	5	of	of	ADP
dpc-3325	116	6	cytokines	cytokine	NOUN
dpc-3325	116	7	in	in	ADP
dpc-3325	116	8	csu	csu	PROPN
dpc-3325	116	9	indicated	indicate	VERB
dpc-3325	116	10	that	that	SCONJ
dpc-3325	116	11	plasma	plasma	NOUN
dpc-3325	116	12	levels	level	NOUN
dpc-3325	116	13	of	of	ADP
dpc-3325	116	14	il-17	il-17	NUM
dpc-3325	116	15	were	be	AUX
dpc-3325	116	16	significantly	significantly	ADV
dpc-3325	116	17	increased	increase	VERB
dpc-3325	116	18	in	in	ADP
dpc-3325	116	19	relation	relation	NOUN
dpc-3325	116	20	to	to	PART
dpc-3325	116	21	disease	disease	NOUN
dpc-3325	116	22	severity	severity	NOUN
dpc-3325	116	23	compared	compare	VERB
dpc-3325	116	24	to	to	ADP
dpc-3325	116	25	the	the	DET
dpc-3325	116	26	control	control	NOUN
dpc-3325	116	27	group	group	NOUN
dpc-3325	117	1	[	[	X
dpc-3325	117	2	6,38,44	6,38,44	NUM
dpc-3325	117	3	]	]	SYM
dpc-3325	117	4	.	.	PUNCT
dpc-3325	118	1	besides	besides	SCONJ
dpc-3325	118	2	,	,	PUNCT
dpc-3325	118	3	there	there	PRON
dpc-3325	118	4	are	be	VERB
dpc-3325	118	5	studies	study	NOUN
dpc-3325	118	6	showing	show	VERB
dpc-3325	118	7	that	that	SCONJ
dpc-3325	118	8	plasma	plasma	NOUN
dpc-3325	118	9	il17	il17	PROPN
dpc-3325	118	10	levels	level	NOUN
dpc-3325	118	11	in	in	ADP
dpc-3325	118	12	csu	csu	PROPN
dpc-3325	118	13	patients	patient	NOUN
dpc-3325	118	14	are	be	AUX
dpc-3325	118	15	similar	similar	ADJ
dpc-3325	118	16	,	,	PUNCT
dpc-3325	118	17	and	and	CCONJ
dpc-3325	118	18	even	even	ADV
dpc-3325	118	19	lower	low	ADJ
dpc-3325	118	20	than	than	ADP
dpc-3325	118	21	,	,	PUNCT
dpc-3325	118	22	healthy	healthy	ADJ
dpc-3325	118	23	controls	control	NOUN
dpc-3325	118	24	[	[	X
dpc-3325	118	25	45	45	NUM
dpc-3325	118	26	]	]	PUNCT
dpc-3325	118	27	.	.	PUNCT
dpc-3325	119	1	previous	previous	ADJ
dpc-3325	119	2	studies	study	NOUN
dpc-3325	119	3	demonstrated	demonstrate	VERB
dpc-3325	119	4	that	that	SCONJ
dpc-3325	119	5	the	the	DET
dpc-3325	119	6	levels	level	NOUN
dpc-3325	119	7	of	of	ADP
dpc-3325	119	8	il-17	il-17	NUM
dpc-3325	119	9	were	be	AUX
dpc-3325	119	10	higher	high	ADJ
dpc-3325	119	11	in	in	ADP
dpc-3325	119	12	autologous	autologous	ADJ
dpc-3325	119	13	serum	serum	NOUN
dpc-3325	119	14	skin	skin	NOUN
dpc-3325	119	15	testing	testing	NOUN
dpc-3325	119	16	-	-	PUNCT
dpc-3325	119	17	positive	positive	ADJ
dpc-3325	119	18	csu	csu	NOUN
dpc-3325	119	19	patients	patient	NOUN
dpc-3325	119	20	[	[	X
dpc-3325	119	21	8	8	NUM
dpc-3325	119	22	]	]	PUNCT
dpc-3325	119	23	.	.	PUNCT
dpc-3325	120	1	in	in	ADP
dpc-3325	120	2	our	our	PRON
dpc-3325	120	3	study	study	NOUN
dpc-3325	120	4	,	,	PUNCT
dpc-3325	120	5	there	there	PRON
dpc-3325	120	6	was	be	VERB
dpc-3325	120	7	no	no	DET
dpc-3325	120	8	difference	difference	NOUN
dpc-3325	120	9	in	in	ADP
dpc-3325	120	10	il-17	il-17	NUM
dpc-3325	120	11	levels	level	NOUN
dpc-3325	120	12	between	between	ADP
dpc-3325	120	13	csu	csu	PROPN
dpc-3325	120	14	and	and	CCONJ
dpc-3325	120	15	control	control	NOUN
dpc-3325	120	16	groups	group	NOUN
dpc-3325	120	17	,	,	PUNCT
dpc-3325	120	18	but	but	CCONJ
dpc-3325	120	19	a	a	DET
dpc-3325	120	20	significant	significant	ADJ
dpc-3325	120	21	correlation	correlation	NOUN
dpc-3325	120	22	was	be	AUX
dpc-3325	120	23	observed	observe	VERB
dpc-3325	120	24	between	between	ADP
dpc-3325	120	25	il-17	il-17	ADV
dpc-3325	120	26	level	level	NOUN
dpc-3325	120	27	and	and	CCONJ
dpc-3325	120	28	urticaria	urticaria	NOUN
dpc-3325	120	29	control	control	PROPN
dpc-3325	120	30	test	test	NOUN
dpc-3325	120	31	among	among	ADP
dpc-3325	120	32	csu	csu	PROPN
dpc-3325	120	33	patients	patient	NOUN
dpc-3325	120	34	,	,	PUNCT
dpc-3325	120	35	which	which	PRON
dpc-3325	120	36	supports	support	VERB
dpc-3325	120	37	previous	previous	ADJ
dpc-3325	120	38	studies	study	NOUN
dpc-3325	120	39	[	[	X
dpc-3325	120	40	8	8	NUM
dpc-3325	120	41	]	]	PUNCT
dpc-3325	120	42	.	.	PUNCT
dpc-3325	121	1	this	this	PRON
dpc-3325	121	2	may	may	AUX
dpc-3325	121	3	be	be	AUX
dpc-3325	121	4	due	due	ADJ
dpc-3325	121	5	to	to	ADP
dpc-3325	121	6	the	the	DET
dpc-3325	121	7	fact	fact	NOUN
dpc-3325	121	8	that	that	SCONJ
dpc-3325	121	9	autologous	autologous	ADJ
dpc-3325	121	10	serum	serum	NOUN
dpc-3325	121	11	skin	skin	NOUN
dpc-3325	121	12	testing	testing	NOUN
dpc-3325	121	13	was	be	AUX
dpc-3325	121	14	not	not	PART
dpc-3325	121	15	performed	perform	VERB
dpc-3325	121	16	in	in	ADP
dpc-3325	121	17	our	our	PRON
dpc-3325	121	18	study	study	NOUN
dpc-3325	121	19	and	and	CCONJ
dpc-3325	121	20	il-17	il-17	NUM
dpc-3325	121	21	levels	level	NOUN
dpc-3325	121	22	were	be	AUX
dpc-3325	121	23	not	not	PART
dpc-3325	121	24	measured	measure	VERB
dpc-3325	121	25	by	by	ADP
dpc-3325	121	26	classifying	classify	VERB
dpc-3325	121	27	accordingly	accordingly	ADV
dpc-3325	121	28	.	.	PUNCT
dpc-3325	122	1	eotaxin	eotaxin	PROPN
dpc-3325	122	2	is	be	AUX
dpc-3325	122	3	a	a	DET
dpc-3325	122	4	potent	potent	ADJ
dpc-3325	122	5	agonist	agonist	NOUN
dpc-3325	122	6	for	for	ADP
dpc-3325	122	7	the	the	DET
dpc-3325	122	8	cysteine	cysteine	NOUN
dpc-3325	122	9	-	-	PUNCT
dpc-3325	122	10	cysteine	cysteine	NOUN
dpc-3325	122	11	(	(	PUNCT
dpc-3325	122	12	cc	cc	NOUN
dpc-3325	122	13	)	)	PUNCT
dpc-3325	122	14	chemokine	chemokine	ADJ
dpc-3325	122	15	receptor-3	receptor-3	PROPN
dpc-3325	122	16	,	,	PUNCT
dpc-3325	122	17	which	which	PRON
dpc-3325	122	18	attracts	attract	VERB
dpc-3325	122	19	eosinophils	eosinophil	NOUN
dpc-3325	122	20	to	to	ADP
dpc-3325	122	21	the	the	DET
dpc-3325	122	22	skin	skin	NOUN
dpc-3325	122	23	,	,	PUNCT
dpc-3325	122	24	thus	thus	ADV
dpc-3325	122	25	suggesting	suggest	VERB
dpc-3325	122	26	its	its	PRON
dpc-3325	122	27	involvement	involvement	NOUN
dpc-3325	122	28	in	in	ADP
dpc-3325	122	29	the	the	DET
dpc-3325	122	30	pathophysiology	pathophysiology	NOUN
dpc-3325	122	31	of	of	ADP
dpc-3325	122	32	csu	csu	PROPN
dpc-3325	122	33	.	.	PUNCT
dpc-3325	123	1	in	in	ADP
dpc-3325	123	2	a	a	DET
dpc-3325	123	3	study	study	NOUN
dpc-3325	123	4	by	by	ADP
dpc-3325	123	5	tedeschi	tedeschi	PROPN
dpc-3325	123	6	et	et	PROPN
dpc-3325	123	7	al	al	PROPN
dpc-3325	123	8	,	,	PUNCT
dpc-3325	123	9	it	it	PRON
dpc-3325	123	10	was	be	AUX
dpc-3325	123	11	indicated	indicate	VERB
dpc-3325	123	12	that	that	SCONJ
dpc-3325	123	13	serum	serum	NOUN
dpc-3325	123	14	eotaxin	eotaxin	PROPN
dpc-3325	123	15	levels	level	NOUN
dpc-3325	123	16	in	in	ADP
dpc-3325	123	17	100	100	NUM
dpc-3325	123	18	csu	csu	NOUN
dpc-3325	123	19	patients	patient	NOUN
dpc-3325	123	20	were	be	AUX
dpc-3325	123	21	slightly	slightly	ADV
dpc-3325	123	22	higher	high	ADJ
dpc-3325	123	23	in	in	ADP
dpc-3325	123	24	chronic	chronic	ADJ
dpc-3325	123	25	urticaria	urticaria	NOUN
dpc-3325	123	26	patients	patient	NOUN
dpc-3325	123	27	and	and	CCONJ
dpc-3325	123	28	were	be	AUX
dpc-3325	123	29	correlated	correlate	VERB
dpc-3325	123	30	with	with	ADP
dpc-3325	123	31	the	the	DET
dpc-3325	123	32	disease	disease	NOUN
dpc-3325	123	33	severity	severity	NOUN
dpc-3325	123	34	.	.	PUNCT
dpc-3325	124	1	in	in	ADP
dpc-3325	124	2	our	our	PRON
dpc-3325	124	3	analysis	analysis	NOUN
dpc-3325	124	4	,	,	PUNCT
dpc-3325	124	5	eotaxin	eotaxin	PROPN
dpc-3325	124	6	levels	level	NOUN
dpc-3325	124	7	were	be	AUX
dpc-3325	124	8	comparable	comparable	ADJ
dpc-3325	124	9	in	in	ADP
dpc-3325	124	10	healthy	healthy	ADJ
dpc-3325	124	11	controls	control	NOUN
dpc-3325	124	12	and	and	CCONJ
dpc-3325	124	13	csu	csu	NOUN
dpc-3325	124	14	patients	patient	NOUN
dpc-3325	124	15	.	.	PUNCT
dpc-3325	125	1	rantes	rante	NOUN
dpc-3325	125	2	promotes	promote	VERB
dpc-3325	125	3	the	the	DET
dpc-3325	125	4	mast	mast	NOUN
dpc-3325	125	5	cell	cell	NOUN
dpc-3325	125	6	progenitors	progenitor	NOUN
dpc-3325	125	7	for	for	ADP
dpc-3325	125	8	differentiation	differentiation	NOUN
dpc-3325	125	9	and	and	CCONJ
dpc-3325	125	10	activation	activation	NOUN
dpc-3325	125	11	,	,	PUNCT
dpc-3325	125	12	thereby	thereby	ADV
dpc-3325	125	13	inducing	induce	VERB
dpc-3325	125	14	the	the	DET
dpc-3325	125	15	histamine	histamine	NOUN
dpc-3325	125	16	release	release	NOUN
dpc-3325	125	17	,	,	PUNCT
dpc-3325	125	18	and	and	CCONJ
dpc-3325	125	19	conclusions	conclusion	NOUN
dpc-3325	125	20	in	in	ADP
dpc-3325	125	21	the	the	DET
dpc-3325	125	22	current	current	ADJ
dpc-3325	125	23	study	study	NOUN
dpc-3325	125	24	,	,	PUNCT
dpc-3325	125	25	the	the	DET
dpc-3325	125	26	biomarker	biomarker	NOUN
dpc-3325	125	27	profile	profile	NOUN
dpc-3325	125	28	in	in	ADP
dpc-3325	125	29	csu	csu	PROPN
dpc-3325	125	30	was	be	AUX
dpc-3325	125	31	investigated	investigate	VERB
dpc-3325	125	32	by	by	ADP
dpc-3325	125	33	comparing	compare	VERB
dpc-3325	125	34	the	the	DET
dpc-3325	125	35	th1	th1	PROPN
dpc-3325	125	36	,	,	PUNCT
dpc-3325	125	37	th2	th2	PROPN
dpc-3325	125	38	,	,	PUNCT
dpc-3325	125	39	and	and	CCONJ
dpc-3325	125	40	th17	th17	PROPN
dpc-3325	125	41	cytokines	cytokine	NOUN
dpc-3325	125	42	,	,	PUNCT
dpc-3325	125	43	which	which	PRON
dpc-3325	125	44	are	be	AUX
dpc-3325	125	45	considered	consider	VERB
dpc-3325	125	46	to	to	PART
dpc-3325	125	47	be	be	AUX
dpc-3325	125	48	valuable	valuable	ADJ
dpc-3325	125	49	in	in	ADP
dpc-3325	125	50	the	the	DET
dpc-3325	125	51	pathogenesis	pathogenesis	NOUN
dpc-3325	125	52	,	,	PUNCT
dpc-3325	125	53	in	in	ADP
dpc-3325	125	54	csu	csu	PROPN
dpc-3325	125	55	patients	patient	NOUN
dpc-3325	125	56	and	and	CCONJ
dpc-3325	125	57	healthy	healthy	ADJ
dpc-3325	125	58	controls	control	NOUN
dpc-3325	125	59	.	.	PUNCT
dpc-3325	126	1	of	of	ADP
dpc-3325	126	2	the	the	DET
dpc-3325	126	3	biomarkers	biomarker	NOUN
dpc-3325	126	4	studied	study	VERB
dpc-3325	126	5	(	(	PUNCT
dpc-3325	126	6	tnf	tnf	PROPN
dpc-3325	126	7	-	-	PUNCT
dpc-3325	126	8	α	α	PROPN
dpc-3325	126	9	,	,	PUNCT
dpc-3325	126	10	il-6	il-6	NUM
dpc-3325	126	11	,	,	PUNCT
dpc-3325	126	12	il-31	il-31	X
dpc-3325	126	13	,	,	PUNCT
dpc-3325	126	14	tslp	tslp	VERB
dpc-3325	126	15	,	,	PUNCT
dpc-3325	126	16	il-17	il-17	ADV
dpc-3325	126	17	,	,	PUNCT
dpc-3325	126	18	eotaxin	eotaxin	PROPN
dpc-3325	126	19	,	,	PUNCT
dpc-3325	126	20	rantes	rante	NOUN
dpc-3325	126	21	)	)	PUNCT
dpc-3325	126	22	,	,	PUNCT
dpc-3325	126	23	tnf	tnf	PROPN
dpc-3325	126	24	-	-	PUNCT
dpc-3325	126	25	α	α	PROPN
dpc-3325	126	26	and	and	CCONJ
dpc-3325	126	27	rantes	rante	NOUN
dpc-3325	126	28	were	be	AUX
dpc-3325	126	29	considered	consider	VERB
dpc-3325	126	30	as	as	ADP
dpc-3325	126	31	potential	potential	ADJ
dpc-3325	126	32	biomarkers	biomarker	NOUN
dpc-3325	126	33	of	of	ADP
dpc-3325	126	34	csu	csu	PROPN
dpc-3325	126	35	,	,	PUNCT
dpc-3325	126	36	while	while	SCONJ
dpc-3325	126	37	it	it	PRON
dpc-3325	126	38	was	be	AUX
dpc-3325	126	39	observed	observe	VERB
dpc-3325	126	40	that	that	SCONJ
dpc-3325	126	41	the	the	DET
dpc-3325	126	42	effect	effect	NOUN
dpc-3325	126	43	of	of	ADP
dpc-3325	126	44	omalizumab	omalizumab	NOUN
dpc-3325	126	45	treatment	treatment	NOUN
dpc-3325	126	46	was	be	AUX
dpc-3325	126	47	not	not	PART
dpc-3325	126	48	through	through	ADP
dpc-3325	126	49	these	these	DET
dpc-3325	126	50	biomarkers	biomarker	NOUN
dpc-3325	126	51	.	.	PUNCT
dpc-3325	127	1	consistent	consistent	ADJ
dpc-3325	127	2	with	with	ADP
dpc-3325	127	3	the	the	DET
dpc-3325	127	4	literature	literature	NOUN
dpc-3325	127	5	,	,	PUNCT
dpc-3325	127	6	in	in	ADP
dpc-3325	127	7	our	our	PRON
dpc-3325	127	8	study	study	NOUN
dpc-3325	127	9	,	,	PUNCT
dpc-3325	127	10	tnf	tnf	PROPN
dpc-3325	127	11	-	-	PUNCT
dpc-3325	127	12	α	α	PROPN
dpc-3325	127	13	levels	level	NOUN
dpc-3325	127	14	were	be	AUX
dpc-3325	127	15	significantly	significantly	ADV
dpc-3325	127	16	higher	high	ADJ
dpc-3325	127	17	in	in	ADP
dpc-3325	127	18	the	the	DET
dpc-3325	127	19	csu	csu	PROPN
dpc-3325	127	20	patient	patient	PROPN
dpc-3325	127	21	group	group	NOUN
dpc-3325	127	22	[	[	X
dpc-3325	127	23	24	24	NUM
dpc-3325	127	24	]	]	PUNCT
dpc-3325	127	25	.	.	PUNCT
dpc-3325	128	1	this	this	PRON
dpc-3325	128	2	can	can	AUX
dpc-3325	128	3	be	be	AUX
dpc-3325	128	4	explained	explain	VERB
dpc-3325	128	5	by	by	ADP
dpc-3325	128	6	the	the	DET
dpc-3325	128	7	theory	theory	NOUN
dpc-3325	128	8	previously	previously	ADV
dpc-3325	128	9	presented	present	VERB
dpc-3325	128	10	by	by	ADP
dpc-3325	128	11	walsh	walsh	PROPN
dpc-3325	128	12	et	et	PROPN
dpc-3325	128	13	al	al	PROPN
dpc-3325	128	14	.	.	PUNCT
dpc-3325	129	1	that	that	PRON
dpc-3325	129	2	dermal	dermal	VERB
dpc-3325	129	3	mast	mast	NOUN
dpc-3325	129	4	cells	cell	NOUN
dpc-3325	129	5	include	include	VERB
dpc-3325	129	6	a	a	DET
dpc-3325	129	7	high	high	ADJ
dpc-3325	129	8	amount	amount	NOUN
dpc-3325	129	9	of	of	ADP
dpc-3325	129	10	immunoreactive	immunoreactive	ADJ
dpc-3325	129	11	tnf	tnf	PROPN
dpc-3325	129	12	-	-	PUNCT
dpc-3325	129	13	α	α	PROPN
dpc-3325	129	14	in	in	ADP
dpc-3325	129	15	their	their	PRON
dpc-3325	129	16	granules	granule	NOUN
dpc-3325	129	17	and	and	CCONJ
dpc-3325	129	18	that	that	SCONJ
dpc-3325	129	19	they	they	PRON
dpc-3325	129	20	can	can	AUX
dpc-3325	129	21	be	be	AUX
dpc-3325	129	22	rapidly	rapidly	ADV
dpc-3325	129	23	released	release	VERB
dpc-3325	129	24	into	into	ADP
dpc-3325	129	25	the	the	DET
dpc-3325	129	26	extracellular	extracellular	ADJ
dpc-3325	129	27	area	area	NOUN
dpc-3325	129	28	by	by	ADP
dpc-3325	129	29	degranulation	degranulation	NOUN
dpc-3325	129	30	[	[	X
dpc-3325	129	31	25	25	NUM
dpc-3325	129	32	]	]	PUNCT
dpc-3325	129	33	.	.	PUNCT
dpc-3325	130	1	in	in	ADP
dpc-3325	130	2	the	the	DET
dpc-3325	130	3	comparison	comparison	NOUN
dpc-3325	130	4	of	of	ADP
dpc-3325	130	5	patients	patient	NOUN
dpc-3325	130	6	receiving	receive	VERB
dpc-3325	130	7	and	and	CCONJ
dpc-3325	130	8	not	not	PART
dpc-3325	130	9	receiving	receive	VERB
dpc-3325	130	10	omalizumab	omalizumab	NOUN
dpc-3325	130	11	treatment	treatment	NOUN
dpc-3325	130	12	,	,	PUNCT
dpc-3325	130	13	although	although	SCONJ
dpc-3325	130	14	tnf	tnf	PROPN
dpc-3325	130	15	-	-	PUNCT
dpc-3325	130	16	α	α	PROPN
dpc-3325	130	17	levels	level	NOUN
dpc-3325	130	18	were	be	AUX
dpc-3325	130	19	lower	low	ADJ
dpc-3325	130	20	in	in	ADP
dpc-3325	130	21	those	those	PRON
dpc-3325	130	22	receiving	receive	VERB
dpc-3325	130	23	omalizumab	omalizumab	NOUN
dpc-3325	130	24	treatment	treatment	NOUN
dpc-3325	130	25	,	,	PUNCT
dpc-3325	130	26	no	no	DET
dpc-3325	130	27	statistically	statistically	ADV
dpc-3325	130	28	significant	significant	ADJ
dpc-3325	130	29	change	change	NOUN
dpc-3325	130	30	was	be	AUX
dpc-3325	130	31	observed	observe	VERB
dpc-3325	130	32	.	.	PUNCT
dpc-3325	131	1	similarly	similarly	ADV
dpc-3325	131	2	,	,	PUNCT
dpc-3325	131	3	in	in	ADP
dpc-3325	131	4	the	the	DET
dpc-3325	131	5	study	study	NOUN
dpc-3325	131	6	by	by	ADP
dpc-3325	131	7	noga	noga	PROPN
dpc-3325	131	8	et	et	PROPN
dpc-3325	131	9	al	al	PROPN
dpc-3325	131	10	,	,	PUNCT
dpc-3325	131	11	in	in	ADP
dpc-3325	131	12	which	which	PRON
dpc-3325	131	13	19	19	NUM
dpc-3325	131	14	participants	participant	NOUN
dpc-3325	131	15	were	be	AUX
dpc-3325	131	16	compared	compare	VERB
dpc-3325	131	17	,	,	PUNCT
dpc-3325	131	18	no	no	DET
dpc-3325	131	19	significant	significant	ADJ
dpc-3325	131	20	difference	difference	NOUN
dpc-3325	131	21	was	be	AUX
dpc-3325	131	22	observed	observe	VERB
dpc-3325	131	23	in	in	ADP
dpc-3325	131	24	tnf	tnf	PROPN
dpc-3325	131	25	-	-	PUNCT
dpc-3325	131	26	α	α	PROPN
dpc-3325	131	27	levels	level	NOUN
dpc-3325	131	28	between	between	ADP
dpc-3325	131	29	the	the	DET
dpc-3325	131	30	omalizumab	omalizumab	NOUN
dpc-3325	131	31	and	and	CCONJ
dpc-3325	131	32	placebo	placebo	NOUN
dpc-3325	131	33	groups	group	NOUN
dpc-3325	131	34	[	[	X
dpc-3325	131	35	26	26	NUM
dpc-3325	131	36	]	]	PUNCT
dpc-3325	131	37	.	.	PUNCT
dpc-3325	132	1	however	however	ADV
dpc-3325	132	2	,	,	PUNCT
dpc-3325	132	3	in	in	ADP
dpc-3325	132	4	a	a	DET
dpc-3325	132	5	case	case	NOUN
dpc-3325	132	6	series	series	NOUN
dpc-3325	132	7	of	of	ADP
dpc-3325	132	8	patients	patient	NOUN
dpc-3325	132	9	who	who	PRON
dpc-3325	132	10	did	do	AUX
dpc-3325	132	11	not	not	PART
dpc-3325	132	12	respond	respond	VERB
dpc-3325	132	13	to	to	ADP
dpc-3325	132	14	omalizumab	omalizumab	NOUN
dpc-3325	132	15	,	,	PUNCT
dpc-3325	132	16	tnf	tnf	PROPN
dpc-3325	132	17	-	-	PUNCT
dpc-3325	132	18	α	α	PROPN
dpc-3325	132	19	antagonists	antagonist	NOUN
dpc-3325	132	20	were	be	AUX
dpc-3325	132	21	noticed	notice	VERB
dpc-3325	132	22	to	to	PART
dpc-3325	132	23	be	be	AUX
dpc-3325	132	24	efficacious	efficacious	ADJ
dpc-3325	132	25	in	in	ADP
dpc-3325	132	26	60	60	NUM
dpc-3325	132	27	%	%	NOUN
dpc-3325	132	28	of	of	ADP
dpc-3325	132	29	20	20	NUM
dpc-3325	132	30	csu	csu	NOUN
dpc-3325	132	31	patients	patient	NOUN
dpc-3325	132	32	[	[	X
dpc-3325	132	33	27	27	NUM
dpc-3325	132	34	]	]	PUNCT
dpc-3325	132	35	.	.	PUNCT
dpc-3325	133	1	this	this	PRON
dpc-3325	133	2	suggests	suggest	VERB
dpc-3325	133	3	that	that	SCONJ
dpc-3325	133	4	tnf	tnf	PROPN
dpc-3325	133	5	-	-	PUNCT
dpc-3325	133	6	α	α	PROPN
dpc-3325	133	7	may	may	AUX
dpc-3325	133	8	be	be	AUX
dpc-3325	133	9	a	a	DET
dpc-3325	133	10	potential	potential	ADJ
dpc-3325	133	11	biomarker	biomarker	NOUN
dpc-3325	133	12	for	for	ADP
dpc-3325	133	13	determining	determine	VERB
dpc-3325	133	14	disease	disease	NOUN
dpc-3325	133	15	activity	activity	NOUN
dpc-3325	133	16	,	,	PUNCT
dpc-3325	133	17	but	but	CCONJ
dpc-3325	133	18	it	it	PRON
dpc-3325	133	19	is	be	AUX
dpc-3325	133	20	insufficient	insufficient	ADJ
dpc-3325	133	21	to	to	PART
dpc-3325	133	22	assess	assess	VERB
dpc-3325	133	23	omalizumab	omalizumab	NOUN
dpc-3325	133	24	treatment	treatment	NOUN
dpc-3325	133	25	response	response	NOUN
dpc-3325	133	26	,	,	PUNCT
dpc-3325	133	27	but	but	CCONJ
dpc-3325	133	28	may	may	AUX
dpc-3325	133	29	be	be	AUX
dpc-3325	133	30	an	an	DET
dpc-3325	133	31	alternative	alternative	ADJ
dpc-3325	133	32	pathway	pathway	NOUN
dpc-3325	133	33	in	in	ADP
dpc-3325	133	34	patients	patient	NOUN
dpc-3325	133	35	resistant	resistant	ADJ
dpc-3325	133	36	to	to	ADP
dpc-3325	133	37	omalizumab	omalizumab	NOUN
dpc-3325	133	38	.	.	PUNCT
dpc-3325	134	1	it	it	PRON
dpc-3325	134	2	has	have	AUX
dpc-3325	134	3	been	be	AUX
dpc-3325	134	4	reported	report	VERB
dpc-3325	134	5	that	that	SCONJ
dpc-3325	134	6	il-6	il-6	NOUN
dpc-3325	134	7	which	which	PRON
dpc-3325	134	8	is	be	AUX
dpc-3325	134	9	known	know	VERB
dpc-3325	134	10	to	to	PART
dpc-3325	134	11	play	play	VERB
dpc-3325	134	12	a	a	DET
dpc-3325	134	13	crucial	crucial	ADJ
dpc-3325	134	14	role	role	NOUN
dpc-3325	134	15	in	in	ADP
dpc-3325	134	16	inflammatory	inflammatory	ADJ
dpc-3325	134	17	responses	response	NOUN
dpc-3325	134	18	,	,	PUNCT
dpc-3325	134	19	is	be	AUX
dpc-3325	134	20	also	also	ADV
dpc-3325	134	21	detected	detect	VERB
dpc-3325	134	22	in	in	ADP
dpc-3325	134	23	high	high	ADJ
dpc-3325	134	24	concentrations	concentration	NOUN
dpc-3325	134	25	in	in	ADP
dpc-3325	134	26	csu	csu	PROPN
dpc-3325	134	27	patients	patient	NOUN
dpc-3325	134	28	,	,	PUNCT
dpc-3325	134	29	and	and	CCONJ
dpc-3325	134	30	it	it	PRON
dpc-3325	134	31	has	have	AUX
dpc-3325	134	32	been	be	AUX
dpc-3325	134	33	stated	state	VERB
dpc-3325	134	34	that	that	SCONJ
dpc-3325	134	35	il-6	il-6	NOUN
dpc-3325	134	36	signaling	signal	VERB
dpc-3325	134	37	may	may	AUX
dpc-3325	134	38	be	be	AUX
dpc-3325	134	39	considered	consider	VERB
dpc-3325	134	40	in	in	ADP
dpc-3325	134	41	the	the	DET
dpc-3325	134	42	pathogenesis	pathogenesis	NOUN
dpc-3325	134	43	and	and	CCONJ
dpc-3325	134	44	inflammatory	inflammatory	ADJ
dpc-3325	134	45	activation	activation	NOUN
dpc-3325	134	46	of	of	ADP
dpc-3325	134	47	this	this	DET
dpc-3325	134	48	disease	disease	NOUN
dpc-3325	135	1	[	[	X
dpc-3325	135	2	28	28	NUM
dpc-3325	135	3	]	]	PUNCT
dpc-3325	135	4	.	.	PUNCT
dpc-3325	136	1	high	high	ADJ
dpc-3325	136	2	il-6	il-6	NOUN
dpc-3325	136	3	level	level	NOUN
dpc-3325	136	4	has	have	AUX
dpc-3325	136	5	been	be	AUX
dpc-3325	136	6	related	relate	VERB
dpc-3325	136	7	to	to	ADP
dpc-3325	136	8	disease	disease	NOUN
dpc-3325	136	9	severity	severity	NOUN
dpc-3325	136	10	and	and	CCONJ
dpc-3325	136	11	activity	activity	NOUN
dpc-3325	136	12	in	in	ADP
dpc-3325	136	13	many	many	ADJ
dpc-3325	136	14	studies	study	NOUN
dpc-3325	136	15	,	,	PUNCT
dpc-3325	136	16	and	and	CCONJ
dpc-3325	136	17	it	it	PRON
dpc-3325	136	18	has	have	AUX
dpc-3325	136	19	been	be	AUX
dpc-3325	136	20	proposed	propose	VERB
dpc-3325	136	21	that	that	SCONJ
dpc-3325	136	22	il-6	il-6	PRON
dpc-3325	136	23	may	may	AUX
dpc-3325	136	24	be	be	AUX
dpc-3325	136	25	a	a	DET
dpc-3325	136	26	good	good	ADJ
dpc-3325	136	27	biomarker	biomarker	NOUN
dpc-3325	136	28	for	for	ADP
dpc-3325	136	29	csu	csu	NOUN
dpc-3325	136	30	disease	disease	NOUN
dpc-3325	136	31	[	[	X
dpc-3325	136	32	15,29	15,29	NUM
dpc-3325	136	33	,	,	PUNCT
dpc-3325	136	34	0	0	NUM
dpc-3325	136	35	]	]	PUNCT
dpc-3325	136	36	.	.	PUNCT
dpc-3325	137	1	on	on	ADP
dpc-3325	137	2	the	the	DET
dpc-3325	137	3	other	other	ADJ
dpc-3325	137	4	hand	hand	NOUN
dpc-3325	137	5	,	,	PUNCT
dpc-3325	137	6	there	there	PRON
dpc-3325	137	7	are	be	VERB
dpc-3325	137	8	also	also	ADV
dpc-3325	137	9	studies	study	NOUN
dpc-3325	137	10	showing	show	VERB
dpc-3325	137	11	that	that	SCONJ
dpc-3325	137	12	il-6	il-6	PRON
dpc-3325	137	13	is	be	AUX
dpc-3325	137	14	not	not	PART
dpc-3325	137	15	related	relate	VERB
dpc-3325	137	16	to	to	ADP
dpc-3325	137	17	disease	disease	NOUN
dpc-3325	137	18	activity	activity	NOUN
dpc-3325	137	19	in	in	ADP
dpc-3325	137	20	csu	csu	PROPN
dpc-3325	138	1	[	[	X
dpc-3325	138	2	31,32	31,32	NUM
dpc-3325	138	3	]	]	PUNCT
dpc-3325	138	4	.	.	PUNCT
dpc-3325	139	1	in	in	ADP
dpc-3325	139	2	a	a	DET
dpc-3325	139	3	study	study	NOUN
dpc-3325	139	4	by	by	ADP
dpc-3325	139	5	noga	noga	PROPN
dpc-3325	139	6	et	et	PROPN
dpc-3325	139	7	al	al	PROPN
dpc-3325	139	8	,	,	PUNCT
dpc-3325	139	9	investigating	investigate	VERB
dpc-3325	139	10	the	the	DET
dpc-3325	139	11	omalizumab	omalizumab	NOUN
dpc-3325	139	12	effect	effect	NOUN
dpc-3325	139	13	on	on	ADP
dpc-3325	139	14	inflammatory	inflammatory	ADJ
dpc-3325	139	15	mediators	mediator	NOUN
dpc-3325	139	16	in	in	ADP
dpc-3325	139	17	moderate	moderate	ADJ
dpc-3325	139	18	and	and	CCONJ
dpc-3325	139	19	severe	severe	ADJ
dpc-3325	139	20	allergic	allergic	ADJ
dpc-3325	139	21	asthma	asthma	NOUN
dpc-3325	139	22	,	,	PUNCT
dpc-3325	139	23	no	no	DET
dpc-3325	139	24	statistically	statistically	ADV
dpc-3325	139	25	significant	significant	ADJ
dpc-3325	139	26	change	change	NOUN
dpc-3325	139	27	was	be	AUX
dpc-3325	139	28	observed	observe	VERB
dpc-3325	139	29	in	in	ADP
dpc-3325	139	30	il-6	il-6	NOUN
dpc-3325	139	31	levels	level	NOUN
dpc-3325	139	32	after	after	ADP
dpc-3325	139	33	omalizumab	omalizumab	NOUN
dpc-3325	139	34	treatment	treatment	NOUN
dpc-3325	139	35	[	[	X
dpc-3325	139	36	33	33	NUM
dpc-3325	139	37	]	]	PUNCT
dpc-3325	139	38	.	.	PUNCT
dpc-3325	140	1	in	in	ADP
dpc-3325	140	2	the	the	DET
dpc-3325	140	3	present	present	ADJ
dpc-3325	140	4	study	study	NOUN
dpc-3325	140	5	,	,	PUNCT
dpc-3325	140	6	il-6	il-6	NUM
dpc-3325	140	7	levels	level	NOUN
dpc-3325	140	8	were	be	AUX
dpc-3325	140	9	also	also	ADV
dpc-3325	140	10	comparable	comparable	ADJ
dpc-3325	140	11	between	between	ADP
dpc-3325	140	12	the	the	DET
dpc-3325	140	13	study	study	NOUN
dpc-3325	140	14	groups	group	NOUN
dpc-3325	140	15	.	.	PUNCT
dpc-3325	141	1	additionally	additionally	ADV
dpc-3325	141	2	,	,	PUNCT
dpc-3325	141	3	similar	similar	ADJ
dpc-3325	141	4	results	result	NOUN
dpc-3325	141	5	were	be	AUX
dpc-3325	141	6	observed	observe	VERB
dpc-3325	141	7	in	in	ADP
dpc-3325	141	8	those	those	PRON
dpc-3325	141	9	receiving	receive	VERB
dpc-3325	141	10	and	and	CCONJ
dpc-3325	141	11	not	not	PART
dpc-3325	141	12	receiving	receive	VERB
dpc-3325	141	13	omalizumab	omalizumab	NOUN
dpc-3325	141	14	.	.	PUNCT
dpc-3325	142	1	therefore	therefore	ADV
dpc-3325	142	2	,	,	PUNCT
dpc-3325	142	3	il-6	il-6	PRON
dpc-3325	142	4	,	,	PUNCT
dpc-3325	142	5	which	which	PRON
dpc-3325	142	6	has	have	VERB
dpc-3325	142	7	many	many	ADJ
dpc-3325	142	8	important	important	ADJ
dpc-3325	142	9	physiological	physiological	ADJ
dpc-3325	142	10	and	and	CCONJ
dpc-3325	142	11	anti	anti	ADJ
dpc-3325	142	12	-	-	ADJ
dpc-3325	142	13	inflammatory	inflammatory	ADJ
dpc-3325	142	14	functions	function	NOUN
dpc-3325	142	15	such	such	ADJ
dpc-3325	142	16	as	as	ADP
dpc-3325	142	17	inflammation	inflammation	NOUN
dpc-3325	142	18	,	,	PUNCT
dpc-3325	142	19	fever	fever	NOUN
dpc-3325	142	20	,	,	PUNCT
dpc-3325	142	21	and	and	CCONJ
dpc-3325	142	22	tumorigenesis	tumorigenesis	NOUN
dpc-3325	142	23	,	,	PUNCT
dpc-3325	142	24	has	have	AUX
dpc-3325	142	25	not	not	PART
dpc-3325	142	26	been	be	AUX
dpc-3325	142	27	considered	consider	VERB
dpc-3325	142	28	as	as	ADP
dpc-3325	142	29	a	a	DET
dpc-3325	142	30	specific	specific	ADJ
dpc-3325	142	31	and	and	CCONJ
dpc-3325	142	32	reliable	reliable	ADJ
dpc-3325	142	33	marker	marker	NOUN
dpc-3325	142	34	for	for	ADP
dpc-3325	142	35	csu	csu	PROPN
dpc-3325	142	36	.	.	PUNCT
dpc-3325	143	1	tslp	tslp	PROPN
dpc-3325	143	2	is	be	AUX
dpc-3325	143	3	a	a	DET
dpc-3325	143	4	cytokine	cytokine	NOUN
dpc-3325	143	5	with	with	ADP
dpc-3325	143	6	a	a	DET
dpc-3325	143	7	critical	critical	ADJ
dpc-3325	143	8	role	role	NOUN
dpc-3325	143	9	in	in	ADP
dpc-3325	143	10	regulating	regulate	VERB
dpc-3325	143	11	inflammatory	inflammatory	ADJ
dpc-3325	143	12	responses	response	NOUN
dpc-3325	143	13	.	.	PUNCT
dpc-3325	144	1	tslp	tslp	PROPN
dpc-3325	144	2	was	be	AUX
dpc-3325	144	3	observed	observe	VERB
dpc-3325	144	4	higher	higher	ADV
dpc-3325	144	5	in	in	ADP
dpc-3325	144	6	the	the	DET
dpc-3325	144	7	lesions	lesion	NOUN
dpc-3325	144	8	than	than	ADP
dpc-3325	144	9	in	in	ADP
dpc-3325	144	10	non	non	ADJ
dpc-3325	144	11	-	-	ADJ
dpc-3325	144	12	lesional	lesional	ADJ
dpc-3325	144	13	skin	skin	NOUN
dpc-3325	144	14	areas	area	NOUN
dpc-3325	144	15	of	of	ADP
dpc-3325	144	16	csu	csu	PROPN
dpc-3325	144	17	patients	patient	NOUN
dpc-3325	144	18	[	[	X
dpc-3325	144	19	34	34	NUM
dpc-3325	144	20	]	]	PUNCT
dpc-3325	144	21	.	.	PUNCT
dpc-3325	145	1	original	original	ADJ
dpc-3325	145	2	article	article	NOUN
dpc-3325	145	3	|	|	ADV
dpc-3325	145	4	dermatol	dermatol	ADJ
dpc-3325	145	5	pract	pract	NOUN
dpc-3325	145	6	concept	concept	NOUN
dpc-3325	145	7	.	.	PUNCT
dpc-3325	146	1	2023;13(4):e2023272	2023;13(4):e2023272	NUM
dpc-3325	146	2	7	7	NUM
dpc-3325	146	3	7	7	NUM
dpc-3325	146	4	.	.	PUNCT
dpc-3325	147	1	elias	elias	PROPN
dpc-3325	147	2	j	j	PROPN
dpc-3325	147	3	,	,	PUNCT
dpc-3325	147	4	boss	boss	NOUN
dpc-3325	147	5	e	e	PROPN
dpc-3325	147	6	,	,	PUNCT
dpc-3325	147	7	kaplan	kaplan	PROPN
dpc-3325	147	8	ap	ap	PROPN
dpc-3325	147	9	.	.	PUNCT
dpc-3325	148	1	studies	study	NOUN
dpc-3325	148	2	of	of	ADP
dpc-3325	148	3	the	the	DET
dpc-3325	148	4	cellular	cellular	ADJ
dpc-3325	148	5	infiltrate	infiltrate	NOUN
dpc-3325	148	6	of	of	ADP
dpc-3325	148	7	chronic	chronic	ADJ
dpc-3325	148	8	idiopathic	idiopathic	ADJ
dpc-3325	148	9	urticaria	urticaria	NOUN
dpc-3325	148	10	:	:	PUNCT
dpc-3325	148	11	prominence	prominence	NOUN
dpc-3325	148	12	of	of	ADP
dpc-3325	148	13	t	t	PROPN
dpc-3325	148	14	-	-	PUNCT
dpc-3325	148	15	lymphocytes	lymphocyte	NOUN
dpc-3325	148	16	,	,	PUNCT
dpc-3325	148	17	monocytes	monocyte	NOUN
dpc-3325	148	18	,	,	PUNCT
dpc-3325	148	19	and	and	CCONJ
dpc-3325	148	20	mast	mast	NOUN
dpc-3325	148	21	cells	cell	NOUN
dpc-3325	148	22	.	.	PUNCT
dpc-3325	149	1	j	j	PROPN
dpc-3325	149	2	allergy	allergy	PROPN
dpc-3325	149	3	clin	clin	PROPN
dpc-3325	149	4	immunol	immunol	PROPN
dpc-3325	149	5	.	.	PUNCT
dpc-3325	150	1	1986;78(5	1986;78(5	NUM
dpc-3325	150	2	 	 	SPACE
dpc-3325	150	3	pt	pt	NOUN
dpc-3325	150	4	 	 	SPACE
dpc-3325	150	5	1):914	1):914	PROPN
dpc-3325	150	6	-	-	PUNCT
dpc-3325	150	7	918	918	NUM
dpc-3325	150	8	.	.	PUNCT
dpc-3325	151	1	doi	doi	NOUN
dpc-3325	151	2	:	:	PUNCT
dpc-3325	151	3	10.1016/0091	10.1016/0091	NUM
dpc-3325	151	4	-	-	PUNCT
dpc-3325	151	5	6749(86)90240	6749(86)90240	NUM
dpc-3325	151	6	-	-	PUNCT
dpc-3325	151	7	x.	x.	NOUN
dpc-3325	151	8	pmid	pmid	PROPN
dpc-3325	151	9	:	:	PUNCT
dpc-3325	151	10	3491100	3491100	NUM
dpc-3325	151	11	.	.	PUNCT
dpc-3325	152	1	8	8	X
dpc-3325	152	2	.	.	X
dpc-3325	152	3	atwa	atwa	PROPN
dpc-3325	152	4	ma	ma	PROPN
dpc-3325	152	5	,	,	PUNCT
dpc-3325	152	6	emara	emara	VERB
dpc-3325	152	7	as	as	ADP
dpc-3325	152	8	,	,	PUNCT
dpc-3325	152	9	youssef	youssef	PROPN
dpc-3325	152	10	n	n	CCONJ
dpc-3325	152	11	,	,	PUNCT
dpc-3325	152	12	bayoumy	bayoumy	PROPN
dpc-3325	152	13	nm	nm	VERB
dpc-3325	152	14	.	.	PUNCT
dpc-3325	153	1	serum	serum	NOUN
dpc-3325	153	2	concentration	concentration	NOUN
dpc-3325	153	3	of	of	ADP
dpc-3325	153	4	il-17	il-17	NOUN
dpc-3325	153	5	,	,	PUNCT
dpc-3325	153	6	il-23	il-23	NOUN
dpc-3325	153	7	and	and	CCONJ
dpc-3325	153	8	tnf	tnf	PROPN
dpc-3325	153	9	-	-	PUNCT
dpc-3325	153	10	α	α	PROPN
dpc-3325	153	11	among	among	ADP
dpc-3325	153	12	patients	patient	NOUN
dpc-3325	153	13	with	with	ADP
dpc-3325	153	14	chronic	chronic	ADJ
dpc-3325	153	15	spontaneous	spontaneous	ADJ
dpc-3325	153	16	urticaria	urticaria	NOUN
dpc-3325	153	17	:	:	PUNCT
dpc-3325	153	18	association	association	NOUN
dpc-3325	153	19	with	with	ADP
dpc-3325	153	20	disease	disease	NOUN
dpc-3325	153	21	activity	activity	NOUN
dpc-3325	153	22	and	and	CCONJ
dpc-3325	153	23	autologous	autologous	ADJ
dpc-3325	153	24	serum	serum	NOUN
dpc-3325	153	25	skin	skin	NOUN
dpc-3325	153	26	test	test	NOUN
dpc-3325	153	27	.	.	PUNCT
dpc-3325	154	1	j	j	PROPN
dpc-3325	154	2	eur	eur	PROPN
dpc-3325	154	3	acad	acad	PROPN
dpc-3325	154	4	dermatol	dermatol	NOUN
dpc-3325	154	5	venereol	venereol	NOUN
dpc-3325	154	6	.	.	PUNCT
dpc-3325	155	1	2014;28(4):|	2014;28(4):|	NUM
dpc-3325	155	2	469	469	NUM
dpc-3325	155	3	-	-	SYM
dpc-3325	155	4	474	474	NUM
dpc-3325	155	5	.	.	PUNCT
dpc-3325	156	1	doi	doi	NOUN
dpc-3325	156	2	:	:	PUNCT
dpc-3325	156	3	10.1111	10.1111	NUM
dpc-3325	156	4	/	/	SYM
dpc-3325	156	5	jdv.12124	jdv.12124	PROPN
dpc-3325	156	6	.	.	PUNCT
dpc-3325	157	1	pmid	pmid	NOUN
dpc-3325	157	2	:	:	PUNCT
dpc-3325	157	3	23451767	23451767	NUM
dpc-3325	157	4	.	.	PUNCT
dpc-3325	158	1	9	9	X
dpc-3325	158	2	.	.	X
dpc-3325	158	3	takahagi	takahagi	PROPN
dpc-3325	158	4	s	s	PROPN
dpc-3325	158	5	,	,	PUNCT
dpc-3325	158	6	mihara	mihara	PROPN
dpc-3325	158	7	s	s	PROPN
dpc-3325	158	8	,	,	PUNCT
dpc-3325	158	9	iwamoto	iwamoto	ADJ
dpc-3325	158	10	k	k	NOUN
dpc-3325	158	11	,	,	PUNCT
dpc-3325	158	12	et	et	PROPN
dpc-3325	158	13	al	al	PROPN
dpc-3325	158	14	.	.	PUNCT
dpc-3325	159	1	coagulation	coagulation	NOUN
dpc-3325	159	2	/	/	SYM
dpc-3325	159	3	fibrinolysis	fibrinolysis	NOUN
dpc-3325	159	4	and	and	CCONJ
dpc-3325	159	5	inflammation	inflammation	NOUN
dpc-3325	159	6	markers	marker	NOUN
dpc-3325	159	7	are	be	AUX
dpc-3325	159	8	associated	associate	VERB
dpc-3325	159	9	with	with	ADP
dpc-3325	159	10	disease	disease	NOUN
dpc-3325	159	11	activity	activity	NOUN
dpc-3325	159	12	in	in	ADP
dpc-3325	159	13	patients	patient	NOUN
dpc-3325	159	14	with	with	ADP
dpc-3325	159	15	chronic	chronic	ADJ
dpc-3325	159	16	urticaria	urticaria	NOUN
dpc-3325	159	17	.	.	PUNCT
dpc-3325	160	1	allergy	allergy	NOUN
dpc-3325	160	2	.	.	PUNCT
dpc-3325	161	1	2010;65(5):649	2010;65(5):649	NUM
dpc-3325	161	2	-	-	SYM
dpc-3325	161	3	656	656	NUM
dpc-3325	161	4	.	.	PUNCT
dpc-3325	162	1	doi	doi	NOUN
dpc-3325	162	2	:	:	PUNCT
dpc-3325	162	3	10.1111	10.1111	NUM
dpc-3325	162	4	/	/	SYM
dpc-3325	162	5	j.1398	j.1398	PROPN
dpc-3325	162	6	-	-	PUNCT
dpc-3325	162	7	9995.2009.02222.x	9995.2009.02222.x	NUM
dpc-3325	162	8	.	.	PUNCT
dpc-3325	163	1	pmid	pmid	NOUN
dpc-3325	163	2	:	:	PUNCT
dpc-3325	163	3	19845571	19845571	NUM
dpc-3325	163	4	.	.	PUNCT
dpc-3325	164	1	10	10	NUM
dpc-3325	164	2	.	.	X
dpc-3325	165	1	altrichter	altrichter	PROPN
dpc-3325	165	2	s	s	PROPN
dpc-3325	165	3	,	,	PUNCT
dpc-3325	165	4	hawro	hawro	PROPN
dpc-3325	165	5	t	t	PROPN
dpc-3325	165	6	,	,	PUNCT
dpc-3325	165	7	hänel	hänel	PROPN
dpc-3325	165	8	k	k	PROPN
dpc-3325	165	9	,	,	PUNCT
dpc-3325	165	10	et	et	PROPN
dpc-3325	165	11	al	al	PROPN
dpc-3325	165	12	.	.	PROPN
dpc-3325	166	1	successful	successful	ADJ
dpc-3325	166	2	omalizumab	omalizumab	NOUN
dpc-3325	166	3	treatment	treatment	NOUN
dpc-3325	166	4	in	in	ADP
dpc-3325	166	5	chronic	chronic	ADJ
dpc-3325	166	6	spontaneous	spontaneous	ADJ
dpc-3325	166	7	urticaria	urticaria	NOUN
dpc-3325	166	8	is	be	AUX
dpc-3325	166	9	associated	associate	VERB
dpc-3325	166	10	with	with	ADP
dpc-3325	166	11	lowering	lower	VERB
dpc-3325	166	12	of	of	ADP
dpc-3325	166	13	serum	serum	NOUN
dpc-3325	166	14	il-31	il-31	ADJ
dpc-3325	166	15	levels	level	NOUN
dpc-3325	166	16	.	.	PUNCT
dpc-3325	167	1	j	j	PROPN
dpc-3325	167	2	eur	eur	PROPN
dpc-3325	167	3	acad	acad	PROPN
dpc-3325	167	4	dermatol	dermatol	NOUN
dpc-3325	167	5	venereol	venereol	NOUN
dpc-3325	167	6	.	.	PUNCT
dpc-3325	168	1	2016;30(3):454	2016;30(3):454	NUM
dpc-3325	168	2	-	-	SYM
dpc-3325	168	3	455	455	NUM
dpc-3325	168	4	.	.	PUNCT
dpc-3325	169	1	doi	doi	NOUN
dpc-3325	169	2	:	:	PUNCT
dpc-3325	169	3	10.1111	10.1111	NUM
dpc-3325	169	4	/	/	SYM
dpc-3325	169	5	jdv.12831	jdv.12831	PROPN
dpc-3325	169	6	.	.	PUNCT
dpc-3325	170	1	pmid	pmid	NOUN
dpc-3325	170	2	:	:	PUNCT
dpc-3325	170	3	25371135.11	25371135.11	NUM
dpc-3325	170	4	.	.	PUNCT
dpc-3325	171	1	romano	romano	NOUN
dpc-3325	171	2	c	c	PROPN
dpc-3325	171	3	,	,	PUNCT
dpc-3325	171	4	sellitto	sellitto	NOUN
dpc-3325	171	5	a	a	PRON
dpc-3325	171	6	,	,	PUNCT
dpc-3325	171	7	de	de	X
dpc-3325	171	8	fanis	fanis	X
dpc-3325	171	9	u	u	PROPN
dpc-3325	171	10	,	,	PUNCT
dpc-3325	171	11	et	et	PROPN
dpc-3325	171	12	al	al	PROPN
dpc-3325	171	13	.	.	PROPN
dpc-3325	171	14	omalizumab	omalizumab	NOUN
dpc-3325	171	15	for	for	ADP
dpc-3325	171	16	difficult	difficult	ADJ
dpc-3325	171	17	-	-	PUNCT
dpc-3325	171	18	to	to	AUX
dpc-3325	171	19	-	-	PUNCT
dpc-3325	171	20	treat	treat	VERB
dpc-3325	171	21	dermatological	dermatological	ADJ
dpc-3325	171	22	conditions	condition	NOUN
dpc-3325	171	23	:	:	PUNCT
dpc-3325	171	24	clinical	clinical	ADJ
dpc-3325	171	25	and	and	CCONJ
dpc-3325	171	26	immunological	immunological	ADJ
dpc-3325	171	27	features	feature	NOUN
dpc-3325	171	28	from	from	ADP
dpc-3325	171	29	a	a	DET
dpc-3325	171	30	retrospective	retrospective	ADJ
dpc-3325	171	31	real	real	ADJ
dpc-3325	171	32	-	-	PUNCT
dpc-3325	171	33	life	life	NOUN
dpc-3325	171	34	experience	experience	NOUN
dpc-3325	171	35	.	.	PUNCT
dpc-3325	172	1	clin	clin	PROPN
dpc-3325	172	2	drug	drug	PROPN
dpc-3325	172	3	investig	investig	PROPN
dpc-3325	172	4	.	.	PUNCT
dpc-3325	173	1	2015;35(3):159	2015;35(3):159	PROPN
dpc-3325	173	2	-	-	PUNCT
dpc-3325	173	3	168	168	NUM
dpc-3325	173	4	.	.	PUNCT
dpc-3325	174	1	doi	doi	NOUN
dpc-3325	174	2	:	:	PUNCT
dpc-3325	174	3	10.1007	10.1007	NUM
dpc-3325	174	4	/s40261	/s40261	NOUN
dpc-3325	174	5	-	-	PUNCT
dpc-3325	174	6	015	015	NUM
dpc-3325	174	7	-	-	PUNCT
dpc-3325	174	8	0267	0267	NUM
dpc-3325	174	9	-	-	PUNCT
dpc-3325	174	10	9	9	NUM
dpc-3325	174	11	.	.	PUNCT
dpc-3325	175	1	pmid	pmid	NOUN
dpc-3325	175	2	:	:	PUNCT
dpc-3325	175	3	25578818	25578818	NUM
dpc-3325	175	4	.	.	PUNCT
dpc-3325	176	1	11	11	NUM
dpc-3325	176	2	.	.	PUNCT
dpc-3325	177	1	yalcin	yalcin	PROPN
dpc-3325	177	2	ad	ad	NOUN
dpc-3325	177	3	,	,	PUNCT
dpc-3325	177	4	celik	celik	VERB
dpc-3325	177	5	b	b	NUM
dpc-3325	177	6	,	,	PUNCT
dpc-3325	177	7	gumuslu	gumuslu	NOUN
dpc-3325	177	8	s.	s.	PROPN
dpc-3325	177	9	d	d	PROPN
dpc-3325	177	10	-	-	PUNCT
dpc-3325	177	11	dimer	dimer	ADJ
dpc-3325	177	12	levels	level	NOUN
dpc-3325	177	13	decreased	decrease	VERB
dpc-3325	177	14	in	in	ADP
dpc-3325	177	15	severe	severe	ADJ
dpc-3325	177	16	allergic	allergic	ADJ
dpc-3325	177	17	asthma	asthma	NOUN
dpc-3325	177	18	and	and	CCONJ
dpc-3325	177	19	chronic	chronic	ADJ
dpc-3325	177	20	urticaria	urticaria	NOUN
dpc-3325	177	21	patients	patient	NOUN
dpc-3325	177	22	with	with	ADP
dpc-3325	177	23	the	the	DET
dpc-3325	177	24	omalizumab	omalizumab	NOUN
dpc-3325	177	25	treatment	treatment	NOUN
dpc-3325	177	26	.	.	PUNCT
dpc-3325	178	1	expert	expert	NOUN
dpc-3325	178	2	opin	opin	NOUN
dpc-3325	178	3	biol	biol	NOUN
dpc-3325	178	4	ther	ther	ADV
dpc-3325	178	5	.	.	PUNCT
dpc-3325	179	1	2014;14(3):283	2014;14(3):283	NUM
dpc-3325	179	2	-	-	PUNCT
dpc-3325	179	3	286	286	NUM
dpc-3325	179	4	.	.	PUNCT
dpc-3325	180	1	doi	doi	NOUN
dpc-3325	180	2	:	:	PUNCT
dpc-3325	180	3	10.1517/14712598.2014.875525	10.1517/14712598.2014.875525	NUM
dpc-3325	180	4	.	.	PUNCT
dpc-3325	181	1	pmid	pmid	NOUN
dpc-3325	181	2	:	:	PUNCT
dpc-3325	181	3	24359555	24359555	NUM
dpc-3325	181	4	.	.	PUNCT
dpc-3325	182	1	12	12	NUM
dpc-3325	182	2	.	.	PUNCT
dpc-3325	183	1	puxeddu	puxeddu	PROPN
dpc-3325	183	2	i	i	PROPN
dpc-3325	183	3	,	,	PUNCT
dpc-3325	183	4	panza	panza	PROPN
dpc-3325	183	5	f	f	PROPN
dpc-3325	183	6	,	,	PUNCT
dpc-3325	183	7	pratesi	pratesi	PROPN
dpc-3325	183	8	f	f	X
dpc-3325	183	9	,	,	PUNCT
dpc-3325	183	10	et	et	PROPN
dpc-3325	183	11	al	al	PROPN
dpc-3325	183	12	.	.	PUNCT
dpc-3325	183	13	ccl5	ccl5	PROPN
dpc-3325	183	14	/	/	SYM
dpc-3325	183	15	rantes	rantes	PROPN
dpc-3325	183	16	,	,	PUNCT
dpc-3325	183	17	svcam-1	svcam-1	PROPN
dpc-3325	183	18	,	,	PUNCT
dpc-3325	183	19	and	and	CCONJ
dpc-3325	183	20	sicam-1	sicam-1	NUM
dpc-3325	183	21	in	in	ADP
dpc-3325	183	22	chronic	chronic	ADJ
dpc-3325	183	23	spontaneous	spontaneous	ADJ
dpc-3325	183	24	urticaria	urticaria	NOUN
dpc-3325	183	25	.	.	PUNCT
dpc-3325	184	1	int	int	PROPN
dpc-3325	184	2	arch	arch	ADJ
dpc-3325	184	3	allergy	allergy	PROPN
dpc-3325	184	4	immunol	immunol	NOUN
dpc-3325	184	5	.	.	PUNCT
dpc-3325	185	1	2013;162(4):330	2013;162(4):330	NUM
dpc-3325	185	2	-	-	SYM
dpc-3325	185	3	334	334	NUM
dpc-3325	185	4	.	.	PUNCT
dpc-3325	186	1	doi	doi	NOUN
dpc-3325	186	2	:	:	PUNCT
dpc-3325	186	3	10.1159/000354922	10.1159/000354922	NUM
dpc-3325	186	4	.	.	PUNCT
dpc-3325	187	1	pmid	pmid	NOUN
dpc-3325	187	2	:	:	PUNCT
dpc-3325	187	3	24157824	24157824	NUM
dpc-3325	187	4	.	.	PUNCT
dpc-3325	188	1	13	13	NUM
dpc-3325	188	2	.	.	X
dpc-3325	188	3	hossny	hossny	NOUN
dpc-3325	188	4	e	e	NOUN
dpc-3325	188	5	,	,	PUNCT
dpc-3325	188	6	aboul	aboul	PROPN
dpc-3325	188	7	-	-	PUNCT
dpc-3325	188	8	magd	magd	NOUN
dpc-3325	188	9	m	m	PROPN
dpc-3325	188	10	,	,	PUNCT
dpc-3325	188	11	bakr	bakr	PROPN
dpc-3325	188	12	s.	s.	PROPN
dpc-3325	188	13	increased	increase	VERB
dpc-3325	188	14	plasma	plasma	NOUN
dpc-3325	188	15	eotaxin	eotaxin	PROPN
dpc-3325	188	16	in	in	ADP
dpc-3325	188	17	atopic	atopic	NOUN
dpc-3325	188	18	dermatitis	dermatitis	NOUN
dpc-3325	188	19	and	and	CCONJ
dpc-3325	188	20	acute	acute	ADJ
dpc-3325	188	21	urticaria	urticaria	NOUN
dpc-3325	188	22	in	in	ADP
dpc-3325	188	23	infants	infant	NOUN
dpc-3325	188	24	and	and	CCONJ
dpc-3325	188	25	children	child	NOUN
dpc-3325	188	26	.	.	PUNCT
dpc-3325	189	1	allergy	allergy	NOUN
dpc-3325	189	2	.	.	PUNCT
dpc-3325	190	1	2001;56(10):996	2001;56(10):996	PROPN
dpc-3325	190	2	-	-	PUNCT
dpc-3325	190	3	1002	1002	NUM
dpc-3325	190	4	.	.	PUNCT
dpc-3325	191	1	doi	doi	NOUN
dpc-3325	191	2	:	:	PUNCT
dpc-3325	191	3	10.1034	10.1034	NUM
dpc-3325	191	4	/	/	SYM
dpc-3325	191	5	j.13989995.2001.00169.x	j.13989995.2001.00169.x	PROPN
dpc-3325	191	6	.	.	PUNCT
dpc-3325	192	1	pmid	pmid	NOUN
dpc-3325	192	2	:	:	PUNCT
dpc-3325	192	3	11576081	11576081	NUM
dpc-3325	192	4	.	.	PUNCT
dpc-3325	193	1	14	14	NUM
dpc-3325	193	2	.	.	PUNCT
dpc-3325	194	1	kolkhir	kolkhir	PROPN
dpc-3325	194	2	p	p	NOUN
dpc-3325	194	3	,	,	PUNCT
dpc-3325	194	4	andré	andré	VERB
dpc-3325	194	5	f	f	PROPN
dpc-3325	194	6	,	,	PUNCT
dpc-3325	194	7	church	church	PROPN
dpc-3325	194	8	mk	mk	PROPN
dpc-3325	194	9	,	,	PUNCT
dpc-3325	194	10	maurer	maurer	PROPN
dpc-3325	194	11	m	m	PROPN
dpc-3325	194	12	,	,	PUNCT
dpc-3325	194	13	metz	metz	PROPN
dpc-3325	194	14	m.	m.	NOUN
dpc-3325	194	15	potential	potential	ADJ
dpc-3325	194	16	blood	blood	NOUN
dpc-3325	194	17	biomarkers	biomarker	NOUN
dpc-3325	194	18	in	in	ADP
dpc-3325	194	19	chronic	chronic	ADJ
dpc-3325	194	20	spontaneous	spontaneous	ADJ
dpc-3325	194	21	urticaria	urticaria	NOUN
dpc-3325	194	22	.	.	PUNCT
dpc-3325	195	1	clin	clin	PROPN
dpc-3325	195	2	exp	exp	NOUN
dpc-3325	195	3	allergy	allergy	PROPN
dpc-3325	195	4	.	.	PUNCT
dpc-3325	196	1	2017;47(1):19	2017;47(1):19	NUM
dpc-3325	196	2	-	-	SYM
dpc-3325	196	3	36	36	NUM
dpc-3325	196	4	.	.	PUNCT
dpc-3325	197	1	doi	doi	NOUN
dpc-3325	197	2	:	:	PUNCT
dpc-3325	197	3	10.1111	10.1111	NUM
dpc-3325	197	4	/	/	SYM
dpc-3325	197	5	cea.12870	cea.12870	PROPN
dpc-3325	197	6	.	.	PUNCT
dpc-3325	198	1	pmid	pmid	NOUN
dpc-3325	198	2	:	:	PUNCT
dpc-3325	198	3	27926978	27926978	NUM
dpc-3325	198	4	.	.	PUNCT
dpc-3325	199	1	15	15	NUM
dpc-3325	199	2	.	.	X
dpc-3325	200	1	ying	ying	PROPN
dpc-3325	200	2	s	s	PROPN
dpc-3325	200	3	,	,	PUNCT
dpc-3325	200	4	kikuchi	kikuchi	PROPN
dpc-3325	200	5	y	y	PROPN
dpc-3325	200	6	,	,	PUNCT
dpc-3325	200	7	meng	meng	PROPN
dpc-3325	200	8	q	q	PROPN
dpc-3325	200	9	,	,	PUNCT
dpc-3325	200	10	kay	kay	PROPN
dpc-3325	200	11	ab	ab	PROPN
dpc-3325	200	12	,	,	PUNCT
dpc-3325	200	13	kaplan	kaplan	PROPN
dpc-3325	200	14	ap	ap	PROPN
dpc-3325	200	15	.	.	PUNCT
dpc-3325	201	1	th1	th1	PROPN
dpc-3325	201	2	/	/	SYM
dpc-3325	201	3	th2	th2	PROPN
dpc-3325	201	4	cytokines	cytokine	NOUN
dpc-3325	201	5	and	and	CCONJ
dpc-3325	201	6	inflammatory	inflammatory	ADJ
dpc-3325	201	7	cells	cell	NOUN
dpc-3325	201	8	in	in	ADP
dpc-3325	201	9	skin	skin	NOUN
dpc-3325	201	10	biopsy	biopsy	NOUN
dpc-3325	201	11	specimens	specimen	NOUN
dpc-3325	201	12	from	from	ADP
dpc-3325	201	13	patients	patient	NOUN
dpc-3325	201	14	with	with	ADP
dpc-3325	201	15	chronic	chronic	ADJ
dpc-3325	201	16	idiopathic	idiopathic	ADJ
dpc-3325	201	17	urticaria	urticaria	NOUN
dpc-3325	201	18	:	:	PUNCT
dpc-3325	201	19	comparison	comparison	NOUN
dpc-3325	201	20	with	with	ADP
dpc-3325	201	21	the	the	DET
dpc-3325	201	22	allergen	allergen	NOUN
dpc-3325	201	23	-	-	PUNCT
dpc-3325	201	24	induced	induce	VERB
dpc-3325	201	25	late	late	ADJ
dpc-3325	201	26	-	-	PUNCT
dpc-3325	201	27	phase	phase	NOUN
dpc-3325	201	28	cutaneous	cutaneous	ADJ
dpc-3325	201	29	reaction	reaction	NOUN
dpc-3325	201	30	.	.	PUNCT
dpc-3325	202	1	j	j	PROPN
dpc-3325	202	2	allergy	allergy	PROPN
dpc-3325	202	3	clin	clin	PROPN
dpc-3325	202	4	immunol	immunol	PROPN
dpc-3325	202	5	.	.	PUNCT
dpc-3325	203	1	2002;109(4):694	2002;109(4):694	NUM
dpc-3325	203	2	-	-	SYM
dpc-3325	203	3	700	700	NUM
dpc-3325	203	4	.	.	PUNCT
dpc-3325	204	1	doi	doi	NOUN
dpc-3325	204	2	:	:	PUNCT
dpc-3325	204	3	10.1067	10.1067	NUM
dpc-3325	204	4	/	/	SYM
dpc-3325	204	5	mai.2002.123236	mai.2002.123236	NUM
dpc-3325	204	6	.	.	PUNCT
dpc-3325	204	7	pmid	pmid	NOUN
dpc-3325	204	8	:	:	PUNCT
dpc-3325	204	9	11941321	11941321	NUM
dpc-3325	204	10	.	.	PUNCT
dpc-3325	205	1	16	16	NUM
dpc-3325	205	2	.	.	PUNCT
dpc-3325	206	1	tedeschi	tedeschi	PROPN
dpc-3325	206	2	a	a	PROPN
dpc-3325	206	3	,	,	PUNCT
dpc-3325	206	4	asero	asero	NOUN
dpc-3325	206	5	r	r	NOUN
dpc-3325	206	6	,	,	PUNCT
dpc-3325	206	7	marzano	marzano	PROPN
dpc-3325	206	8	av	av	PROPN
dpc-3325	206	9	,	,	PUNCT
dpc-3325	206	10	et	et	PROPN
dpc-3325	206	11	al	al	PROPN
dpc-3325	206	12	.	.	PUNCT
dpc-3325	206	13	plasma	plasma	NOUN
dpc-3325	206	14	levels	level	NOUN
dpc-3325	206	15	and	and	CCONJ
dpc-3325	206	16	skin	skin	NOUN
dpc-3325	206	17	-	-	PUNCT
dpc-3325	206	18	eosinophil	eosinophil	ADJ
dpc-3325	206	19	-	-	PUNCT
dpc-3325	206	20	expression	expression	NOUN
dpc-3325	206	21	of	of	ADP
dpc-3325	206	22	vascular	vascular	ADJ
dpc-3325	206	23	endothelial	endothelial	ADJ
dpc-3325	206	24	growth	growth	NOUN
dpc-3325	206	25	factor	factor	NOUN
dpc-3325	206	26	in	in	ADP
dpc-3325	206	27	patients	patient	NOUN
dpc-3325	206	28	with	with	ADP
dpc-3325	206	29	chronic	chronic	ADJ
dpc-3325	206	30	urticaria	urticaria	NOUN
dpc-3325	206	31	.	.	PUNCT
dpc-3325	207	1	allergy	allergy	NOUN
dpc-3325	207	2	.	.	PUNCT
dpc-3325	208	1	2009;64(11):1616	2009;64(11):1616	NUM
dpc-3325	208	2	-	-	SYM
dpc-3325	208	3	1622	1622	NUM
dpc-3325	208	4	.	.	PUNCT
dpc-3325	209	1	doi	doi	NOUN
dpc-3325	209	2	:	:	PUNCT
dpc-3325	209	3	10.1111	10.1111	NUM
dpc-3325	209	4	/	/	SYM
dpc-3325	209	5	j.1398	j.1398	PROPN
dpc-3325	209	6	-	-	PUNCT
dpc-3325	209	7	9995.2009.02069.x	9995.2009.02069.x	NOUN
dpc-3325	209	8	.	.	PUNCT
dpc-3325	210	1	pmid	pmid	NOUN
dpc-3325	210	2	:	:	PUNCT
dpc-3325	210	3	19485983	19485983	NUM
dpc-3325	210	4	.	.	PUNCT
dpc-3325	211	1	17	17	NUM
dpc-3325	211	2	.	.	X
dpc-3325	212	1	degirmenci	degirmenci	PROPN
dpc-3325	212	2	pb	pb	PROPN
dpc-3325	212	3	,	,	PUNCT
dpc-3325	212	4	kırmaz	kırmaz	NOUN
dpc-3325	212	5	c	c	NOUN
dpc-3325	212	6	,	,	PUNCT
dpc-3325	212	7	vatansever	vatansever	PROPN
dpc-3325	212	8	s	s	PROPN
dpc-3325	212	9	,	,	PUNCT
dpc-3325	212	10	et	et	PROPN
dpc-3325	212	11	al	al	PROPN
dpc-3325	212	12	.	.	PUNCT
dpc-3325	213	1	analysis	analysis	NOUN
dpc-3325	213	2	of	of	ADP
dpc-3325	213	3	the	the	DET
dpc-3325	213	4	association	association	NOUN
dpc-3325	213	5	of	of	ADP
dpc-3325	213	6	chronic	chronic	ADJ
dpc-3325	213	7	spontaneous	spontaneous	ADJ
dpc-3325	213	8	urticaria	urticaria	NOUN
dpc-3325	213	9	with	with	ADP
dpc-3325	213	10	interlekin-4	interlekin-4	PRON
dpc-3325	213	11	,	,	PUNCT
dpc-3325	213	12	-10	-10	PROPN
dpc-3325	213	13	,	,	PUNCT
dpc-3325	213	14	transforming	transform	VERB
dpc-3325	213	15	growth	growth	NOUN
dpc-3325	213	16	factor	factor	NOUN
dpc-3325	213	17	-	-	PUNCT
dpc-3325	213	18	β1	β1	PROPN
dpc-3325	213	19	,	,	PUNCT
dpc-3325	213	20	interferon	interferon	ADJ
dpc-3325	213	21	-	-	PUNCT
dpc-3325	213	22	γ	γ	PROPN
dpc-3325	213	23	,	,	PUNCT
dpc-3325	213	24	interleukin-17a	interleukin-17a	PROPN
dpc-3325	213	25	and	and	CCONJ
dpc-3325	213	26	-23	-23	PUNCT
dpc-3325	213	27	by	by	ADP
dpc-3325	213	28	autologous	autologous	ADJ
dpc-3325	213	29	serum	serum	NOUN
dpc-3325	213	30	skin	skin	NOUN
dpc-3325	213	31	test	test	NOUN
dpc-3325	213	32	.	.	PUNCT
dpc-3325	214	1	postepy	postepy	ADJ
dpc-3325	214	2	dermatol	dermatol	NOUN
dpc-3325	214	3	alergol	alergol	NOUN
dpc-3325	214	4	.	.	PUNCT
dpc-3325	215	1	2017;34(1):70	2017;34(1):70	NUM
dpc-3325	215	2	-	-	SYM
dpc-3325	215	3	76	76	NUM
dpc-3325	215	4	.	.	PUNCT
dpc-3325	216	1	doi	doi	NOUN
dpc-3325	216	2	:	:	PUNCT
dpc-3325	216	3	10.5114	10.5114	NUM
dpc-3325	216	4	/	/	SYM
dpc-3325	216	5	pdia.2016.57679	pdia.2016.57679	NOUN
dpc-3325	216	6	.	.	PUNCT
dpc-3325	217	1	pmid	pmid	NOUN
dpc-3325	217	2	:	:	PUNCT
dpc-3325	217	3	28261034	28261034	NUM
dpc-3325	217	4	.	.	PUNCT
dpc-3325	218	1	pmcid	pmcid	NOUN
dpc-3325	218	2	:	:	PUNCT
dpc-3325	218	3	pmc5329100	pmc5329100	NOUN
dpc-3325	218	4	.	.	PUNCT
dpc-3325	219	1	18	18	NUM
dpc-3325	219	2	.	.	X
dpc-3325	219	3	irinyi	irinyi	PROPN
dpc-3325	219	4	b	b	PROPN
dpc-3325	219	5	,	,	PUNCT
dpc-3325	219	6	aleksza	aleksza	PROPN
dpc-3325	219	7	m	m	PROPN
dpc-3325	219	8	,	,	PUNCT
dpc-3325	219	9	antal	antal	PROPN
dpc-3325	219	10	-	-	PUNCT
dpc-3325	219	11	szalmás	szalmás	PROPN
dpc-3325	219	12	p	p	NOUN
dpc-3325	219	13	,	,	PUNCT
dpc-3325	219	14	sipka	sipka	NOUN
dpc-3325	219	15	s	s	PART
dpc-3325	219	16	,	,	PUNCT
dpc-3325	219	17	hunyadi	hunyadi	ADJ
dpc-3325	219	18	  	  	SPACE
dpc-3325	219	19	j	j	PROPN
dpc-3325	219	20	,	,	PUNCT
dpc-3325	219	21	szegedi	szegedi	ADJ
dpc-3325	219	22	a.	a.	NOUN
dpc-3325	219	23	cytokine	cytokine	PROPN
dpc-3325	219	24	production	production	NOUN
dpc-3325	219	25	of	of	ADP
dpc-3325	219	26	cd4	cd4	PROPN
dpc-3325	219	27	+	+	PROPN
dpc-3325	219	28	and	and	CCONJ
dpc-3325	219	29	cd8	cd8	PROPN
dpc-3325	219	30	+	+	PROPN
dpc-3325	219	31	peripheral	peripheral	ADJ
dpc-3325	219	32	  	  	SPACE
dpc-3325	219	33	t	t	NOUN
dpc-3325	219	34	lymphocytes	lymphocyte	VERB
dpc-3325	219	35	in	in	ADP
dpc-3325	219	36	patients	patient	NOUN
dpc-3325	219	37	with	with	ADP
dpc-3325	219	38	chronic	chronic	ADJ
dpc-3325	219	39	idiopathic	idiopathic	ADJ
dpc-3325	219	40	urticaria	urticaria	NOUN
dpc-3325	219	41	.	.	PUNCT
dpc-3325	220	1	acta	acta	PROPN
dpc-3325	220	2	derm	derm	PROPN
dpc-3325	220	3	venereol	venereol	NOUN
dpc-3325	220	4	.	.	PUNCT
dpc-3325	221	1	2002;82(4):249	2002;82(4):249	NUM
dpc-3325	221	2	-	-	SYM
dpc-3325	221	3	253	253	NUM
dpc-3325	221	4	.	.	PUNCT
dpc-3325	222	1	doi	doi	NOUN
dpc-3325	222	2	:	:	PUNCT
dpc-3325	222	3	10.1080/000155502320323199	10.1080/000155502320323199	NUM
dpc-3325	222	4	.	.	PUNCT
dpc-3325	223	1	pmid	pmid	NOUN
dpc-3325	223	2	:	:	PUNCT
dpc-3325	223	3	12361127	12361127	NUM
dpc-3325	223	4	.	.	PUNCT
dpc-3325	224	1	19	19	NUM
dpc-3325	224	2	.	.	PUNCT
dpc-3325	224	3	weller	weller	PROPN
dpc-3325	224	4	k	k	PROPN
dpc-3325	224	5	,	,	PUNCT
dpc-3325	224	6	groffik	groffik	PROPN
dpc-3325	224	7	a	a	NOUN
dpc-3325	224	8	,	,	PUNCT
dpc-3325	224	9	church	church	NOUN
dpc-3325	224	10	mk	mk	PROPN
dpc-3325	224	11	,	,	PUNCT
dpc-3325	224	12	et	et	PROPN
dpc-3325	224	13	al	al	PROPN
dpc-3325	224	14	.	.	PROPN
dpc-3325	224	15	development	development	PROPN
dpc-3325	224	16	and	and	CCONJ
dpc-3325	224	17	validation	validation	NOUN
dpc-3325	224	18	of	of	ADP
dpc-3325	224	19	the	the	DET
dpc-3325	224	20	urticaria	urticaria	PROPN
dpc-3325	224	21	control	control	PROPN
dpc-3325	224	22	test	test	NOUN
dpc-3325	224	23	:	:	PUNCT
dpc-3325	224	24	a	a	DET
dpc-3325	224	25	patient	patient	NOUN
dpc-3325	224	26	-	-	PUNCT
dpc-3325	224	27	reported	report	VERB
dpc-3325	224	28	outcome	outcome	NOUN
dpc-3325	224	29	is	be	AUX
dpc-3325	224	30	therefore	therefore	ADV
dpc-3325	224	31	considered	consider	VERB
dpc-3325	224	32	to	to	PART
dpc-3325	224	33	be	be	AUX
dpc-3325	224	34	involved	involve	VERB
dpc-3325	224	35	in	in	ADP
dpc-3325	224	36	csu	csu	PROPN
dpc-3325	224	37	pathogenesis	pathogenesis	NOUN
dpc-3325	224	38	 	 	SPACE
dpc-3325	225	1	[	[	X
dpc-3325	225	2	46	46	NUM
dpc-3325	225	3	]	]	PUNCT
dpc-3325	225	4	.	.	PUNCT
dpc-3325	226	1	in	in	ADP
dpc-3325	226	2	a	a	DET
dpc-3325	226	3	study	study	NOUN
dpc-3325	226	4	by	by	ADP
dpc-3325	226	5	puxeddu	puxeddu	PROPN
dpc-3325	226	6	et	et	PROPN
dpc-3325	226	7	al	al	PROPN
dpc-3325	226	8	,	,	PUNCT
dpc-3325	226	9	levels	level	NOUN
dpc-3325	226	10	of	of	ADP
dpc-3325	226	11	rantes	rante	NOUN
dpc-3325	226	12	and	and	CCONJ
dpc-3325	226	13	il-8	il-8	NOUN
dpc-3325	226	14	were	be	AUX
dpc-3325	226	15	quantified	quantify	VERB
dpc-3325	226	16	in	in	ADP
dpc-3325	226	17	csu	csu	PROPN
dpc-3325	226	18	patients	patient	NOUN
dpc-3325	226	19	,	,	PUNCT
dpc-3325	226	20	and	and	CCONJ
dpc-3325	226	21	rantes	rante	NOUN
dpc-3325	226	22	was	be	AUX
dpc-3325	226	23	observed	observe	VERB
dpc-3325	226	24	to	to	PART
dpc-3325	226	25	be	be	AUX
dpc-3325	226	26	remarkably	remarkably	ADV
dpc-3325	226	27	higher	high	ADJ
dpc-3325	226	28	in	in	ADP
dpc-3325	226	29	csu	csu	PROPN
dpc-3325	226	30	compared	compare	VERB
dpc-3325	226	31	to	to	ADP
dpc-3325	226	32	healthy	healthy	ADJ
dpc-3325	226	33	controls	control	NOUN
dpc-3325	226	34	.	.	PUNCT
dpc-3325	227	1	however	however	ADV
dpc-3325	227	2	,	,	PUNCT
dpc-3325	227	3	no	no	DET
dpc-3325	227	4	association	association	NOUN
dpc-3325	227	5	was	be	AUX
dpc-3325	227	6	found	find	VERB
dpc-3325	227	7	between	between	ADP
dpc-3325	227	8	other	other	ADJ
dpc-3325	227	9	markers	marker	NOUN
dpc-3325	227	10	and	and	CCONJ
dpc-3325	227	11	rantes	rante	NOUN
dpc-3325	227	12	[	[	X
dpc-3325	227	13	13	13	NUM
dpc-3325	227	14	]	]	PUNCT
dpc-3325	227	15	.	.	PUNCT
dpc-3325	228	1	consistent	consistent	ADJ
dpc-3325	228	2	with	with	ADP
dpc-3325	228	3	these	these	DET
dpc-3325	228	4	findings	finding	NOUN
dpc-3325	228	5	,	,	PUNCT
dpc-3325	228	6	in	in	ADP
dpc-3325	228	7	the	the	DET
dpc-3325	228	8	current	current	ADJ
dpc-3325	228	9	study	study	NOUN
dpc-3325	228	10	,	,	PUNCT
dpc-3325	228	11	rantes	rante	NOUN
dpc-3325	228	12	levels	level	NOUN
dpc-3325	228	13	were	be	AUX
dpc-3325	228	14	detected	detect	VERB
dpc-3325	228	15	to	to	PART
dpc-3325	228	16	be	be	AUX
dpc-3325	228	17	higher	high	ADJ
dpc-3325	228	18	in	in	ADP
dpc-3325	228	19	csu	csu	PROPN
dpc-3325	228	20	patients	patient	NOUN
dpc-3325	228	21	regardless	regardless	ADV
dpc-3325	228	22	of	of	ADP
dpc-3325	228	23	disease	disease	NOUN
dpc-3325	228	24	activity	activity	NOUN
dpc-3325	228	25	.	.	PUNCT
dpc-3325	229	1	this	this	DET
dpc-3325	229	2	study	study	NOUN
dpc-3325	229	3	had	have	VERB
dpc-3325	229	4	certain	certain	ADJ
dpc-3325	229	5	limitations	limitation	NOUN
dpc-3325	229	6	.	.	PUNCT
dpc-3325	230	1	first	first	ADV
dpc-3325	230	2	,	,	PUNCT
dpc-3325	230	3	due	due	ADP
dpc-3325	230	4	to	to	ADP
dpc-3325	230	5	the	the	DET
dpc-3325	230	6	cross	cross	ADJ
dpc-3325	230	7	-	-	ADJ
dpc-3325	230	8	sectional	sectional	ADJ
dpc-3325	230	9	study	study	NOUN
dpc-3325	230	10	design	design	NOUN
dpc-3325	230	11	,	,	PUNCT
dpc-3325	230	12	the	the	DET
dpc-3325	230	13	study	study	NOUN
dpc-3325	230	14	outcomes	outcome	NOUN
dpc-3325	230	15	were	be	AUX
dpc-3325	230	16	not	not	PART
dpc-3325	230	17	fully	fully	ADV
dpc-3325	230	18	sufficient	sufficient	ADJ
dpc-3325	230	19	to	to	PART
dpc-3325	230	20	evaluate	evaluate	VERB
dpc-3325	230	21	the	the	DET
dpc-3325	230	22	efficacy	efficacy	NOUN
dpc-3325	230	23	of	of	ADP
dpc-3325	230	24	omalizumab	omalizumab	NOUN
dpc-3325	230	25	treatment	treatment	NOUN
dpc-3325	230	26	on	on	ADP
dpc-3325	230	27	biomarkers	biomarker	NOUN
dpc-3325	230	28	.	.	PUNCT
dpc-3325	231	1	it	it	PRON
dpc-3325	231	2	would	would	AUX
dpc-3325	231	3	be	be	AUX
dpc-3325	231	4	more	more	ADV
dpc-3325	231	5	reliable	reliable	ADJ
dpc-3325	231	6	to	to	PART
dpc-3325	231	7	analyze	analyze	VERB
dpc-3325	231	8	the	the	DET
dpc-3325	231	9	present	present	ADJ
dpc-3325	231	10	outcomes	outcome	NOUN
dpc-3325	231	11	with	with	ADP
dpc-3325	231	12	longitudinal	longitudinal	ADJ
dpc-3325	231	13	studies	study	NOUN
dpc-3325	231	14	.	.	PUNCT
dpc-3325	232	1	however	however	ADV
dpc-3325	232	2	,	,	PUNCT
dpc-3325	232	3	despite	despite	SCONJ
dpc-3325	232	4	its	its	PRON
dpc-3325	232	5	cross	cross	ADJ
dpc-3325	232	6	-	-	ADJ
dpc-3325	232	7	sectional	sectional	ADJ
dpc-3325	232	8	design	design	NOUN
dpc-3325	232	9	,	,	PUNCT
dpc-3325	232	10	the	the	DET
dpc-3325	232	11	fact	fact	NOUN
dpc-3325	232	12	that	that	SCONJ
dpc-3325	232	13	patients	patient	NOUN
dpc-3325	232	14	have	have	AUX
dpc-3325	232	15	been	be	AUX
dpc-3325	232	16	on	on	ADP
dpc-3325	232	17	omalizumab	omalizumab	NOUN
dpc-3325	232	18	treatment	treatment	NOUN
dpc-3325	232	19	for	for	ADP
dpc-3325	232	20	a	a	DET
dpc-3325	232	21	long	long	ADJ
dpc-3325	232	22	time	time	NOUN
dpc-3325	232	23	and	and	CCONJ
dpc-3325	232	24	the	the	DET
dpc-3325	232	25	cytokine	cytokine	ADJ
dpc-3325	232	26	profiles	profile	NOUN
dpc-3325	232	27	of	of	ADP
dpc-3325	232	28	those	those	PRON
dpc-3325	232	29	receiving	receive	VERB
dpc-3325	232	30	and	and	CCONJ
dpc-3325	232	31	not	not	PART
dpc-3325	232	32	receiving	receive	VERB
dpc-3325	232	33	omalizumab	omalizumab	NOUN
dpc-3325	232	34	were	be	AUX
dpc-3325	232	35	similar	similar	ADJ
dpc-3325	232	36	despite	despite	SCONJ
dpc-3325	232	37	better	well	ADJ
dpc-3325	232	38	clinical	clinical	ADJ
dpc-3325	232	39	scores	score	NOUN
dpc-3325	232	40	,	,	PUNCT
dpc-3325	232	41	suggests	suggest	VERB
dpc-3325	232	42	that	that	SCONJ
dpc-3325	232	43	omalizumab	omalizumab	NOUN
dpc-3325	232	44	might	might	AUX
dpc-3325	232	45	be	be	AUX
dpc-3325	232	46	effective	effective	ADJ
dpc-3325	232	47	through	through	ADP
dpc-3325	232	48	different	different	ADJ
dpc-3325	232	49	pathways	pathway	NOUN
dpc-3325	232	50	than	than	ADP
dpc-3325	232	51	these	these	DET
dpc-3325	232	52	cytokines	cytokine	NOUN
dpc-3325	232	53	.	.	PUNCT
dpc-3325	233	1	the	the	DET
dpc-3325	233	2	second	second	ADJ
dpc-3325	233	3	limitation	limitation	NOUN
dpc-3325	233	4	was	be	AUX
dpc-3325	233	5	the	the	DET
dpc-3325	233	6	limited	limited	ADJ
dpc-3325	233	7	number	number	NOUN
dpc-3325	233	8	of	of	ADP
dpc-3325	233	9	participants	participant	NOUN
dpc-3325	233	10	in	in	ADP
dpc-3325	233	11	the	the	DET
dpc-3325	233	12	control	control	NOUN
dpc-3325	233	13	group	group	NOUN
dpc-3325	233	14	.	.	PUNCT
dpc-3325	234	1	some	some	DET
dpc-3325	234	2	p	p	NOUN
dpc-3325	234	3	-	-	PUNCT
dpc-3325	234	4	values	value	NOUN
dpc-3325	234	5	could	could	AUX
dpc-3325	234	6	be	be	AUX
dpc-3325	234	7	more	more	ADV
dpc-3325	234	8	significant	significant	ADJ
dpc-3325	234	9	with	with	ADP
dpc-3325	234	10	a	a	DET
dpc-3325	234	11	larger	large	ADJ
dpc-3325	234	12	sample	sample	NOUN
dpc-3325	234	13	size	size	NOUN
dpc-3325	234	14	in	in	ADP
dpc-3325	234	15	the	the	DET
dpc-3325	234	16	control	control	NOUN
dpc-3325	234	17	group	group	NOUN
dpc-3325	234	18	.	.	PUNCT
dpc-3325	235	1	in	in	ADP
dpc-3325	235	2	conclusion	conclusion	NOUN
dpc-3325	235	3	,	,	PUNCT
dpc-3325	235	4	our	our	PRON
dpc-3325	235	5	results	result	NOUN
dpc-3325	235	6	suggest	suggest	VERB
dpc-3325	235	7	that	that	SCONJ
dpc-3325	235	8	the	the	DET
dpc-3325	235	9	investigated	investigate	VERB
dpc-3325	235	10	cytokine	cytokine	NOUN
dpc-3325	235	11	profile	profile	NOUN
dpc-3325	235	12	in	in	ADP
dpc-3325	235	13	csu	csu	PROPN
dpc-3325	235	14	patients	patient	NOUN
dpc-3325	235	15	may	may	AUX
dpc-3325	235	16	differ	differ	VERB
dpc-3325	235	17	from	from	ADP
dpc-3325	235	18	healthy	healthy	ADJ
dpc-3325	235	19	controls	control	NOUN
dpc-3325	235	20	and	and	CCONJ
dpc-3325	235	21	omalizumab	omalizumab	NOUN
dpc-3325	235	22	does	do	AUX
dpc-3325	235	23	not	not	PART
dpc-3325	235	24	seem	seem	VERB
dpc-3325	235	25	to	to	PART
dpc-3325	235	26	affect	affect	VERB
dpc-3325	235	27	that	that	DET
dpc-3325	235	28	profile	profile	NOUN
dpc-3325	235	29	in	in	ADP
dpc-3325	235	30	csu	csu	PROPN
dpc-3325	235	31	patients	patient	NOUN
dpc-3325	235	32	.	.	PUNCT
dpc-3325	236	1	references	reference	NOUN
dpc-3325	236	2	1	1	NUM
dpc-3325	236	3	.	.	PUNCT
dpc-3325	236	4	zuberbier	zuberbier	PROPN
dpc-3325	236	5	t	t	PROPN
dpc-3325	236	6	,	,	PUNCT
dpc-3325	236	7	aberer	aberer	PROPN
dpc-3325	236	8	w	w	PROPN
dpc-3325	236	9	,	,	PUNCT
dpc-3325	236	10	asero	asero	NOUN
dpc-3325	236	11	r	r	NOUN
dpc-3325	236	12	,	,	PUNCT
dpc-3325	236	13	et	et	PROPN
dpc-3325	236	14	al	al	PROPN
dpc-3325	236	15	.	.	PUNCT
dpc-3325	237	1	the	the	DET
dpc-3325	237	2	eaaci	eaaci	PROPN
dpc-3325	237	3	/	/	SYM
dpc-3325	237	4	ga²len/	ga²len/	PROPN
dpc-3325	237	5	edf	edf	PROPN
dpc-3325	237	6	/	/	SYM
dpc-3325	237	7	wao	wao	PROPN
dpc-3325	237	8	guideline	guideline	NOUN
dpc-3325	237	9	for	for	ADP
dpc-3325	237	10	the	the	DET
dpc-3325	237	11	definition	definition	NOUN
dpc-3325	237	12	,	,	PUNCT
dpc-3325	237	13	classification	classification	NOUN
dpc-3325	237	14	,	,	PUNCT
dpc-3325	237	15	diagnosis	diagnosis	NOUN
dpc-3325	237	16	and	and	CCONJ
dpc-3325	237	17	management	management	NOUN
dpc-3325	237	18	of	of	ADP
dpc-3325	237	19	urticaria	urticaria	NOUN
dpc-3325	237	20	.	.	PUNCT
dpc-3325	238	1	allergy	allergy	NOUN
dpc-3325	238	2	.	.	PUNCT
dpc-3325	239	1	2018;73(7):1393	2018;73(7):1393	PROPN
dpc-3325	239	2	-	-	SYM
dpc-3325	239	3	1414	1414	NUM
dpc-3325	239	4	.	.	PUNCT
dpc-3325	240	1	doi	doi	NOUN
dpc-3325	240	2	:	:	PUNCT
dpc-3325	240	3	10.1111	10.1111	NUM
dpc-3325	240	4	/	/	SYM
dpc-3325	240	5	all.13397	all.13397	PROPN
dpc-3325	240	6	.	.	PUNCT
dpc-3325	241	1	pmid	pmid	NOUN
dpc-3325	241	2	:	:	PUNCT
dpc-3325	241	3	29336054	29336054	NUM
dpc-3325	241	4	.	.	PUNCT
dpc-3325	242	1	2	2	X
dpc-3325	242	2	.	.	X
dpc-3325	242	3	weller	weller	PROPN
dpc-3325	242	4	k	k	PROPN
dpc-3325	242	5	,	,	PUNCT
dpc-3325	242	6	zuberbier	zuberbier	PROPN
dpc-3325	242	7	t	t	PROPN
dpc-3325	242	8	,	,	PUNCT
dpc-3325	242	9	maurer	maurer	PROPN
dpc-3325	242	10	m.	m.	PROPN
dpc-3325	242	11	clinically	clinically	ADV
dpc-3325	242	12	relevant	relevant	ADJ
dpc-3325	242	13	outcome	outcome	NOUN
dpc-3325	242	14	measures	measure	NOUN
dpc-3325	242	15	for	for	ADP
dpc-3325	242	16	assessing	assess	VERB
dpc-3325	242	17	disease	disease	NOUN
dpc-3325	242	18	activity	activity	NOUN
dpc-3325	242	19	,	,	PUNCT
dpc-3325	242	20	disease	disease	NOUN
dpc-3325	242	21	control	control	NOUN
dpc-3325	242	22	and	and	CCONJ
dpc-3325	242	23	quality	quality	NOUN
dpc-3325	242	24	of	of	ADP
dpc-3325	242	25	life	life	NOUN
dpc-3325	242	26	impairment	impairment	ADJ
dpc-3325	242	27	in	in	ADP
dpc-3325	242	28	patients	patient	NOUN
dpc-3325	242	29	with	with	ADP
dpc-3325	242	30	chronic	chronic	ADJ
dpc-3325	242	31	spontaneous	spontaneous	ADJ
dpc-3325	242	32	urticaria	urticaria	NOUN
dpc-3325	242	33	and	and	CCONJ
dpc-3325	242	34	recurrent	recurrent	ADJ
dpc-3325	242	35	angioedema	angioedema	NOUN
dpc-3325	242	36	.	.	PUNCT
dpc-3325	243	1	curr	curr	PROPN
dpc-3325	243	2	opin	opin	PROPN
dpc-3325	243	3	allergy	allergy	PROPN
dpc-3325	243	4	clin	clin	PROPN
dpc-3325	243	5	immunol	immunol	PROPN
dpc-3325	243	6	.	.	PUNCT
dpc-3325	244	1	2015;15(3):220	2015;15(3):220	NUM
dpc-3325	244	2	-	-	PUNCT
dpc-3325	244	3	226	226	NUM
dpc-3325	244	4	.	.	PUNCT
dpc-3325	245	1	doi	doi	NOUN
dpc-3325	245	2	:	:	PUNCT
dpc-3325	245	3	10.1097	10.1097	NUM
dpc-3325	245	4	/	/	SYM
dpc-3325	245	5	aci.0000000000000163	aci.0000000000000163	NUM
dpc-3325	245	6	.	.	PUNCT
dpc-3325	246	1	pmid	pmid	NOUN
dpc-3325	246	2	:	:	PUNCT
dpc-3325	246	3	25899695	25899695	NUM
dpc-3325	246	4	.	.	PUNCT
dpc-3325	247	1	3	3	X
dpc-3325	247	2	.	.	X
dpc-3325	247	3	zhang	zhang	PROPN
dpc-3325	247	4	y	y	PROPN
dpc-3325	247	5	,	,	PUNCT
dpc-3325	247	6	zhang	zhang	PROPN
dpc-3325	247	7	h	h	PROPN
dpc-3325	247	8	,	,	PUNCT
dpc-3325	247	9	du	du	PROPN
dpc-3325	247	10	s	s	PROPN
dpc-3325	247	11	,	,	PUNCT
dpc-3325	247	12	yan	yan	PROPN
dpc-3325	247	13	s	s	PROPN
dpc-3325	247	14	,	,	PUNCT
dpc-3325	247	15	zeng	zeng	PROPN
dpc-3325	247	16	j.	j.	PROPN
dpc-3325	247	17	advanced	advanced	PROPN
dpc-3325	247	18	biomarkers	biomarker	NOUN
dpc-3325	247	19	:	:	PUNCT
dpc-3325	247	20	therapeutic	therapeutic	ADJ
dpc-3325	247	21	and	and	CCONJ
dpc-3325	247	22	diagnostic	diagnostic	ADJ
dpc-3325	247	23	targets	target	NOUN
dpc-3325	247	24	in	in	ADP
dpc-3325	247	25	urticaria	urticaria	NOUN
dpc-3325	247	26	.	.	PUNCT
dpc-3325	248	1	int	int	PROPN
dpc-3325	248	2	arch	arch	ADJ
dpc-3325	248	3	allergy	allergy	PROPN
dpc-3325	248	4	immunol	immunol	NOUN
dpc-3325	248	5	.	.	PUNCT
dpc-3325	249	1	2021;182(10):917	2021;182(10):917	NUM
dpc-3325	249	2	-	-	SYM
dpc-3325	249	3	931	931	NUM
dpc-3325	249	4	.	.	PUNCT
dpc-3325	250	1	doi	doi	NOUN
dpc-3325	250	2	:	:	PUNCT
dpc-3325	250	3	10.1159/000515753	10.1159/000515753	NUM
dpc-3325	250	4	.	.	PUNCT
dpc-3325	251	1	pmid	pmid	NOUN
dpc-3325	251	2	:	:	PUNCT
dpc-3325	251	3	33915552	33915552	NUM
dpc-3325	251	4	.	.	PUNCT
dpc-3325	252	1	4	4	X
dpc-3325	252	2	.	.	X
dpc-3325	252	3	deza	deza	ADV
dpc-3325	252	4	g	g	NOUN
dpc-3325	252	5	,	,	PUNCT
dpc-3325	252	6	ricketti	ricketti	X
dpc-3325	252	7	pa	pa	PROPN
dpc-3325	252	8	,	,	PUNCT
dpc-3325	252	9	giménez	giménez	PROPN
dpc-3325	252	10	-	-	PUNCT
dpc-3325	252	11	arnau	arnau	PROPN
dpc-3325	252	12	am	be	AUX
dpc-3325	252	13	,	,	PUNCT
dpc-3325	252	14	casale	casale	NOUN
dpc-3325	252	15	tb	tb	NOUN
dpc-3325	252	16	.	.	PUNCT
dpc-3325	252	17	emerging	emerge	VERB
dpc-3325	252	18	biomarkers	biomarker	NOUN
dpc-3325	252	19	and	and	CCONJ
dpc-3325	252	20	therapeutic	therapeutic	ADJ
dpc-3325	252	21	pipelines	pipeline	NOUN
dpc-3325	252	22	for	for	ADP
dpc-3325	252	23	chronic	chronic	ADJ
dpc-3325	252	24	spontaneous	spontaneous	ADJ
dpc-3325	252	25	urticaria	urticaria	NOUN
dpc-3325	252	26	.	.	PUNCT
dpc-3325	253	1	j	j	PROPN
dpc-3325	253	2	allergy	allergy	PROPN
dpc-3325	253	3	clin	clin	PROPN
dpc-3325	253	4	immunol	immunol	PROPN
dpc-3325	253	5	pract	pract	PROPN
dpc-3325	253	6	.	.	PUNCT
dpc-3325	254	1	2018;6(4):1108	2018;6(4):1108	NUM
dpc-3325	254	2	-	-	SYM
dpc-3325	254	3	1117	1117	NUM
dpc-3325	254	4	.	.	PUNCT
dpc-3325	255	1	doi	doi	NOUN
dpc-3325	255	2	:	:	PUNCT
dpc-3325	255	3	10.1016	10.1016	NUM
dpc-3325	255	4	/	/	SYM
dpc-3325	255	5	j.jaip.2018.02.024	j.jaip.2018.02.024	PROPN
dpc-3325	255	6	.	.	PUNCT
dpc-3325	256	1	pmid	pmid	NOUN
dpc-3325	256	2	:	:	PUNCT
dpc-3325	256	3	30033912	30033912	NUM
dpc-3325	256	4	.	.	PUNCT
dpc-3325	257	1	5	5	X
dpc-3325	257	2	.	.	X
dpc-3325	257	3	kolkhir	kolkhir	PROPN
dpc-3325	257	4	p	p	NOUN
dpc-3325	257	5	,	,	PUNCT
dpc-3325	257	6	pogorelov	pogorelov	PROPN
dpc-3325	257	7	d	d	NOUN
dpc-3325	257	8	,	,	PUNCT
dpc-3325	257	9	olisova	olisova	PROPN
dpc-3325	257	10	o.	o.	PROPN
dpc-3325	257	11	crp	crp	PROPN
dpc-3325	257	12	,	,	PUNCT
dpc-3325	257	13	d	d	X
dpc-3325	257	14	-	-	PUNCT
dpc-3325	257	15	dimer	dimer	ADJ
dpc-3325	257	16	,	,	PUNCT
dpc-3325	257	17	fibrinogen	fibrinogen	NOUN
dpc-3325	257	18	and	and	CCONJ
dpc-3325	257	19	esr	esr	PROPN
dpc-3325	257	20	as	as	ADP
dpc-3325	257	21	predictive	predictive	ADJ
dpc-3325	257	22	markers	marker	NOUN
dpc-3325	257	23	of	of	ADP
dpc-3325	257	24	response	response	NOUN
dpc-3325	257	25	to	to	ADP
dpc-3325	257	26	standard	standard	ADJ
dpc-3325	257	27	doses	dose	NOUN
dpc-3325	257	28	of	of	ADP
dpc-3325	257	29	levocetirizine	levocetirizine	NOUN
dpc-3325	257	30	in	in	ADP
dpc-3325	257	31	patients	patient	NOUN
dpc-3325	257	32	with	with	ADP
dpc-3325	257	33	chronic	chronic	ADJ
dpc-3325	257	34	spontaneous	spontaneous	ADJ
dpc-3325	257	35	urticaria	urticaria	NOUN
dpc-3325	257	36	.	.	PUNCT
dpc-3325	258	1	eur	eur	PROPN
dpc-3325	258	2	ann	ann	PROPN
dpc-3325	258	3	allergy	allergy	PROPN
dpc-3325	258	4	clin	clin	PROPN
dpc-3325	258	5	immunol	immunol	PROPN
dpc-3325	258	6	.	.	PUNCT
dpc-3325	259	1	2017;49(4):189	2017;49(4):189	NUM
dpc-3325	259	2	-	-	PUNCT
dpc-3325	259	3	192	192	NUM
dpc-3325	259	4	.	.	PUNCT
dpc-3325	260	1	doi	doi	NOUN
dpc-3325	260	2	:	:	PUNCT
dpc-3325	260	3	10.23822	10.23822	NUM
dpc-3325	260	4	/	/	SYM
dpc-3325	260	5	eurannaci.1764	eurannaci.1764	PROPN
dpc-3325	260	6	-	-	PUNCT
dpc-3325	260	7	1489.05	1489.05	NUM
dpc-3325	260	8	.	.	PUNCT
dpc-3325	261	1	pmid	pmid	NOUN
dpc-3325	261	2	:	:	PUNCT
dpc-3325	261	3	28752724	28752724	NUM
dpc-3325	261	4	.	.	PUNCT
dpc-3325	262	1	6	6	NUM
dpc-3325	262	2	.	.	NOUN
dpc-3325	262	3	toubi	toubi	NOUN
dpc-3325	262	4	e	e	NOUN
dpc-3325	262	5	,	,	PUNCT
dpc-3325	262	6	vadasz	vadasz	NOUN
dpc-3325	262	7	z.	z.	PROPN
dpc-3325	263	1	the	the	DET
dpc-3325	263	2	emerging	emerge	VERB
dpc-3325	263	3	role	role	NOUN
dpc-3325	263	4	of	of	ADP
dpc-3325	263	5	il-17	il-17	NUM
dpc-3325	263	6	in	in	ADP
dpc-3325	263	7	the	the	DET
dpc-3325	263	8	immune	immune	NOUN
dpc-3325	263	9	-	-	PUNCT
dpc-3325	263	10	pathogenesis	pathogenesis	NOUN
dpc-3325	263	11	of	of	ADP
dpc-3325	263	12	chronic	chronic	ADJ
dpc-3325	263	13	spontaneous	spontaneous	ADJ
dpc-3325	263	14	urticaria	urticaria	NOUN
dpc-3325	263	15	.	.	PUNCT
dpc-3325	264	1	immunotargets	immunotarget	NOUN
dpc-3325	264	2	ther	ther	ADV
dpc-3325	264	3	.	.	PUNCT
dpc-3325	265	1	2020;9:217	2020;9:217	NUM
dpc-3325	265	2	-	-	SYM
dpc-3325	265	3	223	223	NUM
dpc-3325	265	4	.	.	PUNCT
dpc-3325	266	1	doi	doi	NOUN
dpc-3325	266	2	:	:	PUNCT
dpc-3325	266	3	10.2147	10.2147	NUM
dpc-3325	266	4	/	/	SYM
dpc-3325	266	5	itt.s266410	itt.s266410	ADJ
dpc-3325	266	6	.	.	PUNCT
dpc-3325	267	1	pmid	pmid	NOUN
dpc-3325	267	2	:	:	PUNCT
dpc-3325	267	3	33134229	33134229	NUM
dpc-3325	267	4	.	.	PUNCT
dpc-3325	268	1	pmcid	pmcid	NOUN
dpc-3325	268	2	:	:	PUNCT
dpc-3325	268	3	pmc7592154	pmc7592154	PROPN
dpc-3325	268	4	.	.	PUNCT
dpc-3325	269	1	8	8	NUM
dpc-3325	269	2	original	original	ADJ
dpc-3325	269	3	article	article	NOUN
dpc-3325	269	4	|	|	ADV
dpc-3325	269	5	dermatol	dermatol	ADJ
dpc-3325	269	6	pract	pract	NOUN
dpc-3325	269	7	concept	concept	NOUN
dpc-3325	269	8	.	.	PUNCT
dpc-3325	270	1	2023;13(4):e2023272	2023;13(4):e2023272	NUM
dpc-3325	270	2	32	32	NUM
dpc-3325	270	3	.	.	PUNCT
dpc-3325	271	1	noga	noga	PROPN
dpc-3325	271	2	o	o	PROPN
dpc-3325	271	3	,	,	PUNCT
dpc-3325	271	4	hanf	hanf	PROPN
dpc-3325	271	5	g	g	PROPN
dpc-3325	271	6	,	,	PUNCT
dpc-3325	271	7	kunkel	kunkel	PROPN
dpc-3325	271	8	g.	g.	PROPN
dpc-3325	271	9	immunological	immunological	ADJ
dpc-3325	271	10	and	and	CCONJ
dpc-3325	271	11	clinical	clinical	ADJ
dpc-3325	271	12	changes	change	NOUN
dpc-3325	271	13	in	in	ADP
dpc-3325	271	14	allergic	allergic	ADJ
dpc-3325	271	15	asthmatics	asthmatic	NOUN
dpc-3325	271	16	following	follow	VERB
dpc-3325	271	17	treatment	treatment	NOUN
dpc-3325	271	18	with	with	ADP
dpc-3325	271	19	omalizumab	omalizumab	NOUN
dpc-3325	271	20	.	.	PUNCT
dpc-3325	272	1	int	int	PROPN
dpc-3325	272	2	arch	arch	ADJ
dpc-3325	272	3	allergy	allergy	PROPN
dpc-3325	272	4	immunol	immunol	NOUN
dpc-3325	272	5	.	.	PUNCT
dpc-3325	273	1	2003;131(1):46	2003;131(1):46	PROPN
dpc-3325	273	2	-	-	PUNCT
dpc-3325	273	3	52	52	NUM
dpc-3325	273	4	.	.	PUNCT
dpc-3325	274	1	doi	doi	NOUN
dpc-3325	274	2	:	:	PUNCT
dpc-3325	274	3	10.1159/000070434	10.1159/000070434	NUM
dpc-3325	274	4	.	.	PUNCT
dpc-3325	275	1	pmid	pmid	NOUN
dpc-3325	275	2	:	:	PUNCT
dpc-3325	275	3	12759489	12759489	NUM
dpc-3325	275	4	.	.	PUNCT
dpc-3325	276	1	33	33	NUM
dpc-3325	276	2	.	.	PUNCT
dpc-3325	277	1	kay	kay	PROPN
dpc-3325	277	2	ab	ab	PROPN
dpc-3325	277	3	,	,	PUNCT
dpc-3325	277	4	clark	clark	PROPN
dpc-3325	277	5	p	p	PROPN
dpc-3325	277	6	,	,	PUNCT
dpc-3325	277	7	maurer	maurer	PROPN
dpc-3325	277	8	m	m	PROPN
dpc-3325	277	9	,	,	PUNCT
dpc-3325	277	10	ying	ying	PROPN
dpc-3325	277	11	s.	s.	PROPN
dpc-3325	277	12	elevations	elevation	NOUN
dpc-3325	277	13	in	in	ADP
dpc-3325	277	14	thelper2	thelper2	NOUN
dpc-3325	277	15	-	-	PUNCT
dpc-3325	277	16	initiating	initiate	VERB
dpc-3325	277	17	cytokines	cytokine	NOUN
dpc-3325	277	18	(	(	PUNCT
dpc-3325	277	19	interleukin-33	interleukin-33	PROPN
dpc-3325	277	20	,	,	PUNCT
dpc-3325	277	21	interleukin-25	interleukin-25	PROPN
dpc-3325	277	22	and	and	CCONJ
dpc-3325	277	23	thymic	thymic	ADJ
dpc-3325	277	24	stromal	stromal	ADJ
dpc-3325	277	25	lymphopoietin	lymphopoietin	NOUN
dpc-3325	277	26	)	)	PUNCT
dpc-3325	277	27	in	in	ADP
dpc-3325	277	28	lesional	lesional	ADJ
dpc-3325	277	29	skin	skin	NOUN
dpc-3325	277	30	from	from	ADP
dpc-3325	277	31	chronic	chronic	ADJ
dpc-3325	277	32	spontaneous	spontaneous	ADJ
dpc-3325	277	33	(	(	PUNCT
dpc-3325	277	34	'	'	PUNCT
dpc-3325	277	35	idiopathic	idiopathic	ADJ
dpc-3325	277	36	'	'	PUNCT
dpc-3325	277	37	)	)	PUNCT
dpc-3325	277	38	urticaria	urticaria	NOUN
dpc-3325	277	39	.	.	PUNCT
dpc-3325	278	1	br	br	PROPN
dpc-3325	278	2	j	j	PROPN
dpc-3325	278	3	dermatol	dermatol	NOUN
dpc-3325	278	4	.	.	PUNCT
dpc-3325	279	1	2015;172(5):12941302	2015;172(5):12941302	X
dpc-3325	279	2	.	.	PUNCT
dpc-3325	279	3	doi	doi	NOUN
dpc-3325	279	4	:	:	PUNCT
dpc-3325	279	5	10.1111	10.1111	NUM
dpc-3325	279	6	/	/	SYM
dpc-3325	279	7	bjd.13621	bjd.13621	PROPN
dpc-3325	279	8	.	.	PUNCT
dpc-3325	280	1	pmid	pmid	NOUN
dpc-3325	280	2	:	:	PUNCT
dpc-3325	280	3	25523947	25523947	NUM
dpc-3325	280	4	.	.	PUNCT
dpc-3325	281	1	34	34	NUM
dpc-3325	281	2	.	.	PUNCT
dpc-3325	281	3	kocatürk	kocatürk	PROPN
dpc-3325	282	1	e	e	PROPN
dpc-3325	282	2	,	,	PUNCT
dpc-3325	282	3	maurer	maurer	PROPN
dpc-3325	282	4	m	m	PROPN
dpc-3325	282	5	,	,	PUNCT
dpc-3325	282	6	metz	metz	PROPN
dpc-3325	282	7	m	m	PROPN
dpc-3325	282	8	,	,	PUNCT
dpc-3325	282	9	grattan	grattan	PROPN
dpc-3325	282	10	c.	c.	PROPN
dpc-3325	282	11	looking	look	VERB
dpc-3325	282	12	forward	forward	ADV
dpc-3325	282	13	to	to	ADP
dpc-3325	282	14	new	new	ADJ
dpc-3325	282	15	targeted	target	VERB
dpc-3325	282	16	treatments	treatment	NOUN
dpc-3325	282	17	for	for	ADP
dpc-3325	282	18	chronic	chronic	ADJ
dpc-3325	282	19	spontaneous	spontaneous	ADJ
dpc-3325	282	20	urticaria	urticaria	NOUN
dpc-3325	282	21	.	.	PUNCT
dpc-3325	283	1	clin	clin	PROPN
dpc-3325	283	2	transl	transl	PROPN
dpc-3325	283	3	allergy	allergy	PROPN
dpc-3325	283	4	.	.	PUNCT
dpc-3325	284	1	2017;7:1	2017;7:1	NUM
dpc-3325	284	2	.	.	PUNCT
dpc-3325	284	3	doi	doi	PROPN
dpc-3325	284	4	:	:	PUNCT
dpc-3325	284	5	10.1186	10.1186	NUM
dpc-3325	284	6	/	/	SYM
dpc-3325	284	7	s13601	s13601	NOUN
dpc-3325	284	8	-	-	PUNCT
dpc-3325	284	9	016	016	NUM
dpc-3325	284	10	-	-	PUNCT
dpc-3325	284	11	0139	0139	NUM
dpc-3325	284	12	-	-	PUNCT
dpc-3325	284	13	2	2	NUM
dpc-3325	284	14	.	.	PUNCT
dpc-3325	285	1	pmid	pmid	NOUN
dpc-3325	285	2	:	:	PUNCT
dpc-3325	285	3	28078079	28078079	NUM
dpc-3325	285	4	.	.	PUNCT
dpc-3325	286	1	pmcid	pmcid	NOUN
dpc-3325	286	2	:	:	PUNCT
dpc-3325	286	3	pmc5223554	pmc5223554	NOUN
dpc-3325	286	4	.	.	PUNCT
dpc-3325	287	1	35	35	NUM
dpc-3325	287	2	.	.	PUNCT
dpc-3325	287	3	raap	raap	PROPN
dpc-3325	287	4	u	u	PROPN
dpc-3325	287	5	,	,	PUNCT
dpc-3325	287	6	wichmann	wichmann	PROPN
dpc-3325	287	7	k	k	PROPN
dpc-3325	287	8	,	,	PUNCT
dpc-3325	287	9	bruder	bruder	NOUN
dpc-3325	287	10	m	m	PROPN
dpc-3325	287	11	,	,	PUNCT
dpc-3325	287	12	ständer	ständer	NOUN
dpc-3325	287	13	s	s	PART
dpc-3325	287	14	,	,	PUNCT
dpc-3325	287	15	wedi	wedi	PROPN
dpc-3325	287	16	b	b	PROPN
dpc-3325	287	17	,	,	PUNCT
dpc-3325	287	18	kapp	kapp	PROPN
dpc-3325	287	19	a	a	PROPN
dpc-3325	287	20	,	,	PUNCT
dpc-3325	287	21	werfel	werfel	ADJ
dpc-3325	287	22	t.	t.	NOUN
dpc-3325	287	23	correlation	correlation	NOUN
dpc-3325	287	24	of	of	ADP
dpc-3325	287	25	il-31	il-31	ADJ
dpc-3325	287	26	serum	serum	NOUN
dpc-3325	287	27	levels	level	NOUN
dpc-3325	287	28	with	with	ADP
dpc-3325	287	29	severity	severity	NOUN
dpc-3325	287	30	of	of	ADP
dpc-3325	287	31	atopic	atopic	NOUN
dpc-3325	287	32	dermatitis	dermatitis	NOUN
dpc-3325	287	33	.	.	PUNCT
dpc-3325	288	1	j	j	PROPN
dpc-3325	288	2	allergy	allergy	PROPN
dpc-3325	288	3	clin	clin	PROPN
dpc-3325	288	4	immunol	immunol	NOUN
dpc-3325	288	5	.	.	PUNCT
dpc-3325	289	1	2008;122(2):421	2008;122(2):421	X
dpc-3325	289	2	-	-	SYM
dpc-3325	289	3	423	423	NUM
dpc-3325	289	4	.	.	PUNCT
dpc-3325	290	1	doi	doi	NOUN
dpc-3325	290	2	:	:	PUNCT
dpc-3325	290	3	10.1016	10.1016	NUM
dpc-3325	290	4	/	/	SYM
dpc-3325	290	5	j.jaci.2008.05.047	j.jaci.2008.05.047	PROPN
dpc-3325	290	6	.	.	PUNCT
dpc-3325	291	1	pmid	pmid	NOUN
dpc-3325	291	2	:	:	PUNCT
dpc-3325	291	3	18678344	18678344	NUM
dpc-3325	291	4	.	.	PUNCT
dpc-3325	292	1	36	36	NUM
dpc-3325	292	2	.	.	PUNCT
dpc-3325	293	1	kasraie	kasraie	PROPN
dpc-3325	293	2	s	s	PROPN
dpc-3325	293	3	,	,	PUNCT
dpc-3325	293	4	niebuhr	niebuhr	PROPN
dpc-3325	293	5	m	m	PROPN
dpc-3325	293	6	,	,	PUNCT
dpc-3325	293	7	werfel	werfel	ADJ
dpc-3325	293	8	t.	t.	NOUN
dpc-3325	293	9	interleukin	interleukin	NOUN
dpc-3325	293	10	(	(	PUNCT
dpc-3325	293	11	il)-31	il)-31	NOUN
dpc-3325	293	12	induces	induce	VERB
dpc-3325	293	13	pro	pro	ADJ
dpc-3325	293	14	inflammatory	inflammatory	ADJ
dpc-3325	293	15	cytokines	cytokine	NOUN
dpc-3325	293	16	in	in	ADP
dpc-3325	293	17	human	human	ADJ
dpc-3325	293	18	monocytes	monocyte	NOUN
dpc-3325	293	19	and	and	CCONJ
dpc-3325	293	20	macrophages	macrophage	NOUN
dpc-3325	293	21	following	follow	VERB
dpc-3325	293	22	stimulation	stimulation	NOUN
dpc-3325	293	23	with	with	ADP
dpc-3325	293	24	staphylococcal	staphylococcal	ADJ
dpc-3325	293	25	exotoxins	exotoxin	NOUN
dpc-3325	293	26	.	.	PUNCT
dpc-3325	294	1	allergy	allergy	NOUN
dpc-3325	294	2	.	.	PUNCT
dpc-3325	295	1	2010;65(6):712	2010;65(6):712	NOUN
dpc-3325	295	2	-	-	PUNCT
dpc-3325	295	3	721	721	NUM
dpc-3325	295	4	.	.	PUNCT
dpc-3325	296	1	doi	doi	NOUN
dpc-3325	296	2	:	:	PUNCT
dpc-3325	296	3	10.1111	10.1111	NUM
dpc-3325	296	4	/	/	SYM
dpc-3325	296	5	j.1398	j.1398	PROPN
dpc-3325	296	6	-	-	PUNCT
dpc-3325	296	7	9995.2009.02255.x	9995.2009.02255.x	NOUN
dpc-3325	296	8	.	.	PUNCT
dpc-3325	297	1	pmid	pmid	NOUN
dpc-3325	297	2	:	:	PUNCT
dpc-3325	297	3	19889120	19889120	NUM
dpc-3325	297	4	.	.	PUNCT
dpc-3325	298	1	37	37	NUM
dpc-3325	298	2	.	.	PUNCT
dpc-3325	299	1	lin	lin	PROPN
dpc-3325	299	2	w	w	PROPN
dpc-3325	299	3	,	,	PUNCT
dpc-3325	299	4	zhou	zhou	PROPN
dpc-3325	299	5	q	q	PROPN
dpc-3325	299	6	,	,	PUNCT
dpc-3325	299	7	liu	liu	PROPN
dpc-3325	299	8	c	c	PROPN
dpc-3325	299	9	,	,	PUNCT
dpc-3325	299	10	ying	ying	PROPN
dpc-3325	299	11	m	m	PROPN
dpc-3325	299	12	,	,	PUNCT
dpc-3325	299	13	xu	xu	PROPN
dpc-3325	299	14	s.	s.	PROPN
dpc-3325	299	15	increased	increase	VERB
dpc-3325	299	16	plasma	plasma	NOUN
dpc-3325	299	17	il-17	il-17	ADV
dpc-3325	299	18	,	,	PUNCT
dpc-3325	299	19	il-31	il-31	X
dpc-3325	299	20	,	,	PUNCT
dpc-3325	299	21	and	and	CCONJ
dpc-3325	299	22	il-33	il-33	VERB
dpc-3325	299	23	levels	level	NOUN
dpc-3325	299	24	in	in	ADP
dpc-3325	299	25	chronic	chronic	ADJ
dpc-3325	299	26	spontaneous	spontaneous	ADJ
dpc-3325	299	27	urticaria	urticaria	NOUN
dpc-3325	299	28	.	.	PUNCT
dpc-3325	300	1	sci	sci	PROPN
dpc-3325	300	2	rep	rep	PROPN
dpc-3325	300	3	.	.	PROPN
dpc-3325	300	4	2017;7(1):17797	2017;7(1):17797	PROPN
dpc-3325	300	5	.	.	PUNCT
dpc-3325	301	1	doi	doi	NOUN
dpc-3325	301	2	:	:	PUNCT
dpc-3325	301	3	10.1038	10.1038	NUM
dpc-3325	301	4	/	/	SYM
dpc-3325	301	5	s41598	s41598	NOUN
dpc-3325	301	6	-	-	PUNCT
dpc-3325	301	7	017	017	NUM
dpc-3325	301	8	-	-	PUNCT
dpc-3325	301	9	18187	18187	NUM
dpc-3325	301	10	-	-	PUNCT
dpc-3325	301	11	z.	z.	PROPN
dpc-3325	301	12	pmid	pmid	PROPN
dpc-3325	301	13	:	:	PUNCT
dpc-3325	301	14	29259273	29259273	NUM
dpc-3325	301	15	.	.	PUNCT
dpc-3325	302	1	pmcid	pmcid	NOUN
dpc-3325	302	2	:	:	PUNCT
dpc-3325	302	3	pmc5736548	pmc5736548	ADJ
dpc-3325	302	4	.	.	PUNCT
dpc-3325	303	1	38	38	NUM
dpc-3325	303	2	.	.	PUNCT
dpc-3325	303	3	raap	raap	PROPN
dpc-3325	303	4	u	u	PROPN
dpc-3325	303	5	,	,	PUNCT
dpc-3325	303	6	gehring	gehre	VERB
dpc-3325	303	7	m	m	PRON
dpc-3325	303	8	,	,	PUNCT
dpc-3325	303	9	kleiner	kleiner	PROPN
dpc-3325	303	10	s	s	PART
dpc-3325	303	11	,	,	PUNCT
dpc-3325	303	12	et	et	PROPN
dpc-3325	303	13	al	al	PROPN
dpc-3325	303	14	.	.	PUNCT
dpc-3325	304	1	human	human	ADJ
dpc-3325	304	2	basophils	basophils	PROPN
dpc-3325	304	3	are	be	AUX
dpc-3325	304	4	a	a	DET
dpc-3325	304	5	source	source	NOUN
dpc-3325	304	6	of	of	ADP
dpc-3325	304	7	and	and	CCONJ
dpc-3325	304	8	are	be	AUX
dpc-3325	304	9	differentially	differentially	ADV
dpc-3325	304	10	activated	activate	VERB
dpc-3325	304	11	by	by	ADP
dpc-3325	304	12	il-31	il-31	NOUN
dpc-3325	304	13	.	.	PUNCT
dpc-3325	305	1	clin	clin	PROPN
dpc-3325	305	2	exp	exp	NOUN
dpc-3325	305	3	allergy	allergy	PROPN
dpc-3325	305	4	.	.	PUNCT
dpc-3325	306	1	2017;47(4):499	2017;47(4):499	NUM
dpc-3325	306	2	-	-	SYM
dpc-3325	306	3	508	508	NUM
dpc-3325	306	4	.	.	PUNCT
dpc-3325	307	1	doi	doi	NOUN
dpc-3325	307	2	:	:	PUNCT
dpc-3325	307	3	10.1111	10.1111	NUM
dpc-3325	307	4	/	/	SYM
dpc-3325	307	5	cea.12875	cea.12875	X
dpc-3325	307	6	.	.	PUNCT
dpc-3325	308	1	pmid	pmid	NOUN
dpc-3325	308	2	:	:	PUNCT
dpc-3325	308	3	28000952	28000952	NUM
dpc-3325	308	4	.	.	PUNCT
dpc-3325	309	1	39	39	NUM
dpc-3325	309	2	.	.	PUNCT
dpc-3325	310	1	grimstad	grimstad	NOUN
dpc-3325	310	2	o	o	PROPN
dpc-3325	310	3	,	,	PUNCT
dpc-3325	310	4	sawanobori	sawanobori	PROPN
dpc-3325	310	5	y	y	PROPN
dpc-3325	310	6	,	,	PUNCT
dpc-3325	310	7	vestergaard	vestergaard	PROPN
dpc-3325	310	8	c	c	NOUN
dpc-3325	310	9	,	,	PUNCT
dpc-3325	310	10	et	et	PROPN
dpc-3325	310	11	al	al	PROPN
dpc-3325	310	12	.	.	PUNCT
dpc-3325	311	1	anti	anti	ADJ
dpc-3325	311	2	-	-	ADJ
dpc-3325	311	3	interleukin	interleukin	ADJ
dpc-3325	311	4	31	31	NUM
dpc-3325	311	5	-	-	PUNCT
dpc-3325	311	6	antibodies	antibody	NOUN
dpc-3325	311	7	ameliorate	ameliorate	VERB
dpc-3325	311	8	scratching	scratch	VERB
dpc-3325	311	9	behaviour	behaviour	NOUN
dpc-3325	311	10	in	in	ADP
dpc-3325	311	11	nc	nc	PROPN
dpc-3325	311	12	/	/	SYM
dpc-3325	311	13	nga	nga	NOUN
dpc-3325	311	14	mice	mouse	NOUN
dpc-3325	311	15	:	:	PUNCT
dpc-3325	311	16	a	a	DET
dpc-3325	311	17	model	model	NOUN
dpc-3325	311	18	of	of	ADP
dpc-3325	311	19	atopic	atopic	NOUN
dpc-3325	311	20	dermatitis	dermatitis	NOUN
dpc-3325	311	21	.	.	PUNCT
dpc-3325	312	1	exp	exp	NOUN
dpc-3325	312	2	dermatol	dermatol	NOUN
dpc-3325	312	3	.	.	PUNCT
dpc-3325	313	1	2009;18(1):35	2009;18(1):35	NUM
dpc-3325	313	2	-	-	SYM
dpc-3325	313	3	43	43	NUM
dpc-3325	313	4	.	.	PUNCT
dpc-3325	314	1	doi	doi	NOUN
dpc-3325	314	2	:	:	PUNCT
dpc-3325	314	3	10.1111	10.1111	NUM
dpc-3325	314	4	/	/	SYM
dpc-3325	314	5	j.1600	j.1600	NOUN
dpc-3325	314	6	-	-	PUNCT
dpc-3325	314	7	0625.2008.00766.x	0625.2008.00766.x	PROPN
dpc-3325	314	8	.	.	PUNCT
dpc-3325	315	1	pmid	pmid	NOUN
dpc-3325	315	2	:	:	PUNCT
dpc-3325	315	3	19054054	19054054	NUM
dpc-3325	315	4	.	.	PUNCT
dpc-3325	316	1	40	40	NUM
dpc-3325	316	2	.	.	PUNCT
dpc-3325	317	1	raap	raap	PROPN
dpc-3325	317	2	u	u	PROPN
dpc-3325	317	3	,	,	PUNCT
dpc-3325	317	4	weißmantel	weißmantel	PROPN
dpc-3325	317	5	s	s	PROPN
dpc-3325	317	6	,	,	PUNCT
dpc-3325	317	7	gehring	gehre	VERB
dpc-3325	317	8	m	m	PRON
dpc-3325	317	9	,	,	PUNCT
dpc-3325	317	10	eisenberg	eisenberg	PROPN
dpc-3325	317	11	am	be	AUX
dpc-3325	317	12	,	,	PUNCT
dpc-3325	317	13	kapp	kapp	PROPN
dpc-3325	317	14	a	a	PRON
dpc-3325	317	15	,	,	PUNCT
dpc-3325	317	16	fölster	fölster	NOUN
dpc-3325	317	17	-	-	PUNCT
dpc-3325	317	18	holst	holst	NOUN
dpc-3325	317	19	r.	r.	PROPN
dpc-3325	317	20	il-31	il-31	PUNCT
dpc-3325	317	21	significantly	significantly	ADV
dpc-3325	317	22	correlates	correlate	VERB
dpc-3325	317	23	with	with	ADP
dpc-3325	317	24	disease	disease	NOUN
dpc-3325	317	25	activity	activity	NOUN
dpc-3325	317	26	and	and	CCONJ
dpc-3325	317	27	th2	th2	PROPN
dpc-3325	317	28	cytokine	cytokine	ADJ
dpc-3325	317	29	levels	level	NOUN
dpc-3325	317	30	in	in	ADP
dpc-3325	317	31	children	child	NOUN
dpc-3325	317	32	with	with	ADP
dpc-3325	317	33	atopic	atopic	NOUN
dpc-3325	317	34	dermatitis	dermatitis	NOUN
dpc-3325	317	35	.	.	PUNCT
dpc-3325	318	1	pediatr	pediatr	PROPN
dpc-3325	318	2	allergy	allergy	PROPN
dpc-3325	318	3	immunol	immunol	NOUN
dpc-3325	318	4	.	.	PUNCT
dpc-3325	319	1	2012;23(3):285	2012;23(3):285	NUM
dpc-3325	319	2	-	-	SYM
dpc-3325	319	3	288	288	NUM
dpc-3325	319	4	.	.	PUNCT
dpc-3325	320	1	doi	doi	NOUN
dpc-3325	320	2	:	:	PUNCT
dpc-3325	320	3	10.1111	10.1111	NUM
dpc-3325	320	4	/	/	SYM
dpc-3325	320	5	j.1399	j.1399	NOUN
dpc-3325	320	6	-3038.2011.01241.x	-3038.2011.01241.x	NOUN
dpc-3325	320	7	.	.	PUNCT
dpc-3325	321	1	pmid	pmid	NOUN
dpc-3325	321	2	:	:	PUNCT
dpc-3325	321	3	22509760	22509760	NUM
dpc-3325	321	4	.	.	PUNCT
dpc-3325	322	1	41	41	NUM
dpc-3325	322	2	.	.	PUNCT
dpc-3325	323	1	neis	neis	PROPN
dpc-3325	323	2	mm	mm	PROPN
dpc-3325	323	3	,	,	PUNCT
dpc-3325	323	4	peters	peters	PROPN
dpc-3325	323	5	b	b	PROPN
dpc-3325	323	6	,	,	PUNCT
dpc-3325	323	7	dreuw	dreuw	NOUN
dpc-3325	323	8	a	a	X
dpc-3325	323	9	,	,	PUNCT
dpc-3325	323	10	et	et	PROPN
dpc-3325	323	11	al	al	PROPN
dpc-3325	323	12	enhanced	enhance	VERB
dpc-3325	323	13	expression	expression	NOUN
dpc-3325	323	14	levels	level	NOUN
dpc-3325	323	15	of	of	ADP
dpc-3325	323	16	il-31	il-31	NOUN
dpc-3325	323	17	correlate	correlate	VERB
dpc-3325	323	18	with	with	ADP
dpc-3325	323	19	il-4	il-4	PRON
dpc-3325	323	20	and	and	CCONJ
dpc-3325	323	21	il-13	il-13	ADP
dpc-3325	323	22	in	in	ADP
dpc-3325	323	23	atopic	atopic	NOUN
dpc-3325	323	24	and	and	CCONJ
dpc-3325	323	25	allergic	allergic	ADJ
dpc-3325	323	26	contact	contact	NOUN
dpc-3325	323	27	dermatitis	dermatitis	NOUN
dpc-3325	323	28	.	.	PUNCT
dpc-3325	324	1	j	j	PROPN
dpc-3325	324	2	allergy	allergy	PROPN
dpc-3325	324	3	clin	clin	PROPN
dpc-3325	324	4	immunol	immunol	PROPN
dpc-3325	324	5	.	.	PUNCT
dpc-3325	325	1	2006;118(4):930	2006;118(4):930	NUM
dpc-3325	325	2	-	-	SYM
dpc-3325	325	3	937	937	NUM
dpc-3325	325	4	.	.	PUNCT
dpc-3325	326	1	doi	doi	NOUN
dpc-3325	326	2	:	:	PUNCT
dpc-3325	326	3	10.1016	10.1016	NUM
dpc-3325	326	4	/	/	SYM
dpc-3325	326	5	j.jaci.2006.07.015	j.jaci.2006.07.015	PROPN
dpc-3325	326	6	.	.	PUNCT
dpc-3325	327	1	pmid	pmid	NOUN
dpc-3325	327	2	:	:	PUNCT
dpc-3325	327	3	17030248	17030248	NUM
dpc-3325	327	4	.	.	PUNCT
dpc-3325	328	1	42	42	NUM
dpc-3325	328	2	.	.	PUNCT
dpc-3325	328	3	raap	raap	PROPN
dpc-3325	328	4	u	u	PROPN
dpc-3325	328	5	,	,	PUNCT
dpc-3325	328	6	wieczorek	wieczorek	NOUN
dpc-3325	328	7	d	d	PROPN
dpc-3325	328	8	,	,	PUNCT
dpc-3325	328	9	gehring	gehre	VERB
dpc-3325	328	10	m	m	PRON
dpc-3325	328	11	,	,	PUNCT
dpc-3325	328	12	et	et	PROPN
dpc-3325	328	13	al	al	PROPN
dpc-3325	328	14	.	.	PROPN
dpc-3325	328	15	increased	increase	VERB
dpc-3325	328	16	levels	level	NOUN
dpc-3325	328	17	of	of	ADP
dpc-3325	328	18	serum	serum	NOUN
dpc-3325	328	19	il-31	il-31	PUNCT
dpc-3325	328	20	in	in	ADP
dpc-3325	328	21	chronic	chronic	ADJ
dpc-3325	328	22	spontaneous	spontaneous	ADJ
dpc-3325	328	23	urticaria	urticaria	NOUN
dpc-3325	328	24	.	.	PUNCT
dpc-3325	329	1	exp	exp	NOUN
dpc-3325	329	2	dermatol	dermatol	NOUN
dpc-3325	329	3	.	.	PUNCT
dpc-3325	330	1	2010;19(5):464	2010;19(5):464	NUM
dpc-3325	330	2	-	-	PUNCT
dpc-3325	330	3	466	466	NUM
dpc-3325	330	4	.	.	PUNCT
dpc-3325	330	5	doi	doi	NOUN
dpc-3325	330	6	:	:	PUNCT
dpc-3325	330	7	10.1111	10.1111	NUM
dpc-3325	330	8	/	/	SYM
dpc-3325	330	9	j.1600	j.1600	PROPN
dpc-3325	330	10	-	-	PUNCT
dpc-3325	330	11	0625.2010.01067.x	0625.2010.01067.x	NOUN
dpc-3325	330	12	.	.	PUNCT
dpc-3325	331	1	pmid	pmid	NOUN
dpc-3325	331	2	:	:	PUNCT
dpc-3325	331	3	20163453	20163453	NUM
dpc-3325	331	4	.	.	PUNCT
dpc-3325	332	1	43	43	NUM
dpc-3325	332	2	.	.	PUNCT
dpc-3325	333	1	sharma	sharma	PROPN
dpc-3325	333	2	p	p	PROPN
dpc-3325	333	3	,	,	PUNCT
dpc-3325	333	4	sharma	sharma	PROPN
dpc-3325	333	5	pk	pk	PROPN
dpc-3325	333	6	,	,	PUNCT
dpc-3325	333	7	chitkara	chitkara	NOUN
dpc-3325	333	8	a	a	PRON
dpc-3325	333	9	,	,	PUNCT
dpc-3325	333	10	rani	rani	PROPN
dpc-3325	333	11	s.	s.	PROPN
dpc-3325	333	12	to	to	PART
dpc-3325	333	13	evaluate	evaluate	VERB
dpc-3325	333	14	the	the	DET
dpc-3325	333	15	role	role	NOUN
dpc-3325	333	16	and	and	CCONJ
dpc-3325	333	17	relevance	relevance	NOUN
dpc-3325	333	18	of	of	ADP
dpc-3325	333	19	cytokines	cytokine	NOUN
dpc-3325	333	20	il-17	il-17	ADV
dpc-3325	333	21	,	,	PUNCT
dpc-3325	333	22	il-18	il-18	PRON
dpc-3325	333	23	,	,	PUNCT
dpc-3325	333	24	il-23	il-23	NOUN
dpc-3325	333	25	and	and	CCONJ
dpc-3325	333	26	tnf	tnf	PROPN
dpc-3325	333	27	-	-	PUNCT
dpc-3325	333	28	α	α	PROPN
dpc-3325	333	29	and	and	CCONJ
dpc-3325	333	30	their	their	PRON
dpc-3325	333	31	correlation	correlation	NOUN
dpc-3325	333	32	with	with	ADP
dpc-3325	333	33	disease	disease	NOUN
dpc-3325	333	34	severity	severity	NOUN
dpc-3325	333	35	in	in	ADP
dpc-3325	333	36	chronic	chronic	ADJ
dpc-3325	333	37	urticaria	urticaria	NOUN
dpc-3325	333	38	.	.	PUNCT
dpc-3325	334	1	indian	indian	ADJ
dpc-3325	334	2	dermatol	dermatol	NOUN
dpc-3325	334	3	online	online	PROPN
dpc-3325	334	4	j.	j.	PROPN
dpc-3325	334	5	2020;11(4):594	2020;11(4):594	PROPN
dpc-3325	334	6	-	-	SYM
dpc-3325	334	7	597	597	NUM
dpc-3325	334	8	.	.	PUNCT
dpc-3325	335	1	doi	doi	NOUN
dpc-3325	335	2	:	:	PUNCT
dpc-3325	335	3	10.4103	10.4103	NUM
dpc-3325	335	4	/idoj.idoj_396_19	/idoj.idoj_396_19	X
dpc-3325	335	5	.	.	PUNCT
dpc-3325	336	1	pmid	pmid	NOUN
dpc-3325	336	2	:	:	PUNCT
dpc-3325	336	3	32832449	32832449	NUM
dpc-3325	336	4	.	.	PUNCT
dpc-3325	337	1	pmcid	pmcid	NOUN
dpc-3325	337	2	:	:	PUNCT
dpc-3325	337	3	pmc7413447	pmc7413447	VERB
dpc-3325	337	4	.	.	PUNCT
dpc-3325	338	1	44	44	NUM
dpc-3325	338	2	.	.	PUNCT
dpc-3325	339	1	chen	chen	PROPN
dpc-3325	339	2	q	q	PROPN
dpc-3325	339	3	,	,	PUNCT
dpc-3325	339	4	zhong	zhong	PROPN
dpc-3325	339	5	h	h	PROPN
dpc-3325	339	6	,	,	PUNCT
dpc-3325	339	7	chen	chen	PROPN
dpc-3325	339	8	wc	wc	PROPN
dpc-3325	339	9	,	,	PUNCT
dpc-3325	339	10	et	et	PROPN
dpc-3325	339	11	al	al	PROPN
dpc-3325	339	12	.	.	PUNCT
dpc-3325	340	1	different	different	ADJ
dpc-3325	340	2	expression	expression	NOUN
dpc-3325	340	3	patterns	pattern	NOUN
dpc-3325	340	4	of	of	ADP
dpc-3325	340	5	plasma	plasma	NOUN
dpc-3325	340	6	th1-	th1-	PROPN
dpc-3325	340	7	,	,	PUNCT
dpc-3325	340	8	th2-	th2-	NOUN
dpc-3325	340	9	,	,	PUNCT
dpc-3325	340	10	th17and	th17and	PROPN
dpc-3325	340	11	th22	th22	PROPN
dpc-3325	340	12	-	-	PUNCT
dpc-3325	340	13	related	relate	VERB
dpc-3325	340	14	cytokines	cytokine	NOUN
dpc-3325	340	15	correlate	correlate	VERB
dpc-3325	340	16	with	with	ADP
dpc-3325	340	17	serum	serum	NOUN
dpc-3325	340	18	autoreactivity	autoreactivity	NOUN
dpc-3325	340	19	and	and	CCONJ
dpc-3325	340	20	allergen	allergen	NOUN
dpc-3325	340	21	sensitivity	sensitivity	NOUN
dpc-3325	340	22	in	in	ADP
dpc-3325	340	23	chronic	chronic	ADJ
dpc-3325	340	24	spontaneous	spontaneous	ADJ
dpc-3325	340	25	urticaria	urticaria	NOUN
dpc-3325	340	26	.	.	PUNCT
dpc-3325	341	1	j	j	PROPN
dpc-3325	341	2	eur	eur	PROPN
dpc-3325	341	3	acad	acad	PROPN
dpc-3325	341	4	dermatol	dermatol	NOUN
dpc-3325	341	5	venereol	venereol	NOUN
dpc-3325	341	6	.	.	PUNCT
dpc-3325	342	1	2018;32(3):441	2018;32(3):441	NUM
dpc-3325	342	2	-	-	SYM
dpc-3325	342	3	448	448	NUM
dpc-3325	342	4	.	.	PUNCT
dpc-3325	343	1	doi	doi	NOUN
dpc-3325	343	2	:	:	PUNCT
dpc-3325	343	3	10.1111	10.1111	NUM
dpc-3325	343	4	/	/	SYM
dpc-3325	343	5	jdv.14541	jdv.14541	NUM
dpc-3325	343	6	.	.	PUNCT
dpc-3325	344	1	pmid	pmid	NOUN
dpc-3325	344	2	:	:	PUNCT
dpc-3325	344	3	28846158	28846158	NUM
dpc-3325	344	4	.	.	PUNCT
dpc-3325	345	1	45	45	NUM
dpc-3325	345	2	.	.	X
dpc-3325	346	1	giménez	giménez	PROPN
dpc-3325	346	2	-	-	PUNCT
dpc-3325	346	3	arnau	arnau	PROPN
dpc-3325	346	4	am	be	AUX
dpc-3325	346	5	,	,	PUNCT
dpc-3325	346	6	demontojoye	demontojoye	PROPN
dpc-3325	346	7	l	l	NOUN
dpc-3325	346	8	,	,	PUNCT
dpc-3325	346	9	asero	asero	NOUN
dpc-3325	346	10	r	r	NOUN
dpc-3325	346	11	,	,	PUNCT
dpc-3325	346	12	et	et	PROPN
dpc-3325	346	13	al	al	PROPN
dpc-3325	346	14	.	.	PUNCT
dpc-3325	347	1	the	the	DET
dpc-3325	347	2	pathogenesis	pathogenesis	NOUN
dpc-3325	347	3	of	of	ADP
dpc-3325	347	4	chronic	chronic	ADJ
dpc-3325	347	5	spontaneous	spontaneous	ADJ
dpc-3325	347	6	urticaria	urticaria	NOUN
dpc-3325	347	7	:	:	PUNCT
dpc-3325	347	8	the	the	DET
dpc-3325	347	9	role	role	NOUN
dpc-3325	347	10	of	of	ADP
dpc-3325	347	11	infiltrating	infiltrate	VERB
dpc-3325	347	12	cells	cell	NOUN
dpc-3325	347	13	.	.	PUNCT
dpc-3325	348	1	j	j	PROPN
dpc-3325	348	2	allergy	allergy	PROPN
dpc-3325	348	3	clin	clin	PROPN
dpc-3325	348	4	immunol	immunol	PROPN
dpc-3325	348	5	pract	pract	PROPN
dpc-3325	348	6	.	.	PUNCT
dpc-3325	349	1	2021;9(6):2195	2021;9(6):2195	NUM
dpc-3325	349	2	-	-	SYM
dpc-3325	349	3	2208	2208	NUM
dpc-3325	349	4	.	.	PUNCT
dpc-3325	350	1	doi	doi	NOUN
dpc-3325	350	2	:	:	PUNCT
dpc-3325	350	3	10.1016	10.1016	NUM
dpc-3325	350	4	/	/	SYM
dpc-3325	350	5	j.jaip.2021.03.033	j.jaip.2021.03.033	PROPN
dpc-3325	350	6	.	.	PUNCT
dpc-3325	351	1	pmid	pmid	NOUN
dpc-3325	351	2	:	:	PUNCT
dpc-3325	351	3	33823316	33823316	NUM
dpc-3325	351	4	.	.	PUNCT
dpc-3325	352	1	instrument	instrument	NOUN
dpc-3325	352	2	for	for	ADP
dpc-3325	352	3	assessing	assess	VERB
dpc-3325	352	4	urticaria	urticaria	NOUN
dpc-3325	352	5	control	control	NOUN
dpc-3325	352	6	.	.	PUNCT
dpc-3325	353	1	j	j	PROPN
dpc-3325	353	2	allergy	allergy	PROPN
dpc-3325	353	3	clin	clin	PROPN
dpc-3325	353	4	immunol	immunol	NOUN
dpc-3325	353	5	.	.	PUNCT
dpc-3325	354	1	2014;133(5):1365	2014;133(5):1365	NUM
dpc-3325	354	2	-	-	SYM
dpc-3325	354	3	1372	1372	NUM
dpc-3325	354	4	,	,	PUNCT
dpc-3325	354	5	1372.e1	1372.e1	PROPN
dpc-3325	354	6	-	-	PUNCT
dpc-3325	354	7	6	6	NUM
dpc-3325	354	8	.	.	PUNCT
dpc-3325	354	9	doi	doi	NOUN
dpc-3325	354	10	:	:	PUNCT
dpc-3325	354	11	10.1016	10.1016	NUM
dpc-3325	354	12	/	/	SYM
dpc-3325	354	13	j	j	PROPN
dpc-3325	354	14	.jaci.2013.12.1076	.jaci.2013.12.1076	PUNCT
dpc-3325	354	15	.	.	PUNCT
dpc-3325	355	1	pmid	pmid	NOUN
dpc-3325	355	2	:	:	PUNCT
dpc-3325	355	3	24522090	24522090	NUM
dpc-3325	355	4	.	.	PUNCT
dpc-3325	356	1	20	20	NUM
dpc-3325	356	2	.	.	X
dpc-3325	356	3	kocatürk	kocatürk	PROPN
dpc-3325	356	4	e	e	PROPN
dpc-3325	356	5	,	,	PUNCT
dpc-3325	356	6	kızıltaç	kızıltaç	VERB
dpc-3325	356	7	u	u	NOUN
dpc-3325	356	8	,	,	PUNCT
dpc-3325	356	9	can	can	AUX
dpc-3325	356	10	p	p	NOUN
dpc-3325	356	11	,	,	PUNCT
dpc-3325	356	12	et	et	PROPN
dpc-3325	356	13	al	al	PROPN
dpc-3325	356	14	.	.	PUNCT
dpc-3325	357	1	validation	validation	NOUN
dpc-3325	357	2	of	of	ADP
dpc-3325	357	3	the	the	DET
dpc-3325	357	4	turkish	turkish	ADJ
dpc-3325	357	5	version	version	NOUN
dpc-3325	357	6	of	of	ADP
dpc-3325	357	7	the	the	DET
dpc-3325	357	8	urticaria	urticaria	PROPN
dpc-3325	357	9	control	control	PROPN
dpc-3325	357	10	test	test	NOUN
dpc-3325	357	11	:	:	PUNCT
dpc-3325	357	12	correlation	correlation	NOUN
dpc-3325	357	13	with	with	ADP
dpc-3325	357	14	other	other	ADJ
dpc-3325	357	15	tools	tool	NOUN
dpc-3325	357	16	and	and	CCONJ
dpc-3325	357	17	comparison	comparison	NOUN
dpc-3325	357	18	between	between	ADP
dpc-3325	357	19	spontaneous	spontaneous	ADJ
dpc-3325	357	20	and	and	CCONJ
dpc-3325	357	21	inducible	inducible	ADJ
dpc-3325	357	22	chronic	chronic	ADJ
dpc-3325	357	23	urticaria	urticaria	NOUN
dpc-3325	357	24	.	.	PUNCT
dpc-3325	358	1	world	world	PROPN
dpc-3325	358	2	allergy	allergy	PROPN
dpc-3325	358	3	organ	organ	PROPN
dpc-3325	358	4	j.	j.	PROPN
dpc-3325	358	5	2019;12(1):100009	2019;12(1):100009	PROPN
dpc-3325	358	6	.	.	PUNCT
dpc-3325	359	1	doi	doi	NOUN
dpc-3325	359	2	:	:	PUNCT
dpc-3325	359	3	10.1016	10.1016	NUM
dpc-3325	359	4	/	/	SYM
dpc-3325	359	5	j.waojou.2018.11.007	j.waojou.2018.11.007	PROPN
dpc-3325	359	6	.	.	PUNCT
dpc-3325	360	1	pmid	pmid	NOUN
dpc-3325	360	2	:	:	PUNCT
dpc-3325	360	3	30937134	30937134	NUM
dpc-3325	360	4	.	.	PUNCT
dpc-3325	361	1	pmcid	pmcid	NOUN
dpc-3325	361	2	:	:	PUNCT
dpc-3325	361	3	pmc6439411	pmc6439411	ADJ
dpc-3325	361	4	.	.	PUNCT
dpc-3325	362	1	21	21	NUM
dpc-3325	362	2	.	.	PUNCT
dpc-3325	363	1	baiardini	baiardini	PROPN
dpc-3325	363	2	i	i	PRON
dpc-3325	363	3	,	,	PUNCT
dpc-3325	363	4	pasquali	pasquali	PROPN
dpc-3325	363	5	m	m	PROPN
dpc-3325	363	6	,	,	PUNCT
dpc-3325	363	7	braido	braido	PROPN
dpc-3325	363	8	f	f	NOUN
dpc-3325	363	9	,	,	PUNCT
dpc-3325	363	10	et	et	PROPN
dpc-3325	363	11	al	al	PROPN
dpc-3325	363	12	.	.	PUNCT
dpc-3325	364	1	a	a	DET
dpc-3325	364	2	new	new	ADJ
dpc-3325	364	3	tool	tool	NOUN
dpc-3325	364	4	to	to	PART
dpc-3325	364	5	evaluate	evaluate	VERB
dpc-3325	364	6	the	the	DET
dpc-3325	364	7	impact	impact	NOUN
dpc-3325	364	8	of	of	ADP
dpc-3325	364	9	chronic	chronic	ADJ
dpc-3325	364	10	urticaria	urticaria	NOUN
dpc-3325	364	11	on	on	ADP
dpc-3325	364	12	quality	quality	NOUN
dpc-3325	364	13	of	of	ADP
dpc-3325	364	14	life	life	NOUN
dpc-3325	364	15	:	:	PUNCT
dpc-3325	364	16	chronic	chronic	ADJ
dpc-3325	364	17	urticaria	urticaria	NOUN
dpc-3325	364	18	quality	quality	NOUN
dpc-3325	364	19	of	of	ADP
dpc-3325	364	20	life	life	NOUN
dpc-3325	364	21	questionnaire	questionnaire	NOUN
dpc-3325	364	22	(	(	PUNCT
dpc-3325	364	23	cu	cu	NOUN
dpc-3325	364	24	-	-	PUNCT
dpc-3325	364	25	qol	qol	PROPN
dpc-3325	364	26	)	)	PUNCT
dpc-3325	364	27	.	.	PUNCT
dpc-3325	365	1	allergy	allergy	NOUN
dpc-3325	365	2	.	.	PUNCT
dpc-3325	366	1	2005;60(8):1073	2005;60(8):1073	NUM
dpc-3325	366	2	-	-	SYM
dpc-3325	366	3	1078	1078	NUM
dpc-3325	366	4	.	.	PUNCT
dpc-3325	367	1	doi	doi	NOUN
dpc-3325	367	2	:	:	PUNCT
dpc-3325	367	3	10.1111	10.1111	NUM
dpc-3325	367	4	/	/	SYM
dpc-3325	367	5	j.1398	j.1398	PROPN
dpc-3325	367	6	-	-	PUNCT
dpc-3325	367	7	9995.2005.00833.x	9995.2005.00833.x	NUM
dpc-3325	367	8	.	.	PUNCT
dpc-3325	368	1	pmid	pmid	NOUN
dpc-3325	368	2	:	:	PUNCT
dpc-3325	368	3	15969690	15969690	NUM
dpc-3325	368	4	.	.	PUNCT
dpc-3325	369	1	22	22	NUM
dpc-3325	369	2	.	.	PUNCT
dpc-3325	370	1	kocatürk	kocatürk	PROPN
dpc-3325	370	2	e	e	PROPN
dpc-3325	370	3	,	,	PUNCT
dpc-3325	370	4	weller	weller	PROPN
dpc-3325	370	5	k	k	PROPN
dpc-3325	370	6	,	,	PUNCT
dpc-3325	370	7	martus	martus	X
dpc-3325	370	8	p	p	NOUN
dpc-3325	370	9	,	,	PUNCT
dpc-3325	370	10	et	et	PROPN
dpc-3325	370	11	al	al	PROPN
dpc-3325	370	12	.	.	PUNCT
dpc-3325	371	1	turkish	turkish	ADJ
dpc-3325	371	2	version	version	NOUN
dpc-3325	371	3	of	of	ADP
dpc-3325	371	4	the	the	DET
dpc-3325	371	5	chronic	chronic	ADJ
dpc-3325	371	6	urticaria	urticaria	NOUN
dpc-3325	371	7	quality	quality	NOUN
dpc-3325	371	8	of	of	ADP
dpc-3325	371	9	life	life	NOUN
dpc-3325	371	10	questionnaire	questionnaire	NOUN
dpc-3325	371	11	:	:	PUNCT
dpc-3325	371	12	cultural	cultural	ADJ
dpc-3325	371	13	adaptation	adaptation	NOUN
dpc-3325	371	14	,	,	PUNCT
dpc-3325	371	15	assessment	assessment	NOUN
dpc-3325	371	16	of	of	ADP
dpc-3325	371	17	reliability	reliability	NOUN
dpc-3325	371	18	and	and	CCONJ
dpc-3325	371	19	validity	validity	NOUN
dpc-3325	371	20	.	.	PUNCT
dpc-3325	372	1	acta	acta	PROPN
dpc-3325	372	2	derm	derm	PROPN
dpc-3325	372	3	venereol	venereol	NOUN
dpc-3325	372	4	.	.	PUNCT
dpc-3325	373	1	2012;92(4):419	2012;92(4):419	NUM
dpc-3325	373	2	-	-	SYM
dpc-3325	373	3	425	425	NUM
dpc-3325	373	4	.	.	PUNCT
dpc-3325	374	1	doi	doi	NOUN
dpc-3325	374	2	:	:	PUNCT
dpc-3325	374	3	10.2340/00015555	10.2340/00015555	NUM
dpc-3325	374	4	-	-	SYM
dpc-3325	374	5	1199	1199	NUM
dpc-3325	374	6	.	.	PUNCT
dpc-3325	375	1	pmid	pmid	NOUN
dpc-3325	375	2	:	:	PUNCT
dpc-3325	375	3	21918791	21918791	NUM
dpc-3325	375	4	.	.	PUNCT
dpc-3325	376	1	23	23	NUM
dpc-3325	376	2	.	.	PUNCT
dpc-3325	377	1	atwa	atwa	PROPN
dpc-3325	377	2	ma	ma	PROPN
dpc-3325	377	3	,	,	PUNCT
dpc-3325	377	4	emara	emara	VERB
dpc-3325	377	5	as	as	ADP
dpc-3325	377	6	,	,	PUNCT
dpc-3325	377	7	youssef	youssef	PROPN
dpc-3325	377	8	n	n	CCONJ
dpc-3325	377	9	,	,	PUNCT
dpc-3325	377	10	bayoumy	bayoumy	PROPN
dpc-3325	377	11	nm	nm	VERB
dpc-3325	377	12	.	.	PUNCT
dpc-3325	378	1	serum	serum	NOUN
dpc-3325	378	2	concentration	concentration	NOUN
dpc-3325	378	3	of	of	ADP
dpc-3325	378	4	il-17	il-17	NOUN
dpc-3325	378	5	,	,	PUNCT
dpc-3325	378	6	il-23	il-23	NOUN
dpc-3325	378	7	and	and	CCONJ
dpc-3325	378	8	tnf	tnf	PROPN
dpc-3325	378	9	-	-	PUNCT
dpc-3325	378	10	α	α	PROPN
dpc-3325	378	11	among	among	ADP
dpc-3325	378	12	patients	patient	NOUN
dpc-3325	378	13	with	with	ADP
dpc-3325	378	14	chronic	chronic	ADJ
dpc-3325	378	15	spontaneous	spontaneous	ADJ
dpc-3325	378	16	urticaria	urticaria	NOUN
dpc-3325	378	17	:	:	PUNCT
dpc-3325	378	18	association	association	NOUN
dpc-3325	378	19	with	with	ADP
dpc-3325	378	20	disease	disease	NOUN
dpc-3325	378	21	activity	activity	NOUN
dpc-3325	378	22	and	and	CCONJ
dpc-3325	378	23	autologous	autologous	ADJ
dpc-3325	378	24	serum	serum	NOUN
dpc-3325	378	25	skin	skin	NOUN
dpc-3325	378	26	test	test	NOUN
dpc-3325	378	27	.	.	PUNCT
dpc-3325	379	1	j	j	PROPN
dpc-3325	379	2	eur	eur	PROPN
dpc-3325	379	3	acad	acad	PROPN
dpc-3325	379	4	dermatol	dermatol	NOUN
dpc-3325	379	5	venereol	venereol	NOUN
dpc-3325	379	6	.	.	PUNCT
dpc-3325	380	1	2014;28(4	2014;28(4	NUM
dpc-3325	380	2	):	):	PUNCT
dpc-3325	380	3	469	469	NUM
dpc-3325	380	4	-	-	SYM
dpc-3325	380	5	474	474	NUM
dpc-3325	380	6	.	.	PUNCT
dpc-3325	381	1	doi	doi	NOUN
dpc-3325	381	2	:	:	PUNCT
dpc-3325	381	3	10.1111	10.1111	NUM
dpc-3325	381	4	/	/	SYM
dpc-3325	381	5	jdv.12124	jdv.12124	PROPN
dpc-3325	381	6	.	.	PUNCT
dpc-3325	382	1	pmid	pmid	NOUN
dpc-3325	382	2	:	:	PUNCT
dpc-3325	382	3	23451767	23451767	NUM
dpc-3325	382	4	.	.	PUNCT
dpc-3325	383	1	24	24	NUM
dpc-3325	383	2	.	.	PUNCT
dpc-3325	384	1	walsh	walsh	PROPN
dpc-3325	384	2	lj	lj	PROPN
dpc-3325	384	3	,	,	PUNCT
dpc-3325	384	4	trinchieri	trinchieri	PROPN
dpc-3325	384	5	g	g	PROPN
dpc-3325	384	6	,	,	PUNCT
dpc-3325	384	7	waldorf	waldorf	PROPN
dpc-3325	384	8	ha	ha	X
dpc-3325	384	9	,	,	PUNCT
dpc-3325	384	10	whitaker	whitaker	PROPN
dpc-3325	384	11	d	d	PROPN
dpc-3325	384	12	,	,	PUNCT
dpc-3325	384	13	murphy	murphy	PROPN
dpc-3325	384	14	gf	gf	PROPN
dpc-3325	384	15	.	.	PUNCT
dpc-3325	385	1	human	human	ADJ
dpc-3325	385	2	dermal	dermal	ADJ
dpc-3325	385	3	mast	mast	NOUN
dpc-3325	385	4	cells	cell	NOUN
dpc-3325	385	5	contain	contain	VERB
dpc-3325	385	6	and	and	CCONJ
dpc-3325	385	7	release	release	VERB
dpc-3325	385	8	tumor	tumor	NOUN
dpc-3325	385	9	necrosis	necrosis	NOUN
dpc-3325	385	10	factor	factor	NOUN
dpc-3325	385	11	alpha	alpha	NOUN
dpc-3325	385	12	,	,	PUNCT
dpc-3325	385	13	which	which	PRON
dpc-3325	385	14	induces	induce	VERB
dpc-3325	385	15	endothelial	endothelial	ADJ
dpc-3325	385	16	leukocyte	leukocyte	NOUN
dpc-3325	385	17	adhesion	adhesion	NOUN
dpc-3325	385	18	molecule	molecule	NOUN
dpc-3325	385	19	1	1	NUM
dpc-3325	385	20	.	.	PUNCT
dpc-3325	386	1	proc	proc	PROPN
dpc-3325	386	2	natl	natl	PROPN
dpc-3325	386	3	acad	acad	PROPN
dpc-3325	386	4	sci	sci	PROPN
dpc-3325	386	5	u	u	PROPN
dpc-3325	386	6	s	s	NOUN
dpc-3325	386	7	a.	a.	NOUN
dpc-3325	386	8	1991;88(10):4220	1991;88(10):4220	PROPN
dpc-3325	386	9	-	-	NUM
dpc-3325	386	10	4224	4224	NUM
dpc-3325	386	11	.	.	PUNCT
dpc-3325	387	1	doi	doi	NOUN
dpc-3325	387	2	:	:	PUNCT
dpc-3325	387	3	10.1073	10.1073	NUM
dpc-3325	387	4	/pnas.88.10.4220	/pnas.88.10.4220	NOUN
dpc-3325	387	5	.	.	PUNCT
dpc-3325	388	1	pmid	pmid	NOUN
dpc-3325	388	2	:	:	PUNCT
dpc-3325	388	3	1709737	1709737	NUM
dpc-3325	388	4	.	.	PUNCT
dpc-3325	389	1	pmcid	pmcid	NOUN
dpc-3325	389	2	:	:	PUNCT
dpc-3325	389	3	pmc51630	pmc51630	NOUN
dpc-3325	389	4	.	.	PUNCT
dpc-3325	390	1	25	25	NUM
dpc-3325	390	2	.	.	PUNCT
dpc-3325	391	1	noga	noga	PROPN
dpc-3325	391	2	o	o	PROPN
dpc-3325	391	3	,	,	PUNCT
dpc-3325	391	4	hanf	hanf	PROPN
dpc-3325	391	5	g	g	PROPN
dpc-3325	391	6	,	,	PUNCT
dpc-3325	391	7	brachmann	brachmann	PROPN
dpc-3325	391	8	i	i	PROPN
dpc-3325	391	9	,	,	PUNCT
dpc-3325	391	10	et	et	PROPN
dpc-3325	391	11	al	al	PROPN
dpc-3325	391	12	.	.	PROPN
dpc-3325	391	13	effect	effect	NOUN
dpc-3325	391	14	of	of	ADP
dpc-3325	391	15	omalizumab	omalizumab	NOUN
dpc-3325	391	16	treatment	treatment	NOUN
dpc-3325	391	17	on	on	ADP
dpc-3325	391	18	peripheral	peripheral	ADJ
dpc-3325	391	19	eosinophil	eosinophil	ADJ
dpc-3325	391	20	and	and	CCONJ
dpc-3325	391	21	t	t	NOUN
dpc-3325	391	22	-	-	PUNCT
dpc-3325	391	23	lymphocyte	lymphocyte	NOUN
dpc-3325	391	24	function	function	NOUN
dpc-3325	391	25	in	in	ADP
dpc-3325	391	26	patients	patient	NOUN
dpc-3325	391	27	with	with	ADP
dpc-3325	391	28	allergic	allergic	ADJ
dpc-3325	391	29	asthma	asthma	NOUN
dpc-3325	391	30	.	.	PUNCT
dpc-3325	392	1	j	j	PROPN
dpc-3325	392	2	allergy	allergy	PROPN
dpc-3325	392	3	clin	clin	PROPN
dpc-3325	392	4	immunol	immunol	NOUN
dpc-3325	392	5	.	.	PUNCT
dpc-3325	393	1	2006;117(6):1493	2006;117(6):1493	NUM
dpc-3325	393	2	-	-	SYM
dpc-3325	393	3	1499	1499	NUM
dpc-3325	393	4	.	.	PUNCT
dpc-3325	394	1	doi	doi	NOUN
dpc-3325	394	2	:	:	PUNCT
dpc-3325	394	3	10.1016	10.1016	NUM
dpc-3325	394	4	/	/	SYM
dpc-3325	394	5	j.jaci.2006.02.028	j.jaci.2006.02.028	PROPN
dpc-3325	394	6	.	.	PUNCT
dpc-3325	395	1	pmid	pmid	NOUN
dpc-3325	395	2	:	:	PUNCT
dpc-3325	395	3	16751018	16751018	NUM
dpc-3325	395	4	.	.	PUNCT
dpc-3325	396	1	26	26	NUM
dpc-3325	396	2	.	.	X
dpc-3325	397	1	sand	sand	NOUN
dpc-3325	397	2	fl	fl	PROPN
dpc-3325	397	3	,	,	PUNCT
dpc-3325	397	4	thomsen	thomsen	PROPN
dpc-3325	397	5	sf	sf	PROPN
dpc-3325	397	6	.	.	PUNCT
dpc-3325	398	1	tnf	tnf	PROPN
dpc-3325	398	2	-	-	PUNCT
dpc-3325	398	3	alpha	alpha	NOUN
dpc-3325	398	4	inhibitors	inhibitor	NOUN
dpc-3325	398	5	for	for	ADP
dpc-3325	398	6	chronic	chronic	ADJ
dpc-3325	398	7	urticaria	urticaria	NOUN
dpc-3325	398	8	:	:	PUNCT
dpc-3325	398	9	experience	experience	NOUN
dpc-3325	398	10	in	in	ADP
dpc-3325	398	11	20	20	NUM
dpc-3325	398	12	patients	patient	NOUN
dpc-3325	398	13	.	.	PUNCT
dpc-3325	399	1	j	j	PROPN
dpc-3325	399	2	allergy	allergy	PROPN
dpc-3325	399	3	(	(	PUNCT
dpc-3325	399	4	cairo	cairo	PROPN
dpc-3325	399	5	)	)	PUNCT
dpc-3325	399	6	.	.	PUNCT
dpc-3325	400	1	2013;2013:130905	2013;2013:130905	NUM
dpc-3325	400	2	.	.	PUNCT
dpc-3325	401	1	doi	doi	NOUN
dpc-3325	401	2	:	:	PUNCT
dpc-3325	401	3	10.1155/2013/130905	10.1155/2013/130905	NUM
dpc-3325	401	4	.	.	PUNCT
dpc-3325	402	1	pmid	pmid	NOUN
dpc-3325	402	2	:	:	PUNCT
dpc-3325	402	3	24167521	24167521	NUM
dpc-3325	402	4	.	.	PUNCT
dpc-3325	403	1	pmcid	pmcid	ADJ
dpc-3325	403	2	:	:	PUNCT
dpc-3325	403	3	pmc3791586	pmc3791586	ADJ
dpc-3325	403	4	.	.	PUNCT
dpc-3325	404	1	27	27	NUM
dpc-3325	404	2	.	.	PUNCT
dpc-3325	405	1	kasperska	kasperska	PROPN
dpc-3325	405	2	-	-	PUNCT
dpc-3325	405	3	zajac	zajac	PROPN
dpc-3325	405	4	a	a	X
dpc-3325	405	5	,	,	PUNCT
dpc-3325	405	6	grzanka	grzanka	ADV
dpc-3325	405	7	a	a	DET
dpc-3325	405	8	,	,	PUNCT
dpc-3325	405	9	damasiewicz	damasiewicz	NOUN
dpc-3325	405	10	-	-	PUNCT
dpc-3325	405	11	bodzek	bodzek	ADV
dpc-3325	405	12	a.	a.	NOUN
dpc-3325	405	13	il-6	il-6	NOUN
dpc-3325	405	14	transsignaling	transsignale	VERB
dpc-3325	405	15	in	in	ADP
dpc-3325	405	16	patients	patient	NOUN
dpc-3325	405	17	with	with	ADP
dpc-3325	405	18	chronic	chronic	ADJ
dpc-3325	405	19	spontaneous	spontaneous	ADJ
dpc-3325	405	20	urticaria	urticaria	NOUN
dpc-3325	405	21	.	.	PUNCT
dpc-3325	406	1	plos	plos	PROPN
dpc-3325	406	2	one	one	NUM
dpc-3325	406	3	.	.	PUNCT
dpc-3325	407	1	201;10(12):e0145751	201;10(12):e0145751	NUM
dpc-3325	407	2	.	.	PUNCT
dpc-3325	408	1	doi	doi	NOUN
dpc-3325	408	2	:	:	PUNCT
dpc-3325	408	3	10.1371	10.1371	NUM
dpc-3325	408	4	/	/	SYM
dpc-3325	408	5	journal	journal	NOUN
dpc-3325	408	6	.pone.0145751	.pone.0145751	PROPN
dpc-3325	408	7	.	.	PUNCT
dpc-3325	409	1	pmid	pmid	NOUN
dpc-3325	409	2	:	:	PUNCT
dpc-3325	409	3	26699882	26699882	NUM
dpc-3325	409	4	.	.	PUNCT
dpc-3325	410	1	pmcid	pmcid	ADJ
dpc-3325	410	2	:	:	PUNCT
dpc-3325	410	3	pmc4689405	pmc4689405	NOUN
dpc-3325	410	4	.	.	PUNCT
dpc-3325	411	1	28	28	NUM
dpc-3325	411	2	.	.	PUNCT
dpc-3325	412	1	ucmak	ucmak	PROPN
dpc-3325	412	2	d	d	PROPN
dpc-3325	412	3	,	,	PUNCT
dpc-3325	412	4	akkurt	akkurt	PROPN
dpc-3325	412	5	m	m	PROPN
dpc-3325	412	6	,	,	PUNCT
dpc-3325	412	7	toprak	toprak	PROPN
dpc-3325	412	8	g	g	PROPN
dpc-3325	412	9	,	,	PUNCT
dpc-3325	412	10	yesilova	yesilova	X
dpc-3325	412	11	y	y	PROPN
dpc-3325	412	12	,	,	PUNCT
dpc-3325	412	13	turan	turan	PROPN
dpc-3325	412	14	e	e	PROPN
dpc-3325	412	15	,	,	PUNCT
dpc-3325	412	16	yıldız	yıldız	PROPN
dpc-3325	412	17	i.	i.	PROPN
dpc-3325	412	18	determination	determination	NOUN
dpc-3325	412	19	of	of	ADP
dpc-3325	412	20	dermatology	dermatology	NOUN
dpc-3325	412	21	life	life	NOUN
dpc-3325	412	22	quality	quality	NOUN
dpc-3325	412	23	index	index	NOUN
dpc-3325	412	24	,	,	PUNCT
dpc-3325	412	25	and	and	CCONJ
dpc-3325	412	26	serum	serum	NOUN
dpc-3325	412	27	c	c	NOUN
dpc-3325	412	28	-	-	ADJ
dpc-3325	412	29	reactive	reactive	ADJ
dpc-3325	412	30	protein	protein	NOUN
dpc-3325	412	31	and	and	CCONJ
dpc-3325	412	32	plasma	plasma	NOUN
dpc-3325	412	33	interleukin-6	interleukin-6	PROPN
dpc-3325	412	34	levels	level	NOUN
dpc-3325	412	35	in	in	ADP
dpc-3325	412	36	patients	patient	NOUN
dpc-3325	412	37	with	with	ADP
dpc-3325	412	38	chronic	chronic	ADJ
dpc-3325	412	39	urticaria	urticaria	NOUN
dpc-3325	412	40	.	.	PUNCT
dpc-3325	413	1	postepy	postepy	ADJ
dpc-3325	413	2	dermatol	dermatol	NOUN
dpc-3325	413	3	alergol	alergol	NOUN
dpc-3325	413	4	.	.	PUNCT
dpc-3325	414	1	2013;30(3	2013;30(3	NUM
dpc-3325	414	2	):	):	PUNCT
dpc-3325	414	3	146	146	NUM
dpc-3325	414	4	-	-	SYM
dpc-3325	414	5	151	151	NUM
dpc-3325	414	6	.	.	PUNCT
dpc-3325	415	1	doi	doi	NOUN
dpc-3325	415	2	:	:	PUNCT
dpc-3325	415	3	10.5114	10.5114	NUM
dpc-3325	415	4	/	/	SYM
dpc-3325	415	5	pdia.2013.35615	pdia.2013.35615	NOUN
dpc-3325	415	6	.	.	PUNCT
dpc-3325	416	1	pmid	pmid	NOUN
dpc-3325	416	2	:	:	PUNCT
dpc-3325	416	3	24278066	24278066	NUM
dpc-3325	416	4	.	.	PUNCT
dpc-3325	417	1	pmcid	pmcid	NOUN
dpc-3325	417	2	:	:	PUNCT
dpc-3325	417	3	pmc3834718	pmc3834718	ADJ
dpc-3325	417	4	.	.	PUNCT
dpc-3325	418	1	29	29	NUM
dpc-3325	418	2	.	.	PUNCT
dpc-3325	419	1	kasperska	kasperska	PROPN
dpc-3325	419	2	-	-	PUNCT
dpc-3325	419	3	zajac	zajac	PROPN
dpc-3325	419	4	a	a	PRON
dpc-3325	419	5	,	,	PUNCT
dpc-3325	419	6	sztylc	sztylc	PROPN
dpc-3325	419	7	j	j	PROPN
dpc-3325	419	8	,	,	PUNCT
dpc-3325	419	9	machura	machura	NOUN
dpc-3325	419	10	e	e	NOUN
dpc-3325	419	11	,	,	PUNCT
dpc-3325	419	12	jop	jop	PROPN
dpc-3325	419	13	g.	g.	PROPN
dpc-3325	419	14	plasma	plasma	PROPN
dpc-3325	419	15	il-6	il-6	PART
dpc-3325	419	16	concentration	concentration	NOUN
dpc-3325	419	17	correlates	correlate	VERB
dpc-3325	419	18	with	with	ADP
dpc-3325	419	19	clinical	clinical	ADJ
dpc-3325	419	20	disease	disease	NOUN
dpc-3325	419	21	activity	activity	NOUN
dpc-3325	419	22	and	and	CCONJ
dpc-3325	419	23	serum	serum	NOUN
dpc-3325	419	24	c	c	NOUN
dpc-3325	419	25	-	-	ADJ
dpc-3325	419	26	reactive	reactive	ADJ
dpc-3325	419	27	protein	protein	NOUN
dpc-3325	419	28	concentration	concentration	NOUN
dpc-3325	419	29	in	in	ADP
dpc-3325	419	30	chronic	chronic	ADJ
dpc-3325	419	31	urticaria	urticaria	NOUN
dpc-3325	419	32	patients	patient	NOUN
dpc-3325	419	33	.	.	PUNCT
dpc-3325	420	1	clin	clin	PROPN
dpc-3325	420	2	exp	exp	NOUN
dpc-3325	420	3	allergy	allergy	PROPN
dpc-3325	420	4	.	.	PUNCT
dpc-3325	421	1	2011;41(10):1386	2011;41(10):1386	NUM
dpc-3325	421	2	-	-	SYM
dpc-3325	421	3	1391	1391	NUM
dpc-3325	421	4	.	.	PUNCT
dpc-3325	422	1	doi	doi	NOUN
dpc-3325	422	2	:	:	PUNCT
dpc-3325	422	3	10.1111	10.1111	NUM
dpc-3325	422	4	/	/	SYM
dpc-3325	422	5	j.1365	j.1365	NOUN
dpc-3325	422	6	-2222.2011.03789.x	-2222.2011.03789.x	PROPN
dpc-3325	422	7	.	.	PUNCT
dpc-3325	423	1	pmid	pmid	NOUN
dpc-3325	423	2	:	:	PUNCT
dpc-3325	423	3	21645137	21645137	NUM
dpc-3325	423	4	.	.	PUNCT
dpc-3325	424	1	30	30	NUM
dpc-3325	424	2	.	.	PUNCT
dpc-3325	425	1	rasool	rasool	NOUN
dpc-3325	425	2	r	r	PROPN
dpc-3325	425	3	,	,	PUNCT
dpc-3325	425	4	ashiq	ashiq	PROPN
dpc-3325	425	5	i	i	PROPN
dpc-3325	425	6	,	,	PUNCT
dpc-3325	425	7	shera	shera	PROPN
dpc-3325	425	8	ia	ia	PROPN
dpc-3325	425	9	,	,	PUNCT
dpc-3325	425	10	yousuf	yousuf	PROPN
dpc-3325	425	11	q	q	PROPN
dpc-3325	425	12	,	,	PUNCT
dpc-3325	425	13	shah	shah	PROPN
dpc-3325	425	14	za	za	PROPN
dpc-3325	425	15	.	.	PROPN
dpc-3325	425	16	study	study	NOUN
dpc-3325	425	17	of	of	ADP
dpc-3325	425	18	serum	serum	NOUN
dpc-3325	425	19	interleukin	interleukin	NOUN
dpc-3325	425	20	(	(	PUNCT
dpc-3325	425	21	il	il	PROPN
dpc-3325	425	22	)	)	PUNCT
dpc-3325	425	23	18	18	NUM
dpc-3325	425	24	and	and	CCONJ
dpc-3325	425	25	il-6	il-6	NOUN
dpc-3325	425	26	levels	level	NOUN
dpc-3325	425	27	in	in	ADP
dpc-3325	425	28	relation	relation	NOUN
dpc-3325	425	29	with	with	ADP
dpc-3325	425	30	the	the	DET
dpc-3325	425	31	clinical	clinical	ADJ
dpc-3325	425	32	disease	disease	NOUN
dpc-3325	425	33	severity	severity	NOUN
dpc-3325	425	34	in	in	ADP
dpc-3325	425	35	chronic	chronic	ADJ
dpc-3325	425	36	idiopathic	idiopathic	ADJ
dpc-3325	425	37	urticaria	urticaria	NOUN
dpc-3325	425	38	patients	patient	NOUN
dpc-3325	425	39	of	of	ADP
dpc-3325	425	40	kashmir	kashmir	PROPN
dpc-3325	425	41	(	(	PUNCT
dpc-3325	425	42	north	north	PROPN
dpc-3325	425	43	india	india	PROPN
dpc-3325	425	44	)	)	PUNCT
dpc-3325	425	45	.	.	PUNCT
dpc-3325	426	1	asia	asia	PROPN
dpc-3325	426	2	pac	pac	PROPN
dpc-3325	426	3	allergy	allergy	PROPN
dpc-3325	426	4	.	.	PUNCT
dpc-3325	427	1	2014;4(4):206	2014;4(4):206	X
dpc-3325	427	2	-	-	SYM
dpc-3325	427	3	211	211	NUM
dpc-3325	427	4	.	.	PUNCT
dpc-3325	428	1	doi	doi	NOUN
dpc-3325	428	2	:	:	PUNCT
dpc-3325	428	3	10.5415	10.5415	NUM
dpc-3325	428	4	/apallergy.2014.4.4.206	/apallergy.2014.4.4.206	PUNCT
dpc-3325	428	5	.	.	PUNCT
dpc-3325	429	1	pmid	pmid	NOUN
dpc-3325	429	2	:	:	PUNCT
dpc-3325	429	3	25379480	25379480	NUM
dpc-3325	429	4	.	.	PUNCT
dpc-3325	430	1	pmcid	pmcid	NOUN
dpc-3325	430	2	:	:	PUNCT
dpc-3325	430	3	pmc4215435	pmc4215435	ADJ
dpc-3325	430	4	.	.	PUNCT
dpc-3325	431	1	31	31	NUM
dpc-3325	431	2	.	.	PUNCT
dpc-3325	432	1	metz	metz	PROPN
dpc-3325	432	2	m	m	PROPN
dpc-3325	432	3	,	,	PUNCT
dpc-3325	432	4	krull	krull	PROPN
dpc-3325	432	5	c	c	PROPN
dpc-3325	432	6	,	,	PUNCT
dpc-3325	432	7	maurer	maurer	PROPN
dpc-3325	432	8	m.	m.	PROPN
dpc-3325	432	9	histamine	histamine	PROPN
dpc-3325	432	10	,	,	PUNCT
dpc-3325	432	11	tnf	tnf	PROPN
dpc-3325	432	12	,	,	PUNCT
dpc-3325	432	13	c5a	c5a	PROPN
dpc-3325	432	14	,	,	PUNCT
dpc-3325	432	15	il-6	il-6	NUM
dpc-3325	432	16	,	,	PUNCT
dpc-3325	432	17	-9	-9	ADV
dpc-3325	432	18	,	,	PUNCT
dpc-3325	432	19	-18	-18	PROPN
dpc-3325	432	20	,	,	PUNCT
dpc-3325	432	21	-31	-31	NUM
dpc-3325	432	22	,	,	PUNCT
dpc-3325	432	23	-33	-33	PROPN
dpc-3325	432	24	,	,	PUNCT
dpc-3325	432	25	tslp	tslp	VERB
dpc-3325	432	26	,	,	PUNCT
dpc-3325	432	27	neopterin	neopterin	NOUN
dpc-3325	432	28	,	,	PUNCT
dpc-3325	432	29	and	and	CCONJ
dpc-3325	432	30	vegf	vegf	PROPN
dpc-3325	432	31	are	be	AUX
dpc-3325	432	32	not	not	PART
dpc-3325	432	33	elevated	elevate	VERB
dpc-3325	432	34	in	in	ADP
dpc-3325	432	35	chronic	chronic	ADJ
dpc-3325	432	36	spontaneous	spontaneous	ADJ
dpc-3325	432	37	urticaria	urticaria	NOUN
dpc-3325	432	38	.	.	PUNCT
dpc-3325	433	1	j	j	PROPN
dpc-3325	433	2	dermatol	dermatol	NOUN
dpc-3325	433	3	sci	sci	PROPN
dpc-3325	433	4	.	.	PUNCT
dpc-3325	434	1	2013;70(3):222	2013;70(3):222	NUM
dpc-3325	434	2	-	-	PUNCT
dpc-3325	434	3	225	225	NUM
dpc-3325	434	4	.	.	PUNCT
dpc-3325	435	1	doi	doi	NOUN
dpc-3325	435	2	:	:	PUNCT
dpc-3325	435	3	10.1016	10.1016	NUM
dpc-3325	435	4	/	/	SYM
dpc-3325	435	5	j.jdermsci.2013.03.003	j.jdermsci.2013.03.003	PROPN
dpc-3325	435	6	.	.	PUNCT
dpc-3325	436	1	pmid	pmid	NOUN
dpc-3325	436	2	:	:	PUNCT
dpc-3325	436	3	23602531	23602531	NUM
dpc-3325	436	4	.	.	PUNCT